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Androgen deprivation therapy (ADT) is the mainline treatment for men with 
advanced prostate cancer (PCa), with some men remaining on ADT for up to two 
decades. Prolonged use of Gonadotropin Releasing Hormone (GnRH) agonists may 
be associated with survival benefits, but also with potential side-effects in men with 
PCa. One of the more recently investigated side-effects of ADT is an increased risk 
of cardiovascular disease (CVD). Observational studies that have explored CVD 
effects following GnRH agonists have found consistent positive associations 
whereas GnRH antagonists have shown less metabolic characteristics of CVD in 
preclinical models. Moreover, patterns of non-adherence to GnRH agonists among 
men with PCa may be associated with worse prognosis. This thesis used real world 
data to investigate risk of CVD following GnRH agonists and antagonists and to 
explore patterns and factors influencing adherence to GnRH agonists in men with 
PCa.  
Methods 
Data from six countries (United Kingdom (UK) excluding Scotland, Scotland, 
Belgium, the Netherlands, France and Canada) was extracted to evaluate the 
association between GnRH agonists or GnRH antagonists and the risk of CVD. 
Country-specific hazard ratios (HRs) and 95% confidence intervals (CIs) were 
estimated using multivariable adjusted Cox proportional hazards models and then 
pooled using a random effects meta-analysis model. Meta-analytical models 
included stratifications by history of CVD indicator (HCVDi) and age.  
In order to identify patterns affecting non-adherence to GnRH agonists, data from 
Sweden and UK were collated considering determinants at 3 years following GnRH 
agonists’ initiation. Non-adherence was determined by a medication possession 
ratio (MPR) of < 80%. Odds ratios (ORs) and 95% confidence intervals (CI) were 
calculated using logistic regression. Factors contributing to adherence in men with 
PCa on GnRH agonists in the UK were also thematically analysed using qualitative 
data from interviews with men with PCa on GnRH agonists and focus groups with 
their clinicians. 
Results 
Men with PCa on GnRH antagonists had an increased risk of developing any CVD 
(HR = 1.22; 95% CI = 1.03-1.45), arrhythmia (HR = 1.39; 95% CI = 1.13-1.72) and 
heart failure (HF) (HR = 1.33; 95% CI = 1.12-1.58) compared to men on GnRH 
agonists. In men on GnRH antagonists and with a HCVDi, there was an increased risk 
of developing arrhythmia (HR = 1.48; 95% CI = 1.03-2.13), HF (HR = 1.06; 95% CI = 
1.05-1.07) and stroke (HR = 1.04; 95% CI = 1.03-1.05). Stratification by age showed 
an increased risk of developing any CVD (HR = 1.24; 95% CI = 1.04-1.48), ischaemic 
heart disease (IHD) (HR = 1.22; 95% CI = 1.03-1.45), arrhythmia (HR = 1.43; 95% CI = 
1.19-1.73) and HF (HR = 1.39; 95% CI = 1.12-1.73) in those aged ≥ 75 years. 
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MPRs showed an increased adherence both for men with PCa on primary (Sweden = 
88%; UK = 75%) and secondary (Sweden = 84%; UK = 70%) GnRH agonists after 3 
years on the treatment. Analysis from both countries showed that an increased age 
and longer injection intervals were associated with increased adherence to primary 
and secondary GnRH agonists. In Sweden, increased adherence was also observed 
in men with PCa given anti-androgens (OR = 1.53; 95% CI = 1.21-1.93) and 
radiotherapy (OR = 1.77; 95% CI =1.39-2.27) as prior PCa treatment before GnRH 
agonists compared to deferred PCa treatment.  
Qualitative analysis of interviews and focus groups in the UK showed that some 
multi-factorial reasons such as side-effects, strong patient belief system and quality 
over quantity of life contributed to non-adherence in some men. 
Conclusion 
Men with PCa and a HCVDi who were on GnRH antagonists may be at an increased 
risk of developing certain CVD subtypes compared to men on GnRH agonists. 
Pooling data from different countries can be challenging in the real world setting 
and results from both real world data and randomised controlled trials may be 
useful to better understand adverse effects of a drug. Therefore, results from the 
PRONOUNCE trial are required to fully address the potential of indication bias in this 
observational setting.  
Factors such as age, injection intervals and prior PCa treatments can influence 
adherence patterns to GnRH agonists in the PCa population. Moreover, employing 
different strategies by clinicians to support non-adherent men and keeping them 
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engaged with the health care system may lead to the eventual acceptance of 
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1. CHAPTER I – INTRODUCTION  
1.1 RESEARCH OBJECTIVES AND STRUCTURE OF THESIS 
Prostate cancer (PCa) is the second most common cause of cancer death in men, 
with almost 70% of PCa cases occurring in developed countries (1). The incidence of 
clinically significant disease is on a steady increase worldwide. The increasing ageing 
population worldwide means that men diagnosed with PCa will increase 
substantially in the next two decades (2). Age-standardised mortality rates for PCa 
per 100,000 men between 1971-2017 have remained stable in the United Kingdom 
(UK) for those aged < 70 years, whereas the rates have decreased by 11% for those 
between 70-79 years and increased by 45% in those aged > 80 years. The increasing 
mortality rates for PCa in men aged > 80 years may reflect the rising incidence and 
stable survival of men with PCa (3).  
Several risk factors have been established for PCa, with age being the greatest 
contributing factor. The prevalence of microscopic PCa is approximately 80% in men 
aged 80 years or over. Other contributing factors can include family history, genetic 
polymorphisms, environmental factors (i.e. Westernised diet) and geographic and 
ethnic variations (2). The risk of developing PCa is higher in black men than 
Caucasian men suggesting a link between ethnicity and PCa (2).  
Geographic variations have also shown to influence the risk of developing PCa. The 
risk is highest in North America and northern Europe and lowest in Asia. However, 
migration studies have shown that the incidence of PCa in men emigrating from 
low- (i.e. Asia) to high-risk (i.e. North America) areas increases to that of the local 
population within two generations. This suggests that environmental factors, such 
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as diet, as well as differences in healthcare systems may also have an effect in 
detecting clinically significant PCa (4).  
Considering that a large proportion of PCa population may be on hormonal 
treatment or androgen deprivation therapy (ADT), it is important to understand the 
impact of long-term treatment with ADT on PCa-related outcomes and quality of life 
(5, 6).  
This thesis therefore aims to provide more insights into the impact of long-term 
ADT in men with PCa. More specifically, this thesis focuses on the use of real world 
data to investigate adverse effects of hormonal treatment and adherence to 
hormonal treatment on the quality of life in men with PCa through the following 
four projects: 
1. Project 1: Data from six countries (The Health Improvement Network (THIN) 
database from the UK (excluding Scotland), National Health Service Scotland 
(NHSS) from Scotland, Belgian Cancer Registry (BCR) from Belgium, PHARMO 
Database Network from the Netherlands, Systeme National d’Informations Inter 
Regimes de l’Assurance Maladie (SNIIRAM) database from France and Régie de 
l'assurance maladie du Québec (RAMQ) database from Canada) were used to 
compare the cardiovascular disease (CVD) effects of Gonadotropin-releasing 
hormone (GnRH) agonists and GnRH antagonists in men with PCa.  
2. Project 2: Data from Prostate Cancer data Base SwedenTraject (PCBaSeTraject), 
version 4.0 was used to identify patterns of adherence to GnRH agonists in men 
with PCa in Sweden. 
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3. Project 3: Data from THIN was used to identify patterns of adherence to GnRH 
agonists in men with PCa in the UK. 
4. Project 4: Qualitative study based on interviews with men with PCa on GnRH 
agonists and focus groups with their healthcare professionals to better 
understand factors influencing adherence and non-adherence to GnRH agonists 
in men with PCa.  
The next chapter (chapter II) briefly introduces the concept of real world evidence 
and provides a background to PCa, including the anatomy, histology and diagnosis 
and treatment of PCa, epidemiology of PCa, use of ADT and its side-effects and a 
brief introduction into the four projects of this thesis. Chapters III-VI describe the 
methods and results of the four projects outlined above, in chronological order. 
Finally, chapter VII provides an overall conclusion, with interpretation of results and 
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2. CHAPTER II – BACKGROUND 
This chapter introduces the concept of real world evidence and gives an overview of 
PCa including its epidemiology. A summary of ADT, significance of adverse effects 
following ADT and the concept of adherence to long-term ADT is also explored. 
 
2.1 REAL WORLD EVIDENCE 
The term real world evidence is now widely used in the medical field and has 
become an important part of research. The primary characteristic that distinguishes 
real world evidence from other kinds of scientific evidence is the setting in which 
the evidence is gathered. Real world evidence must originate from clinical care, 
home or community settings rather than research-intensive or academic settings 
(7). Real world data includes information derived from multiple sources such as; 
electronic healthcare records, claims and insurance data, disease registries including 
cancer registries, product and pharmacy registries and even data collected through 
personal devices and healthcare applications (8, 9). 
Clinical trials remain a powerful tool for generating scientific evidence regarding the 
safety and efficacy of newly formulated drugs. Trials are needed to understand the 
biological and therapeutic action of drugs in patients. However, the generalisability 
of the internal validity attained by trial studies remain uncertain because the study 
population recruited to clinical trials are different to those seen in clinical practice 
(7). One reason for this distinction in study populations can be due to the selection 
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of healthier patients in trial data because of the rigorous recruitment criteria 
employed in many clinical trials, especially those that include an intervention.  
There is a growing interest among academic and trial researchers, drug companies 
and medical-product developers to integrate clinical research with real world 
settings by increasing access to data from various real world data sources. Whereas 
registries and claims databases provide a platform for data collected at point of 
care, data from personal devices and healthcare applications allow continuous 
monitoring (7, 10).  
The mutual interest for gathering real world evidence among various individual 
institutions has also given rise to consortiums aspiring to increase the quality of real 
world data available. For example, the GetReal Initiative was launched by the 
European Union (EU) in 2018, with the aim of increasing the quality of real world 
evidence in drug development and regulatory and Health Technology Assessment 
(HTA) processes across Europe. The consortium consists of pharmaceutical 
companies, academia, HTA agencies and regulators and patient organisations (11).  
Therefore, real world evidence is a means of incorporating diverse types of real 
world data to increase the general applicability of results in studies. This thesis 
largely includes the use of real world data from electronic healthcare records, 
claims and insurance databases, hospital databases, cancer registries and pharmacy 
registries. Moreover, a small element of the thesis also includes the use of 
qualitative approaches in the real world setting. 
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2.2 ANATOMY, HISTOLOGY AND PHYSIOLOGY OF THE NORMAL 
PROSTATE 
The prostate gland is part of the male reproductive system and is located between 
the bladder and the urethra (Figure 1) (12). It is approximately 20 to 30 grams in 
volume and resembles the size of a walnut (13). The prostate is surrounded by part 
of the urethra (called the prostatic urethra) which explains some of the common 
symptoms such as urinary retention, decreased force of stream or urinary 
frequency reported for prostate-related pathologies (14).  
 
 
 Figure 1: Anatomy of the prostate gland (12).  
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The prostate tissue can be divided into three zones: the transition zone, central 
zone and the peripheral zone (15). The transition zone represents 10% of the 
prostate glandular tissue and the central zone, that surrounds the ejaculatory ducts, 
represents 20% of the prostate glandular tissue. 70% of the prostate is represented 
by the peripheral zone which is located in the posterior and lateral segments of the 
prostate. PCa arises in the glandular tissue as adenocarcinomas, developing from 
the acini of the prostatic ducts (16). Adenocarcinomas can develop in all three zones 
of the prostate, with 20% of adenocarcinomas occurring in the transition zone, 1-5% 
in the central zone and 70% in the peripheral zone (14). 
The primary function of the prostate is the production of an important liquefying 
component of the semen which nourishes the sperm. Once sperm is produced in 
the testicles, it is stored in the seminal vesicles until time of ejaculation. At the time 
of ejaculation, sperm mixes with fluid secreted by the prostate to become semen 
(13).  
Prostate cells need androgens to develop and function normally. 95% of androgens 
originate from the testes, with 5-10% originating from adrenal glands via the 
adrenocorticotropic hormone (ACTH) pathway (Figure 2) (17). Testosterone is the 
androgen that is produced in the testes which is highly bound to plasma proteins 
with 40% bound to sex hormone-binding globulin, 60% bound with low affinity to 
albumin, leaving only 2% as free, unbound hormone (17, 18). Testosterone is 
converted to dihydrotestosterone (DHT) by the enzyme 5 α-reductase in the 
prostate and is the active metabolite of testosterone that is involved in the 
endocrine feedback loop (19).  
Page 32 of 281 
 
The hypothalamic-pituitary-gonadal axis or the endocrine feedback loop (Figure 2) 
controls the secretion of testosterone. Pulsatile release of GnRH every 90-120 
minutes from the hypothalamus stimulates the anterior pituitary gland to release 
luteinizing hormone (LH) and follicle stimulating hormone (FSH), which in turn 
promotes the synthesis and liberation of testosterone and inhibin. The 5α-DHT 
binds onto the androgen receptor (AR) located on the nuclear membrane of the 
prostate cells, thus contributing to normal prostate function and development (17).  
Hypothalamic secretion of GnRH and pituitary secretion of LH is controlled by a 
negative feedback loop system. The release of testosterone and inhibin from the 
testes causes a negative effect on the hypothalamus and the pituitary gland, which 
results in the downregulation of testosterone synthesis (17).  
 
 
Figure 2: The hypothalamic-pituitary-gonadal axis (17). 
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2.3 PROSTATE CANCER 
PCa occurs when cells in the prostate gland divide uncontrollably into cancer cells. 
Nearly all PCa cases diagnosed are adenocarcinomas, which arise in the glandular 
tissue of the prostate. Some rare cases of prostatic transitional cell carcinomas 
(developing from urothelial cells in the prostatic urethra) and neuroendocrine or 
squamous cell carcinomas also exist. These rare cases develop and behave 
differently to prostatic adenocarcinomas and therefore require distinctive 
management options to the adenocarcinomas (20).  
 Diagnosis of prostate cancer 
2.3.1.1 Prostate-specific antigen screening 
The primary method for PCa detection is through a simple blood test aimed to 
screen for a molecule found in prostate cells, the prostate-specific antigen (PSA), 
that is measured in the blood. An elevated PSA of 3.0-4.0 ng/mL is considered as an 
abnormal PSA. Although a raised PSA level can be a sign of PCa, some men can also 
have an elevated PSA due to an inflammation or enlargement of the prostate (21).  
Most PCa cases are diagnosed in men who are asymptomatic due to increasing use 
of PSA testing. PCa cases detected through PSA tests are usually organ-confined and 
may not require immediate medical intervention (active surveillance described in 
section 2.3.2.1) (22). Men with advanced PCa may present with urinary-related 
symptoms, dramatic weight loss, bone pain or other symptoms of metastasis 
including spinal cord compression (23, 24). A physician also performs a digital rectal 
examination to determine the size, consistency and physical abnormalities on the 
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posterior surface of the prostate. Many cancers can be palpated on digital rectal 
examination because they occur in the peripheral zone (22).   
2.3.1.2 Pathological investigation 
Typically, men with persistent elevated PSA levels will undergo a pathological 
investigation through biopsy of the prostate tissue, which is usually the 
confirmatory test (21). Differences in histological characteristics in the biopsy are 
scored based on the grade to which the abnormal cell has differentiated compared 
to the normal prostatic tissue. Based on the appearance of cancer cells in the biopsy 
sample, the pathologist assigns two most common cancer patterns identified – 
Gleason scores (e.g. 3+4). More advanced and more rapidly growing cancers are 
given a higher Gleason grade (21). Gleason scores can range from 2 (non-
aggressive) to 10 (very aggressive) and Gleason grades can range from 1 (well 
differentiated) to 5 (poorly differentiated or anaplastic) (Figure 2).  
 
Figure 3: The Gleason grading system can help physicians to predict how rapidly the cancer is likely to 
spread (21). 
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Recently, a new Gleason grading system was endorsed by International Society of 
Urological Pathology (ISUP) in 2014 to simplify the grading system and improve 
accuracy of grade stratification (Figure 3) (25). The new system is grouped as 
follows: 
 Grade Group 1: (Gleason score 3+3 = 6) Individual, discrete, well-formed 
glands. 
 Grade Group 2: (Gleason score 3+4 = 7) Largely well-formed glands with 
lesser component of poorly formed or fused or cribriform glands. 
 Grade Group 3: (Gleason score 4+3 = 7) Largely poorly formed or fused or 
cribriform glands with lesser component of well-formed glands. 
 Grade Group 4: (Gleason score 8) (i) Only poorly formed/fused/cribriform 
glands or (ii) largely well-formed glands and lesser component lacking glands 
or (iii) largely lacking glands and lesser component of well-formed glands. 
 Grade Group 5: (Gleason scores 9-10) Lack of gland formation with (or 
without) necrosis or with (or without) poorly formed or fused or cribriform 
glands. 
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Figure 4: A new contemporary prostate cancer grading system – the Epstein Gleason grading system 
(25). 
 
Currently, Gleason scores are reported along with the new grading system until the 
new system becomes widely practiced (for example, Gleason score 3+3=6 (Grade 
Group 1)) (25). Further diagnostic imaging tests such as magnetic resonance 
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imaging (MRI), bone scan, ultrasonography and computed tomography may be 
performed in men presenting with high risk disease to assess for extent of disease 
spread (21).  
 
 
Figure 5: Stages of prostate cancer. This is the extent of disease spread classified by all the diagnostic 
tests. PCa uses the Tumour Node Metastasis (TNM) system based on the American Joint Committee 
on cancer. T1 means that the cancer is too small to be detected on a scan or through digital rectal 
examination. T2 is where the cancer is contained within the prostate gland. T3 means that the cancer 
has broken through the capsule surrounding the prostate and spread into the seminal vesicles. T4 is 
where the cancer has spread into other body organs. N0 and N1 determine the involvement of lymph 
nodes and M0 and M1 determine the involvement of other body organs.  
 
 Management of prostate cancer  
Management options for men with detected PCa can include active surveillance 
(regular monitoring for low-risk PCa) or watchful waiting, a prostatectomy (surgical 
removal of the prostate), hormonal treatment or radiation therapy depending on 
stage (Figure 5) and Gleason pattern of PCa (Figures 3 and 4) (21).  
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2.3.2.1 Deferred treatment  
Deferred treatment can include active surveillance or watchful waiting. Active 
surveillance is a treatment option for men with low-risk PCa. This includes a 
treatment plan that monitors the cancer periodically through repeated biopsies, 
digital rectal examination and PSA testing. The purpose of active surveillance is to 
reduce overtreatment in men with low-risk PCa with minimal other health 
complications and only offer curative treatment when the cancer progresses or if 
the patient decides to undergo treatment (26).  
PSA screening has led to an increased detection of early-stage PCa (27, 28). Treating 
these early-stage cancers using the therapies described below cause unwanted risks 
and side-effects that may outweigh the benefits of immediate treatment. Disease 
progression for men who are initially diagnosed with low-risk PCa is slow enough 
that radical treatments can be delayed without reducing overall survival (29, 30). 
Therefore, the aim of active surveillance is to monitor an individual with low-risk 
PCa to the extent where treatment can be avoided permanently because the rate of 
cancer growth is gradual enough that the individual may be more likely to die of 
other causes than PCa.  
Moreover, evidence from trials such as the Prostate Testing for Cancer and 
Treatment (ProtecT) trial have reinforced active surveillance as a valid form of 
treatment for men with low-risk PCa. In the ProtecT trial, effects of active 
surveillance, radical prostatectomy and radical radiotherapy on PCa mortality was 
assessed at a median follow-up of 10 years. No significant difference was observed 
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for overall mortality for men in the active surveillance group compared to the other 
groups (30).  
Currently, no standard protocol for active surveillance exists and institutional 
guidelines determine the clinical and pathological parameters required to offer men 
with PCa the option of active surveillance. However, most active surveillance 
protocols require men to have the following characteristics of cancer to be 
considered for active surveillance: T1-T2 organ-confined cancer with Gleason score 
≤6, ≤ 3 biopsies with cancer and 50% of each biopsy with cancer and a PSA of < 10 
ng/mL (31). 
In men diagnosed with PCa who have a limited life expectancy due to other health 
conditions, another form of deferred treatment called watchful waiting is used 
which consists of monitoring symptoms of PCa. In cases where life expectancy is 
limited and PCa progresses, palliative treatment is offered (26).  
2.3.2.2 Curative treatments 
Curative treatment options can include radical prostatectomy and radiotherapy. 
Radical prostatectomy is the surgical removal of the prostate in men with localised 
PCa (32). Since the adoption of radical prostatectomy in the mid-1980s, the 
technique has evolved to now include laparoscopic radical prostatectomy (33) and 
robotic radical prostatectomy (34). The procedure can involve removing the entire 
prostate with its capsule intact and seminal vesicles (refer to Figure 1 for anatomy 
of the prostate). Side-effects of radical prostatectomy can include: urinary 
incontinence, erectile dysfunction, complications with bowel, injuries relating to the 
Page 40 of 281 
 
rectum, urethra or bladder, neurological injuries and thromboembolic 
complications (35). 
Three prospective randomised-controlled trials (RCTs) (30, 36, 37) have so far 
compared oncological outcomes for radical prostatectomy over deferred treatment 
in organ-confined disease:  
1. Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) (36) 
2. Prostate Cancer Intervention versus Observation Trial (PIVOT) (37)  
3. Prostate Testing for Cancer and Treatment (ProtecT) trial (30) 
SPCG-4 was the only study that showed a benefit for radical prostatectomy 
compared to watchful waiting (36). The three trials (30, 36, 37) highlighted the 
importance of risk stratifying men diagnosed with low-risk, localised PCa so that 
they are managed and treated appropriately.  
The two main types of radiotherapy offered for low-risk PCa are external beam 
radiation therapy (EBRT) and brachytherapy. Although EBRT can also include 
intensity-modulated external-beam radiotherapy (IMRT) and volumetric arc 
external-beam radiotherapy (VMAT), IMRT is considered the gold standard for 
EBRT. Brachytherapy is usually given in early stages of the disease and can include 
two types: low-dose rate (LDR) brachytherapy and high-dose rate (HDR) 
brachytherapy (38). Whereas LDR brachytherapy uses radioactive seeds 
permanently implanted into the prostate, HDR brachytherapy uses a radioactive 
source temporarily introduced into the prostate to deliver radiation (39).  Erectile 
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dysfunction, urinary incontinence, issues with bowel movements and nocturia are 
some negative effects of radical radiotherapy reported by patients (40).  
The type of curative treatment offered depends on the stage of PCa, as well as 
other factors such as comorbidities, age and patient choice. 
2.3.2.3 Hormonal treatment 
ADT interrupts the pathway that leads to the production of testosterone (described 
below in section 2.5). PCa cells can be deprived of androgens in two ways: either by 
suppressing the secretion of androgens from the testes or by inhibiting the action of 
circulating androgens in the blood at their receptor level (39). Detailed description 
including the mechanisms of action for GnRH agonists and GnRH antagonists can be 
found in section 2.5.  
Castration can be achieved by surgical removal of the testes in a process called an 
orchiectomy which leads to a considerable decline in testosterone levels and the 
treatment is irreversible. In addition to orchiectomy, hormonal treatments can also 
include, oestrogens, GnRH (also known as luteinising-hormone-releasing hormone 
(LHRH)) agonists and antagonists (section 2.5.1) and anti-androgens. Oestrogens are 
no longer considered as standard first-line therapy due to severe side-effects such 
as thromboembolic complications even at low doses (39).  
Anti-androgens are oral compounds that compete with androgen receptors and 
inhibit their interaction with testosterone and dihydrotestosterone (41). Androgen 
receptor blockade induces programmed cell death in PCa cells. Structurally, anti-
androgens can be divided into steroidal and non-steroidal anti-androgens. 
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Cyproterone acetate is the most commonly used steroidal anti-androgen that 
competitively inhibit androgen receptors thus lowering LH secretion by a negative 
feedback effect. Steroidal anti-androgens also bind to other steroid receptors, such 
as those for glucocorticoids and progestin, leading to non-specific effects. Non-
steroidal anti-androgens such as bicalutamide, flutamide and nilutamide also 
interrupt the negative feedback of testosterone on GnRH secretion but is specific to 
androgen receptors. This difference in modes of mechanisms explain why non-
steroidal anti-androgens have lesser sexual side-effects than steroidal anti-
androgens. However, the excess testosterone after treatment with non-steroidal 
anti-androgens are converted into oestrogens which lead to side-effects such as 
gynaecomastia (41). Anti-androgens are used in combination with GnRH agonists to 
prevent the clinical ‘flare’ associated with GnRH agonists (17) (explained in section 
2.5.1). In some countries such as Sweden, anti-androgens are also given as a 
monotherapy (41). 
ADT can be given as a primary treatment in advanced staged disease, or as a 
secondary treatment when PCa progresses after a curative treatment. It can also be 
given in conjunction with a curative treatment in an adjuvant setting (usually with 
radiotherapy) (39). 
2.3.2.4 Other treatments 
PCa eventually develops into castrate-resistant PCa over time. This is where an 
adaptive mechanism over time leads to increased intracellular androgen levels 
compared to androgen sensitive cells, in addition to an overexpression of androgen 
receptors (42). Abiraterone acetate is approved for treatment of metastatic 
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castrate-resistant PCa. Synthesis of androgens inside the PCa cells and at the 
adrenal level are inhibited by the Cytochrome P450 17A1 (CYP17) enzyme inhibitor, 
Abiraterone acetate. Moreover, the Food and Drug Administration (FDA) has also 
approved for the use of Sipuleucel-T vaccine containing the antigen-presenting cell 
from the patient for the treatment of castrate-resistant PCa (43). 
Enzalutamide and apalutamide are novel anti-androgens with higher affinity for 
androgen receptors than the ones described above (44). Docetaxel and cabazitaxel 
are chemotherapeutic antimircotubule drugs shown to improve overall survival in 
men with very advanced disease (45). In men with very advanced disease and in 
high risk category for bone-related injuries due to bone metastasis, treatment with 
monoclonal antibodies such as denosumab has also shown to be successful because 
the downstream pathway for denosumab acts as a primary signal to promote bone 
renewal (20).  
2.3.2.5 Combination treatment modalities 
Combination treatment modalities for advanced PCa have been part of several 
study investigations. Clinical trials such as the Systemic Therapy in Advancing or 
Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) (46), 
Chemohormonal Androgen Ablation Randomized Trial for Extensive Disease in 
prostate cancer (CHAARTED) (47) and LATITUDE (48) have investigated and reported 
practice-changing results that showed improvement in PCa disease control and life-
expectancy by adding docetaxel or abiraterone acetate to ADT. Moreover, the 
STAMPEDE trial has been investigating several research questions including 
combination treatment modalities since 2005 (49). In 2018, STAMPEDE also showed 
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a substantial improvement in survival of men with low metastatic burden of PCa 
who were given radiotherapy along with ADT (HR = 0.68, 95% CI = 0.52–0.90) (50). 
The trial is currently exploring two research questions: 
1. whether the addition of metformin, the diabetic drug, to the treatment of 
PCa can improve life expectancy in non-diabetic men with PCa and 
2. whether hormone patches can be used to substitute hormonal injections so 
as to avoid some of the side-effects associated with the injections (49).    
2.3.2.6 Prostate cancer treatment by disease stages 
PCa is categorised into six risk groups based on serum PSA values, clinical stage and 
biopsy scores: low-risk, intermediate risk, high-risk localised, high-risk locally-
advanced, metastatic and castrate-resistant PCa. The risk group of PCa will 
determine the type of treatment given for men with PCa (39). Table 1 provides a 
brief summary of the EAU treatment guidelines for the describe above. In addition 
to the therapies discussed in Table 1, additional treatments can be given in an 
adjuvant setting to decrease the risk of PCa recurrence. For example, men with 
node-positive PCa may be offered adjuvant ADT or adjuvant ADT with additional 
radiotherapy, after a radical prostatectomy with an extended lymph node 
dissection. Moreover, adjuvant EBRT may also be offered to men with PCa at an 
increased risk of local relapse (T3 N0 with positive margins and/or invasion of 
seminal vesicle), after a radical prostatectomy (39). 
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 Table 1: Treatment guidelines by PCa stages. Summarised from European Association of Urology 
guidelines on prostate cancer, 2018 (39). 
PCa risk groups Definition of stage Guidelines for treatment 
Low-risk PSA < 10 ng/mL 
and GS < 7 (ISUP 
grade 1) and cT1-
2a 
 WW: Asymptomatic men with low-
risk PCa with a life expectancy of 
more than 10 years based on 
comorbidities 
 AS: Men with low-risk PCa suitable 
for curative treatment but with low-
risk PCa 
 Active treatment: Surgery or 
radiotherapy as alternatives to AS 
 Radiotherapy: Low-dose 
brachytherapy, IMRT without ADT 
 Other treatment options: 
Cryotherapy, focal therapy 
Intermediate 
risk 
PSA 10-20 ng/mL 
or GS 7 (ISUP grade 
2/3) or cT2b 
 AS: Only to highly selected men with 
intermediate-risk PCa (i.e., < 10% 
pattern 4) 
 Radical prostatectomy: Men with 
intermediate-risk PCa and a life 
expectancy > 10 years. Perform 
pelvic node dissection if estimated 
risk is > 5% for a positive lymph 
node  
 Radiotherapy: Low-dose rate 
brachytherapy, EBRT 
 Other treatment options: 
cryotherapy, focal therapy 
High-risk 
localised 
PSA > 20 ng/mL or 
GS > 7 (ISUP grade 
4/5) or cT2c 
 Radical prostatectomy: Men with 
high-risk localised PCa with a life 
expectancy of more than 10 years as 
part of multi-modal therapy and 
with extended pelvic lymph node 
dissection 
 Radiotherapy: EBRT + long-term ADT 
(2-3 years), EBRT + brachytherapy 




Any PSA, any GS 
(any ISUP grade), 
cT3-4 or cN+ 
 Radical prostatectomy: Only to 
highly selected men with cT3b-T4 N0 
or any T N1 disease as part of multi-
modal therapy with extended pelvic 
lymph node dissection 
 Radiotherapy: Radiotherapy + long-
term ADT for men with high-risk 
locally advanced PCa (cN0) 
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 Other treatment options: ADT 
monotherapy only for men with 
high-risk locally advanced PCa who 
refuse or are unable to receive any 
form of local treatment 
Metastatic M1  ADT with chemotherapy (docetaxel) 
to men with metastatic PCa who are 
fit enough to be administered 
docetaxel 
 Abiraterone acetate with 
glucocorticoid (prednisone) 
 ADT with or without an anti-
androgen (instead of the first two 
options) to unfit or unwilling men 
with metastatic disease  
 GnRH antagonists: men with 
metastatic PCa with risk of spinal 
cord compression  
 Intermittent therapy: Asymptomatic 
men with metastatic PCa with major 
PSA response after induction period 






testosterone < 50 
ng/dL or 1.7 
nmol/L and either 
a biochemical 
progression or a 
radiological 
progression 
 Men with non-metastatic castration-
resistant treated within a clinical 
trial setting 
 Life-prolonging treatments in men 
with metastatic castration-resistant 
PCa based on the earlier choice of 
treatment for hormone-sensitive 
metastatic PCa, performance status, 
comorbidities, symptoms, disease 
extent and location and patient 
preference 
* GS: Gleason score; ISUP: International Society for Urological Pathology; PSA: Prostate-specific 
antigen; WW: Watchful waiting; AS: Active surveillance; EBRT: External-beam radiotherapy; 
Biochemical progression: Three consecutive rises in PSA one week apart resulting in two 50% 
increases over the nadir, and a PSA > 2 ng/mL; Radiological progression: appearance of new lesions 
in bone scans. 
 
2.4 EPIDEMIOLOGY OF PROSTATE CANCER 
PCa is the most common cancer among men in Europe and has the third highest 
projected rate in Europe (51, 52) . In England, there is a subtle increase in incidence 
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in age-standardised rates for PCa (Figure 6) (52). Age-standardised rate mortality 
has continued to fall since 2001, which may be attributed to several shifts in 
treatment regimens of men with PCa.  
 
 
Figure 6: Prostate cancer incidence and mortality age-standardised rates, and one- and five-year net 
survival, for England (52). 
 
 Risk factors 
In most cases, PCa is a slow growing tumour that is most commonly detected in the 
adult and elderly population. Ageing is the most important risk factor for developing 
PCa. Autopsy studies most often report PCa which was never even diagnosed (53, 
54). PCa incidence varies with age and age-specific incidence curves reveal that 
after the age of 55 years, PCa risk begins to rise dramatically reaching a peak in the 
70s (52). As a natural process of ageing in most body tissues, there is an increased 
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frequency of deoxyribonucleic acid (DNA) damage that result in tumorigenesis due 
to an accumulation of cellular oxidants, such as free radicals and reactive oxygen 
species (55).  
Another risk factor contributing to PCa is ethnicity. The overall prevalence of PCa is 
significantly higher in men with a Black origin than any other ethnic group. Several 
explanations have been put forward to understand the cause of higher rates of PCa 
in men with a Black origin: 
 there is a downregulation of androgen receptors in the stromal cells of the 
prostate in men with Black origin (56) 
 higher testosterone levels in men with a Black origin  may contribute to PCa 
pathogenesis (57) 
 higher prevalence of polymorphisms in the genes of different enzymes that 
regulate the production, metabolism and function of PCa cells (58) 
In addition to the mentioned risk factors, a 2.3-fold increased risk of developing PCa 
has been associated with a family history of PCa in both a father and brother(s) (59). 
Moreover, the presence of genetic mutations such as the ones present in the 
tumour suppressor gene, breast cancer susceptibility gene 2 (BRCA2), can also 
increase the risk of developing PCa from five to seven-fold (60). Although specific 
dietary components such as refined carbohydrates (61) and animal and dairy 
products (62) have been suggested to increase the risk of PCa, the evidence is less 
conclusive. Other studies investigating reduced fat intake (63) and increased 
consumption of lycopene, vitamin E, cruciferous vegetables and zinc to lower the 
risk of PCa have also shown inconclusive results (20, 64, 65).  
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2.5 ANDROGEN DEPRIVATION THERAPY 
Testosterone is a type of androgen which is a prerequisite for the proliferation and 
progression of PCa (66). Testosterone is produced downstream in a pathway that is 
initiated in the hypothalamus (Figure 7) (67). The dependence of PCa cells on 
androgens was first discovered by Huggins et al. in 1941 (5). In fact, AR signalling 
determine carcinogenesis and progression in PCa (68). As mentioned in section 
2.3.2.3, ADT interrupts the pathway that leads to the production of testosterone: 
either by suppressing the secretion of androgens from the testes or by inhibiting the 
action of circulating androgens in the blood at their receptor level (39). It is the 
mainstream treatment for symptomatic metastatic PCa; more specifically, ADT is 
commonly used in men with biochemical relapse after radical prostatectomy, locally 
advanced PCa and metastasis (69, 70). This thesis mainly focuses on two types of 
ADT, GnRH agonists and GnRH antagonists which are discussed in more detail 
below. 
 GnRH agonists and GnRH antagonists 
ADT aims to reduce the production of testosterone by interfering at various points 
in the AR signalling pathway (67). One such mode by which ADT works is by 
competing with GnRH or LHRH for their receptors. GnRH is then prevented from 
binding onto the GnRH receptor; thus ensuring a block which obstructs the 
production of testosterone (67).  
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Figure 7:  Mode of action of antagonists of luteinizing hormone-releasing hormone (LHRH). (a) LHRH 
secreted by the hypothalamus binds to its receptor in the pituitary and stimulates the release of 
luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These hormones, in turn, stimulate 
the release of sex steroids, which can stimulate growth and development of both normal and tumour 
cells. (b) Some tumours express LHRH receptors and can respond directly to LHRH; cells in these 
tumours can be sex-steroid-dependent or sex-steroid-independent. (c) LHRH antagonists induce a 
state of sex steroid deprivation by competitive blockade of pituitary LHRH receptors, whereas LHRH 
agonists achieve a similar effect by downregulation of the pituitary receptors for LHRH. 
Consequently, levels of FSH and LH, and subsequently levels of sex steroids, are lowered. The 
decrease in the levels of sex steroids inhibits the proliferation of both benign and malignant sex-
steroid-dependent cells. (d) In tumours that express LHRH receptors, both antagonists and agonists of 
LHRH may exert direct effects mediated by these LHRH receptors. Modified from Engel JB and Schally 
AV with permission.18 Copyright 2013 Nature Publishing Group (67). 
 
2.5.1.1 Differences in modes of mechanism 
Although GnRH agonists and GnRH antagonists are both forms of ADT and stimulate 
the reduction of testosterone, they differ in their mechanism of action (Figure 8) 
(17). As seen in Figure 7, GnRH agonists bind to GnRH receptors in the pituitary 
gland and overproduce LH and FSH, thus leading to an increase in testosterone. 
Persistent overstimulation of the pituitary gland by GnRH agonists overrides the 
pulsatile control of LH and FSH release by natural GnRH, leading to a 
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downregulation of GnRH receptors and desensitising of the pituitary gland to GnRH. 
The desensitising process eventually leads to a decrease in the tumour growth 
factor, testosterone. In comparison, GnRH antagonists block the GnRH receptors in 
the pituitary gland, immediately stopping the downstream pathway (Figure 8). The 
blocking effect of GnRH antagonists therefore prevents the initial testosterone 
surge and clinical ‘flare’ (marked by symptoms such as hot flushes) in the disease 
that is associated with GnRH agonists (17). 
 
 
Figure 8: Mechanism of action of gonadotropin-releasing hormone (GnRH) agonists and blockers 
(antagonists) (17).  
 
Degarelix was developed by Ferring Pharmaceuticals and obtained FDA approval in 
2009 (71). It was the first GnRH antagonist that showed weaker histamine-releasing 
properties than other GnRH antagonists that were developed (such as Abarelix) 
(72). Following subcutaneous injection, degarelix immediately forms a gel-like depot 
and the drug is released into the circulation in a controlled manner prolonging the 
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clinical effect of the drug (73). Efficacy and dose-finding studies have established an 
initial dosage of 240mg and maintenance doses of 80mg or 160mg for degarelix (73-
75). These studies (73-75) were carried out in comparison to the GnRH agonist, 
leuprolide, with respect to achieving and maintaining testosterone suppression. 
 
2.6 ADVERSE EFFECTS OF ANDROGEN DEPRIVATION THERAPY 
Adverse effects of ADT are numerous and require pro-active prevention and 
treatment. These adverse effects can include: hot flushes, sexual dysfunction, 
obesity, osteoporosis, cognitive decline, CVD, diabetes and hypercholesterolemia 
(76). 
 Hot flushes  
About 80% of men on ADT report hot flushes, most often described as diaphoresis 
and facial discomfort (77). The reduction in testosterone due to ADT causes an 
instability in the hypothalamic thermoregulatory center which in turn results in 
sudden fluctuations in body temperatures. Hot flushes can last for a considerable 
length of time and cause significant discomfort in men on ADT (78). Hot flushes can 
be managed by avoiding triggers such as increased exposure to hot temperatures or 
eating spicy food (77).    
 Sexual dysfunction 
The biggest component affecting the quality of life of men on ADT for PCa is sexual 
dysfunction (79). Loss of libido was reported by 58-91% of men on GnRH agonists. 
Additionally, men on ADT have also reported erectile dysfunction and cessation of 
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sexual activity as side-effects (77). Reduction or complete elimination of sexual 
activity can lead to  couples having a reduced expression of affection for each other, 
which in turn can lead to relationship issues (80). 50% of  patients (n = 15) 
interviewed for a qualitative study investigating effects of ADT on body, sexuality 
and spousal ties, experienced marital erosion after ADT administration (81). This 
suggests that sexual dysfunction is a cause for concern in men on ADT which may 
lead to issues such as non-adherence to ADT because a negative attitude towards a 
treatment can to influence adherence to a treatment (82). Management options for 
sexual dysfunction can include counselling for couples and intracavernosal 
injections (76). 
 Obesity 
70% of men on ADT experience some form of weight-related issues. Men on ADT 
experience a reduced muscle mass and increased gain of adiposity. This 
phenomenon is known as sarcopenic obesity. Sarcopenic obesity can in itself lead to 
a loss of muscle strength, fatigue and quality of life (83, 84). Men on ADT can 
therefore benefit from referral to dieticians and exercise physiologists (76). 
 Bone health 
In men with PCa, there is an absolute bone mass density loss of around 5% within 
the first year of ADT administration. Bone mass density loss leads to increased risk 
for fractures which underscores the importance of preventing bone mass density 
loss at an early stage (85). The results of an observational study that investigated 
the effects of ADT on fracture risk also showed that the mortality risk doubled after 
a fracture in men with PCa (86). Bisphosphonates are given to men on ADT to 
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reduce bone mass density loss because bisphosphonates weaken the activity of 
osteoclasts that is involved in breaking down bone tissue (87). Zoledronic acid is a 
bisphosphonate that shown an increase of 4% in bone mass density in the hip and 
spinal area within a year (88). A human monoclonal antibody, Denosumab, has also 
been approved by the FDA for the treatment of bone metastases in PCa and in ADT-
induced osteoporosis. Denosumab works by targeting the receptor activator of 
nuclear factor κB ligand (RANKL), which has a pivotal role in osteoclast activity and 
bone loss in osteoporosis (89). 
 Cognitive decline 
Newly diagnosed men with metastatic PCa reported a steady decline in their mood 
over the first 12 months after diagnosis (90). The hormonal effects from ADT 
immediately after diagnosis may also add to the distress levels that men in this 
group experience (76). Moreover, a RCT showed a significant decline in cognition in 
50% of men with PCa after six months on ADT (91). Interventions in the form of 
education packages and patient-support groups can therefore aid to increase the 
overall patient satisfaction and quality of life in men on ADT (92).  
Exposure to ADT was also associated with a subsequent diagnosis of dementia or 
Alzheimer’s disease in men with PCa over a 10-year follow-up period (93). 
Therefore, the risk of dementia needs to be considered in men before ADT 
initiation. 
 Cardiovascular disease 
In 2010, the FDA issued a requisite for GnRH agonists, a main form of ADT for locally 
advanced and metastatic PCa, to carry a safety warning on the drug labels after 
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several observational studies (94-100) and systematic reviews (101) showed an 
increased risk of CVD in individuals on GnRH agonists. Keating et al. (2013) showed 
that men with PCa on ADT were at an increased risk of developing CVD (especially 
myocardial infarction). Risk factors for myocardial infarction (such as hypertension, 
renal insufficiency and prior CVD) were also associated with developing myocardial 
infarction during ADT (102). Similar results have also been demonstrated by a 
nationwide Danish population-based cohort study that showed that ADT was 
associated with a 31% increased risk of developing myocardial infarction (103). 
Although observational studies (101) have shown evidence for association between 
ADT and CVD, no association was identified in RCTs (104). Therefore, the association 
between ADT and CVD has been explored in greater depth in chapter III of this 
thesis.  
 Diabetes 
A substantial increase in fasting insulin was identified in a clinical trial with men on 
ADT, with 13.5 mU/L at baseline to 17 mU/L at 3 months (105). An observational 
study also showed that treatment with ADT may be associated with an increased 
risk of incident diabetes (94). Moreover, in men with pre-existing diabetes, 
glycaemic control declined over time on ADT because of an increase in the levels of 
glycosylated haemoglobin (106). Lifestyle interventions including exercise and 
weight loss programmes, smoking cessation and reduction of alcohol intake may 
help maintain glycaemic control in men with pre-existing diabetes (76).   
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 Hypercholesterolemia 
An 11% increase in total cholesterol was observed within six months of ADT 
administration in men with PCa in a RCT. An increase in triglyceride levels (27%), 
low‐density lipoprotein (LDL) (7%) and high‐density lipoprotein (HDL) (10%) was also 
observed in these men (105). Although an increase in HDL may be cardio-protective, 
the rise in the other three cholesterol markers can have an adverse effect on men 
with PCa on ADT. Moreover, rising fasting cholesterol levels can be an independent 
risk factor for CVD, regardless of the presence or absence of PCa(105). Therefore, 
cholesterols levels need to be monitored in men with PCa on ADT along with 
engaging them with the lifestyle interventions discussed above (section 2.6.7).  
 
2.7 ADHERENCE TO GNRH AGONISTS IN PROSTATE CANCER 
The term adherence refers to the resolve a patient requires to follow their course of 
therapy. Although other terms such as ‘compliance’ and ‘concordance’ are used to 
describe patients taking their prescribed drugs in pharmacology, they are less 
commonly used in the literature (107).  
  As adherence to a treatment regimen contributes to the success of that treatment, 
the loss of adherence to treatment is a global concern that has both clinical and 
economic consequences. Considering that a large proportion of men diagnosed with 
PCa may remain on ADT for the rest of their PCa treatment, there is a need for more 
studies focusing on factors contributing to non-adherence in men with PCa on ADT 
(108, 109). 
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The remaining sections of this chapter provides a brief background for the four 
projects of this thesis: 
 Cardiovascular effects of GnRH analogues in PCa 
 Adherence to GnRH agonists in PCa in Sweden 
 Adherence to GnRH agonists in PCa in the United Kingdom 
 Adherence to GnRH agonists in PCa – a qualitative approach 
 
2.8 CARDIOVASCULAR EFFECTS OF GNRH ANALOGUES IN 
PROSTATE CANCER 
The first project of this thesis investigated the CVD effects of GnRH analogues that 
are routinely used in men with PCa. Several studies have shown an increased risk of 
developing CVD in men with PCa on ADT (94-98). Regardless of the CVD history of 
men with PCa, standardized incidence ratios for CVD in men on ADT were elevated 
(99). Results from these studies (94-99) prompted the FDA to add safety labels on 
drug labels warning ADT users of the risk of developing CVD in 2010. However, 
these results have been challenged due to contradictory results from RCTs and 
observational studies. Whereas meta-analysis of RCTs (104) have shown no 
associations between GnRH agonists and CVD, meta-analysis of observational 
studies (101) have shown an increased risk of developing CVD following GnRH 
agonists’ administration. Moreover, the newly formulated GnRH antagonist, 
degarelix, has shown less atherosclerotic effects in pre-clinical mouse models (110). 
Although risk of side-effects exists, PCa progression is inevitable if the disease is left 
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untreated. Therefore, it is important to compare the CVD effects of GnRH agonists 
and GnRH antagonists to reduce the risk of CVD from GnRH analogues in the long-
term in men with PCa.  
 
2.9 ADHERENCE TO GNRH AGONISTS IN PROSTATE CANCER IN 
SWEDEN 
The second project investigated patterns of adherence to GnRH agonists in men 
with PCa in Sweden. Medication adherence is usually quantified by the Medication 
Possession Ratio (MPR) which is the sum of the days' supply for all fills of a given 
drug in a particular time period, divided by the number of days in the time period 
(111).  
Factors contributing to patterns of non-adherence to a particular medication may 
be manifold (82). Some key factors extensively discussed in the literature include: 
decreasing the frequency of doses and physician visits (112, 113), side-effects 
associated with medication (114, 115), combination treatment modalities (116), 
social support and forgetfulness (117) and degree of behavioural change required 
(82, 118). Since medication non-adherence is generally associated with worse 
prognosis of a disease, it is important to investigate this in men with PCa on GnRH 
agonists (108, 109).  
Currently, recommendations for PCa in Sweden are set by the regional clinical care 
guidelines based on national recommendations. GnRH agonists are offered to men 
with high-risk PCa, metastatic PCa and castration-resistant PCa. Adjuvant GnRH 
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agonists can also be given after radical prostatectomy and radiotherapy for high-risk 
PCa depending on other clinical characteristics such as PSA value and Gleason 
grade. As per the guidelines, once GnRH agonists had been initiated as a treatment 
for metastatic PCa, it should not be discontinued. The injection intervals for GnRH 
agonists can include 30 days, 90 days, 180 days and 365 days implants (119).   
 
2.10 ADHERENCE TO GNRH AGONISTS IN PROSTATE CANCER IN 
THE UNITED KINGDOM 
The third project investigated patterns of adherence to GnRH agonists in men with 
PCa in the UK. As country-specific guidelines may also influence patterns of 
adherence to a medication, data from the UK was used to understand patterns of 
adherence to GnRH agonists in men with PCa in the UK. 
Currently, ADT is offered to men with locally advanced and advanced PCa in the UK 
(NICE NG131) (120) (refer to Table 1 for a detailed overview for the use of GnRH 
agonists by disease stages in the UK). The injection dosages for GnRH agonists 
include 3mg, 11.25mg and 22.5mg formulations given every 28 days, 90 days and 
180 days, respectively (National Institute for Clinical Excellence (NICE) ESNM30) 
(121). The injection is given intramuscularly at the above dosage intervals by local 
health care professionals (most often nurses).  
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2.11 ADHERENCE TO GNRH AGONISTS IN PROSTATE CANCER: A 
QUALITATIVE APPROACH 
The fourth project investigated factors contributing to adherence and non-
adherence to GnRH agonists in men with PCa in the UK by applying qualitative 
methods. Quantitative methods quantify adherence as the MPR (111) which uses a 
relatively simple calculation to quantify adherence. Although MPR is useful in 
understanding the factors contributing to adherence using real world data from 
cancer registries and other national databases, they do not provide sufficient insight 
into reasons contributing to adherence from a patient’s or clinician’s perspective.  
Therefore, both quantitative (using data from Sweden and UK) and qualitative 
(using data collected from a hospital in the UK) methods were used to explore 
adherence to GnRH agonists in men with PCa. Whereas quantitative methods using 
data from Sweden and UK investigated the patterns of adherence to GnRH agonists 
in PCa men, qualitative methods explored the reasons why PCa men on GnRH 
agonists may not adhere to their treatment regimen. Currently, no studies have 
fully investigated patterns of adherence to GnRH in men with PCa. Therefore, the 
three projects on adherence aim to: 
 employ quantitative and qualitative methods to identify whether non-
adherence is an issue among men with PCa on GnRH agonists 
 identify whether country-specific guidelines influence the observed 
patterns of adherence and non-adherence  
 understand patient and clinician perspectives on the issue of adherence and 
non-adherence to GnRH agonists in men with PCa. 
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3. CHAPTER III – CARDIOVASCULAR EFFECTS OF GNRH 
ANALOGUES IN PROSTATE CANCER 
This chapter focuses on adverse effects of GnRH analogues used in men with PCa 
specifically with respect to CVD. Several observational studies and RCTs have 
investigated the CVD effects of GnRH analogues in the literature with contradictory 
results. This chapter aims to use real world data from six different countries to 
compare the risk of developing CVD following GnRH agonists and GnRH antagonists 
in men with PCa. The methods used for this study has already been published (122) 
(section 9.3.2.1, Appendix).     
 
3.1 BACKGROUND 
Prevention and management of adverse effects of ADT is important for men who 
are on some form of long-term ADT. A number of metabolic side-effects have been 
reported for GnRH agonists including, increased body weight, insulin resistance, 
dyslipidemia and hyperglycemia (94, 123-125). The adverse effects of ADT, 
differences between GnRH agonists and GnRH antagonists and CVD effects of the 
GnRH analogues has already been explored in sections 2.5 and 2.6 of chapter II. The 
next two sections discuss in more detail studies previously conducted on CVD 
effects of GnRH agonists and GnRH antagonists.  
3.1.1.1 Cardiovascular effects of GnRH agonists 
One of the more recently investigated side-effects of GnRH agonists is an increased 
risk of CVD, which is believed to be due to a reduced cardio-protective effect of 
testosterone (94-98). A study using the Swedish National PCa Register and 
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Prescribed Drug Register indicated an increased risk of developing CVD within the 
first year of initiating GnRH agonist therapy or orchiectomy. These results were 
identified specifically in patients who had experienced a CVD event one year before 
commencing ADT (100). Moreover, research by Van Hemelrijck et al. (2010) showed 
that standardized incidence ratios for CVD were elevated in all men with PCa, with 
the highest for those undergoing ADT treatment, independent of CVD history (99). 
In 2010, the findings from these studies (94-100) prompted the FDA to issue a new 
requirement for manufacturers of certain types of GnRH agonists to add safety 
information to drug labels in order to warn users of the CVD risks involved.  
A meta-analysis of observational studies that focused on the risk of developing CVD 
following ADT administration found consistent positive associations, especially with 
GnRH agonists compared with men not treated with ADT (101). In contrast, a meta-
analysis of RCTs showed that ADT use was not associated with an increased risk of 
cardiovascular death (104). This contrast with meta-findings from RCTs (104), in 
comparison to observational studies (101), may be due to differences in study 
designs. RCTs typically exclude older patients or those with a higher number of 
comorbidities, which are two common characteristics of PCa patients (126). Real 
world data used in observational studies do not need to exclude these patients 
(127), which may result in findings that are more applicable to the general 
population. RCTs conducted till date to assess risk of CVD following GnRH agonists 
have lacked power and have insufficient follow-up as they were not designed to 
ascertain cardiovascular outcomes as a primary endpoint (other than death) (104). 
Observational studies, when well conducted, have been shown to provide similar 
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estimates of side-effects to RCTs – which is the rationale behind phase IV studies 
(128).  
3.1.1.2 Cardiovascular effects of GnRH antagonists 
Following observations of an increased risk of CVD in men on GnRH agonists, a 
meta-analysis of six pooled RCTs’ results found that degarelix (a GnRH antagonist) 
was associated with lower risk of developing CVD compared to GnRH agonists (129). 
The findings for a lower risk of CVD following degarelix administration are also 
supported by pre-clinical mouse models showing less atherosclerosis and 
characteristics of metabolic syndrome in those treated with degarelix as compared 
to those with orchiectomy or GnRH agonists (110). Based on the contradictory 
findings from meta-analyses that primarily focused on GnRH agonists and the risk of 
CVD in observational (101) and RCT settings (104); there is a need to also investigate 
the risk of CVD following degarelix using real world data. 
GnRH antagonists also have a similar impact on PCa progression in comparison to 
the commonly used GnRH agonists (130). A review by UK-based clinicians 
highlighted that when making treatment decisions, clinicians should consider 
comorbidities, particularly CVD (131). They further suggested that GnRH antagonists 
may be appropriate in the class of patients with significant CVD risk, existing 
osteopenia, lower urinary tract symptoms and significant metastatic disease.  
3.1.1.3 GnRH agonists versus GnRH antagonists 
Studies comparing GnRH agonists and GnRH antagonists have shown PCa outcome-
specific results. Phase II and phase III studies showed no difference in terms of 
efficacy and baseline testosterone levels in men receiving GnRH antagonists 
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compared to men receiving various GnRH agonists for their PCa (132). Comparison 
of CVD safety profile of men on GnRH agonists and antagonists have yielded 
inconclusive results (101, 104), however CVD was not set as a primary outcome 
(133). 
A RCT comparing the risk of cardiovascular morbidity between GnRH agonist and 
GnRH antagonists among men with PCa showed that there was a lower risk of 
developing subsequent CVD events in men on GnRH antagonists with a pre-existing 
CVD event as compared to men on GnRH agonists (134). However, cardiovascular 
biomarkers were used as a surrogate endpoint (which are intended to replace 
clinical endpoints when it can be measured more conveniently and cheaply (135)) in 
the RCT rather than a CVD event.  
Only one observational study has been conducted to date directly comparing risk of 
CVD between GnRH agonists and GnRH antagonists. Scailteux et al. (2017) showed 
no difference in risk of developing stroke and myocardial infarction in men with 
PCa, however overall CVD was not investigated as a specific outcome in the study 
(136). Currently, a phase III RCT (A Trial Comparing Cardiovascular Safety of 
Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and 
Cardiovascular Disease (PRONOUNCE); ClinicalTrials.gov identifier: NCT02663908) is 
recruiting to compare risk of fatal or non-fatal CVD in 900 men with PCa receiving 
degarelix or leuprolide (GnRH agonist) as primary treatment over a year (137) as the 
increase in risk of developing a CVD event is apparent within the first year of 
treatment initiation (94, 97, 138). 
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Therefore, since the impact of GnRH antagonists on PCa progression has been 
shown to be similar to that of commonly used GnRH agonists (130), there is a need 
to identify whether its suggested reduced risk of CVD is also observed in real world 
data. This project is the first to assess real world data for the risk of CVD in men 
with PCa following GnRH agonists versus GnRH antagonist. 
3.1.1.3.1 Switch between GnRH analogues 
There is a possibility of a switch from GnRH agonists to GnRH antagonists or vice-
versa in men with PCa on the GnRH analogues. Switch between the GnRH analogues 
showed stable disease control and no adverse clinical or oncological effects. 
However, one reason that men on GnRH antagonists switch to a GnRH agonist can 
be due to the adverse effects of GnRH antagonists (skin rash at injection site) and 
the more frequent visits required for the monthly administration of the injection 
(139). Therefore, it is important to consider the switch in comparison studies of 
GnRH analogues. 
3.1.1.4 ROBINS-I tool and the target trial 
Risk of bias should be considered when designing an observational study to assess 
effects of different types of drugs. Risk of bias in non-randomised studies of 
interventions (NRSIs) can be evaluated using the Risk Of Bias In Non-randomised 
Studies - of Interventions (ROBINS-I) tool (140). Sterne et al. (2016) first developed 
the ROBINS-I tool in 2016 to assess risk of bias in systematic reviews of non-
randomised studies using the idea of developing a ‘target trial’. A target trial 
renders a pragmatic approach to emulate a hypothetical randomised controlled-
trial in NRSIs. The ROBINS-I tool mimics a hypothetical randomised trial covering 
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seven specific domains through which any bias may be introduced into the study 
design. However, the resulting hypothetical randomised trial may not necessarily be 
feasible or ethical. For example, a target trial may randomly assign no smoking to 
one group of the study population and smoking to the comparative group. The aim 
of the target trial is to design the ideal study where minimal risk of bias exists.  
The seven specific domains of the ROBINS-I tool address details of the study 
population, experimental intervention, comparator and the outcomes of interest at 
pre-, during and after intervention (140). For this study, the ROBINS-I tool was 
modified to emulate a target trial for the risk of CVD following GnRH agonists and 
GnRH antagonists in men with PCa. 
The aim of this study was to investigate the risk of developing CVD following GnRH 
agonists and GnRH antagonists in PCa using real world data from six countries: UK 
(excluding Scotland), Scotland, Belgium, the Netherlands, France and Canada.  
 
3.2 METHODS 
 Study population 
Men with PCa entered the study on the date of ADT (GnRH agonists or antagonists) 
initiation. A diagnosis of advanced or metastatic PCa was also used as an inclusion 
criterion in countries where data on PCa stage was available (Belgium and the 
Netherlands). Following cohort entry into either treatment regimen, men were 
assumed to be on that regimen until time of censoring. 
Page 68 of 281 
 
 Data 
Six different databases from six countries for the following study periods were used 
in this project: 
1. THIN database from the United Kingdom between 2010-2016 
2. NHSS database from Scotland between 2010-2017 
3. BCR from Belgium between 2010-2013 
4. PHARMO database from the Netherlands between 2010-2015 
5. SNIIRAM database from France between 2010-2013 
6. RAMQ database from Canada between 2011-2019 
3.2.2.1 United Kingdom 
The THIN database used in this study covers 6.2% of the UK population and 
comprises anonymised longitudinal data from patients that is processed and 
validated by Cegedim Strategic Data Medical Research UK. Data is extracted from 
more than 500 general practices in England, Wales, Scotland and Northern Ireland 
using the VISION healthcare interface system (In Practice Systems, London, UK) 
(141-144). Contribution to THIN by GPs is as simple as signing a data sharing 
agreement with VISION. THIN medical records include information on 
demographics, medical diagnoses, prescriptions, referrals to specialists in hospitals, 
laboratory results and some lifestyle factors (145). 
The THIN data was provided for the project by IQVIA (previously known as 
QuintilesIMS) following ethical approval from the Scientific Research Committee. 
The data provided was organised into seven different files in the ‘data’ folder along 
with their descriptions in a separate folder, ‘ancil’. The ancil folder is linked to the 
Page 69 of 281 
 
data folder by standardised readcodes or medcodes (146) and Anatomical 
Therapeutic Chemical (ATC) (147) codes or drugcodes. Each of the seven files 
(Figure 9) in the THIN data folder is linked by patient identification codes (patid) and 
GP identification codes (pracid) which meant that patients may have a unique 
identifier within a GP but not across the dataset. As a result, patid and pracid were 
combined to form a combination identification code called combid so that each 
patient in the database had unique identifiers.  
 
Figure 9: Organisation of The Health Improvement Network database (122). 
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3.2.2.2 Scotland 
The NHSS (148) consists of: The Scottish Cancer Registry, the Scottish National 
Prescribing Information System, the General or Acute Inpatient and Day Case 
dataset (SMR01), the Outpatient Attendance dataset (SMR00) and the National 
Records of Scotland Death Records. These five databases are linked by a unique 
identifier, Community Health Index Number. The NHSS captures information on PCa 
diagnosis and treatment the Scottish National Prescribing Information System, the 
General or Acute Inpatient and Day Case dataset (SMR01), the Outpatient 
Attendance dataset (SMR00) and the National Records of Scotland Death Records 
(148). As Scotland is in the UK and there may have been some overlap of men with 
PCa in the UK THIN and Scottish NHSS databases, men with PCa with a postcode in 
Scotland were excluded from THIN. This study included men with PCa from NHSS on 
GnRH agonists and antagonists from 2010-2015 with follow-up until 2017.  
3.2.2.3 Belgium 
The BCR (Figure 10) comprises population-based clinical and pathological 
information on newly diagnosed cancer cases in Belgium. As all newly diagnosed 
cancer cases in Belgium are legally required to be registered in the BCR, the registry 
offers an almost complete coverage of the Belgian population from 2004 onwards 
(149). The BCR links BCR data with data from health insurance companies (150) and 
hospital discharge data (151) using the national social security number which is a 
unique patient identifier (Figure 5). Whereas the data from health insurance 
companies cover information regarding date and type of diagnostic and therapeutic 
procedures (including the amount and dosages of dispensed medications) over a 
period between one year before until five years after cancer diagnosis date, hospital 
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discharge data covers information on hospital admission and discharge dates, 
diagnoses and procedures. Moreover, cause of death for the Belgian population is 
coupled to the BCR data, provided by the three different Belgian regions (150, 151). 
 
Figure 10: Organisation of Belgian Cancer Registry (150, 151). 
 
3.2.2.4 Netherlands 
PHARMO is a population-based network of healthcare databases and combines data 
from both primary and secondary healthcare settings in the Netherlands (151). For 
this study, data from the Out-patient Pharmacy Database, Hospitalisation Database 
and Cancer Registry was used which are linked on a patient level (Figure 11) (152). 
The Cancer Registry comprises information on newly diagnosed cancer patients 
from the Netherlands (151). The Hospitalisation Database comprises hospital 
admissions from the Dutch Hospital Data Foundation for >24 hours and admissions 
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for <24 hours for which a bed is required. The Out-patient Pharmacy Database 
comprises detailed information on GP or specialist prescribed healthcare products 
dispensed by out-patient pharmacies. Detailed information on the methodology 
and the validation of the record linkage method used in PHARMO can be found 
elsewhere (152). The study period used for the Netherlands was from 2010-2015. 
 
 Figure 11: The organisation of the PHARMO Database Network where different healthcare 
databases are linked together by patient level linkage. The PHARMO Database Network includes; the 
Cancer Registry, General Practice Database, Out-patient Pharmacy, In-patient Pharmacy, Clinical 
Laboratory, Hospitalisation Database, Tailored data collection, PRO (patient reported outcomes), 
Mortality Registry, Perinatal Registry and the Pathology Registry (152). 
 
3.2.2.5 France 
SNIIRAM (Figure 12) is the French National Health Database based on claims data 
which combines reimbursed claims from insurance plans with the National Hospital 
discharge Summaries database system (PMSI) (153). The PMSI datamart stems from 
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all private or public hospitals and are provided to the caisse nationale de l'assurance 
maladie des travailleurs salariés (CNAMTS) or the National Health Insurance Fund 
for linkage to the SNIIRAM. The SNIIRAM database includes 98.8% of the French 
population with information on patient demographics, linked and associated 
diagnoses (identified by International Classification of Diseases (ICD)-10 codes) of 
chronic medical conditions extracted from hospital and clinical visits. SNIIRAM 
provides patient-level linkage based on a unique civil registration number assigned 
to all French residents (154). Data of a given individual are linked through a unique 
identification number called numéro d’identification au repertoire, which is a unique 
identifier for each insured person. However, this unique identifier is not accessible 
in the SNIIRAM in order to preserve the identity of patients. The Données de 
Consommation Inter-Régimes (DCIR) datamart includes all outpatient reimbursed 





















Figure 12: Organisation of the SNIIRAM database in France that contains 
Médicalisation des Systèmes d'Information or the National Hospital discharge 
Summaries database system (PMSI) and Données de Consommation Inter-Régimes 
or Inter-Scheme Consumption Data (DCIR) datamarts (154). The three main sources 
the data is gathered from are the healthcare dispensations, hospitals and civil status 
office or Institut national de la statistique et des études économiques (INSEE) 
translated to National Institute of Statistics and Economic Studies.  
 
3.2.2.6 Canada 
The RAMQ database combines the following databases from the province of 
Québec based on medical claims using unique identifiers between 2011-2016: 
 Beneficiaries database provides the demographic information 
  Medical services provide data from the inpatient and ambulatory services 
 Admissibility database derives prescriptions from the Prescription Drug 
Insurance Plan 
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 Pharmaceutical database provides information on drug dispensation data 
(155). 
 Exposures 
The exposure for this large observational study was defined as the first prescription 
or dispensation of GnRH agonists or GnRH antagonists. Men with PCa who were 
hormone treatment naïve were followed up until censoring point (defined below). 
Once an individual was on one drug, they were assumed to be on that drug until 
censoring (defined below). 
 Outcomes 
The outcome was defined as the first incident or fatal CVD event following exposure 
to GnRH agonists or GnRH antagonists. The following CVD outcomes were explored 
separately: any CVD (ICD-10: I20-I99, G45 or ICD-9 equivalent), ischaemic heart 
disease (IHD) (ICD-10: I20-I25), acute myocardial infarction (AMI) (ICD-10: I21), 
arrhythmia (ICD-10: I44-I49), heart failure (HF) (ICD-10: I50, I97.710, I97.790, I11.0) 
and stroke (ICD-10: I60-64, G45). 
 Censoring Point 
Censoring point was defined as any of the following, which ever occurred first: 
switch between GnRH agonists and antagonists and vice-versa, orchiectomy, end of 
study period or death from other causes than CVD death during the study period. 
For example, when IHD was studied as an outcome, men were censored at first 
incident or fatal IHD. Any CVD, AMI, arrhythmia, HF and stroke after treatment 
initiation were overlooked, even if these had occurred before the IHD event. Men 
with PCa were censored at switch between the GnRH analogues because the 
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percentage of men with PCa who made the switch across the six countries were 
low. 
 Other study variables 
Age, follow-up time, year of PCa diagnosis, stage of PCa, total Gleason score, PSA, 
any prior PCa treatment, type of ADT, ADT specifics, history of CVD indicator 
(HCVDi), number of previous CVD events and other socio-demographic variables 
were extracted for the five countries. Detailed data extracted for each country and 
where relevant, reasons data was not extracted for variables are outlined in Table 2 
below. ICD codes, ATC codes, readcodes and drugcodes used to extract study 
variables for each country has been published (122) (section 9.3.2.1, Appendix).     
Table 2: Data extraction for other study variables in the six included countries. 
Study Variables Data Extraction in the United Kingdom, Scotland, Belgium, 
the Netherlands, France and Canada 
Age Age was considered as a timescale in all analytical models 
on the date of study entry (i.e. GnRH agonists or 
antagonists’ initiation). In the UK THIN database, 5,562 out 
of 17,073 men with PCa had missing date of births. For 
these men, multiple imputation was used to impute the 
missing date of births by creating five plausible imputed 
datasets and combining results from each of the five 
datasets. The PHARMO database in the Netherlands only 
contained the year of birth for all men with PCa on the 
exposures. Therefore, age for all men in the Netherlands 
was calculated using the same random day (12th) and month 
(June).  
Follow-up Time Follow-up began on the date of treatment initiation and 
ended when any of the censoring criteria was reached. The 
median, lower and upper quartiles for follow-up time were 
calculated for UK, Scotland, Belgium, the Netherlands, 
France and Canada.  
Year of PCa 
Diagnosis 
Year of PCa diagnosis was available for UK, Scotland, 
Belgium and the Netherlands.  
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Stage of PCa PCa stage at diagnosis was available for Scotland, Belgium 
and the Netherlands. Stage of PCa was defined as locally 
advanced (T3a/bT4 N0M0) and metastatic (TxNxM1) 
because most PCa men on long-term GnRH analogues are 
usually categorized into these stages. In Belgium, the stage 
categories were further split into: TxNxM1, TxN1M0, 
T3aNxMx, T3bNxMx and T4NxMx. 
Total Gleason 
Score 
Total Gleason score was available for Scotland and the 
Netherlands and was divided into Gleason 5-6, 7, 8, 9-10 
and missing. In the Netherlands, men with invalid Gleason 
score (nine patients) were included in the missing category. 
Prostate Specific 
Antigen (PSA) 
PSA, only available for the Netherlands, was categorised 
into: ≤10, 11-20, 21-50 and >50 ng/ml at GnRH at study 
entry. 
Any Prior PCa 
Treatment 
This was one of the most heterogeneous variable across the 
six countries as only some information was available for all 
the included countries. The main categories were divided 
into: radical prostatectomy, radiotherapy and anti-
androgens. Radical prostatectomy and adjuvant or salvage 
radiotherapy was an additional category in Belgium. 
Moreover, in Belgium, radiotherapy was further split into 
palliative radiotherapy (1-10 fractions) and long course 
external beam radiotherapy +/- brachytherapy). 
Chemotherapy regimen prior to study entry was only 
available in the Netherlands. In Canada, brachytherapy and 
external beam therapy was also included in the variable. 
Type of ADT Type of ADT was defined so that GnRH agonists or 
antagonists as to distinguish whether GnRH was given as a 
primary, adjuvant, neo-adjuvant treatment or other 
(Belgium only). In the UK no distinction was made between 
primary, neo-adjuvant and adjuvant ADT due to lack of data 
availability on full radiotherapy profile given to men on the 
GnRH analogues. In Belgium and Scotland, a prescription of 
GnRH agonists or antagonists was considered neo-adjuvant 
if it had appeared in the databases within one month before 
PCa incidence and the date of surgery or radiotherapy. An 
adjuvant prescription was defined as a prescription of GnRH 
agonists or antagonists within a six months’ period following 
surgery or radiotherapy. In Belgium, men with PCa for 
whom a GnRH treatment was discovered but had not 
fulfilled the definitions of primary, adjuvant or neo-adjuvant 
ADT treatment (e.g. GnRH treatment started more than six 
months following surgery), were classed into the ‘other’ 
category. The cancer registry in the PHARMO Database 
Network in Netherlands only extracted treatment 
information given at PCa diagnosis and six months after 
diagnosis. Moreover, combination treatment modalities 
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were not derived for the study. As information for 
radiotherapy dosages was not available in France, a 
distinction between primary, adjuvant and neo-adjuvant 
was not made. 
ADT Specifics This variable was defined as with PCa who had received 
anti-androgens as flare protection or combined androgen 
blockade. Flare protection was defined as receiving anti-
androgens for ≤ 30 days, whereas combined androgen 
blockade was defined as receiving anti-androgens for more 
than 30 days. 
History of CVD 
Indicator 
(HCVDi) 
HCVDi was defined as any of the following 12 months prior 
to entering the cohort: any CVD event (ICD-10 codes: I20-
I99, G45), hypertension (ICD-10 and ATC codes), 
dyslipidaemia (ATC codes or drugcodes) or diabetes (ATC 
codes or drugcodes). HCVDi was further sub-categorised to 
specifically indicate history of hypertension, dyslipidemia or 




The number of CVD events prior to entering the cohort 
were coded as 0, 1, 2 or ≥ 3 CVD events. As data in Belgium 
was only available one year before first ADT prescription, 
previous CVD events and time of last previous CVD was 
limited to the 12 months prior to entering the cohort. 
Previous history of CVD was stratified as time of last 
previous CVD, defined as: No CVD, 0-3 months, 4-6 months, 
7-12 months prior to treatment initiation. 
Other Socio-
Demographics 
Body Mass Index (BMI), socio-economic status (SES), civil 
status, smoking status and ethnicity were extracted in the 
UK using the readcodes (122) (section 9.3.2.1, Appendix for 
specific codes). BMI was defined as: underweight at ≤ 18.5 
kg/m2, normal at 18.6-24 kg/m2, overweight at 25-30 kg/m2 
and obese at ≥ 30 kg/m2.  
Townsend scores (156) were used to extract the SES of the 
study population. Townsend scores incorporated four 
different variables: unemployment, non-car ownership, 
non-home ownership and household overcrowding. The 
Townsend scores were given as quintiles (i.e. five groups of 
equal size ranging from 1 (least deprived) to 5 (most 
deprived) (156).  
In THIN, civil status was coded as 12 different codes that 
were combined to form three categories: single, married 
and unknown (section 9.3.2.1, Appendix for specific codes). 
Smoking status was defined as: current smokers, non-
smokers and past smokers.  
Ethnicity was defined as men with an origin of: Caucasian, 
Black, Asian and other (readcodes other than these three 
categories). 
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 Analysis 
3.2.7.1 ROBINS-I tool and target trial 
To ensure a clinically applicable research design for this real world study, a modified 
version of the ROBINS-I tool was used. The modified version compared study 
variables and trial characteristics between a target trial and the current study. The 
focus of the target trial was to understand the different types of biases when 
assessing risk of CVD following GnRH agonists and GnRH antagonists in men with 
PCa in six different countries and highlight the challenges encountered in 
addressing these biases.  
3.2.7.2 Stage 1: Country-specific analysis 
Multivariable Cox proportional hazard models were used to estimate country-
specific HRs with age as a timescale. Men with PCa entered the cohort at baseline 
age (left-truncation) and exited at CVD event age or censoring age. Stage one 
analysis was conducted using age as a timescale for: (i) outcomes, (ii) stratified 
analysis for those with HCVDi, (iii) stratified analysis for those without HCVDi, (iv) 
stratified analysis for men aged < 75 years and (v) stratified analysis for men aged ≥ 
75 years. 
3.2.7.3 Stage 2: Meta-analysis 
Country-specific HRs for risk of CVD following GnRH agonists and GnRH antagonists 
were log-transformed and pooled in a random-effects meta-analytical model. The I2 
statistic from the meta-analysis assessed the percentage of variation between the 
databases. Each country in the meta-analysis was weighted by the inverse of its 
variance (i.e. HRs), and adjustment to the weight was made based upon the degree 
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of heterogeneity between the six countries. Heterogeneity in the assessment of 
exposure and outcome data was further evaluated by performing sensitivity 
analyses. This included only those countries that had collected data in a similar way 
– incident CVD (ICD-9-CM codes) sourced from hospital discharge date and fatal 
CVD (ICD-10 codes) sourced from death certificates in Belgium, ICD-10 codes in 
Scotland, the Netherlands, France and Canada versus readcodes in the UK. 
Additional stratifications by HCVDi as well as age (< 75 and ≥ 75 years) were 
conducted to assess effect modification in all countries. 
 Results 
3.2.8.1 ROBINS-I tool and target trial 
A target trial was emulated to assess the risk of CVD following GnRH agonists and 
GnRH antagonists in men with PCa using the ROBINS-I tool (140) (Table 3). 
 
Table 3: Risk Of Bias In Non-randomised Studies – of Interventions (ROBINS-I) tool was used to 
emulate a target trial to assess the risk of CVD following GnRH agonists and GnRH antagonists in 
men with PCa (122). 
Types of bias 
addressed 
Trial Characteristics  
Challenges 
Encountered 
Target Trial This Study 
Randomisation 
Distribution 
50/50 split Uneven number of 
patients in GnRH 
agonists and GnRH 
antagonists 
Observational data 
does not guarantee 
even distribution 
between trial arms. 
Information Bias Information on 
compliance to 
treatment 
An individual is 
assumed to be in the 
same cohort at end of 
study as they are in at 
start of the study 
There is no 
information on 













Lifestyle factors are 
often not well-
recorded in healthcare 
databases leading to 
an unmeasured 
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confounding. UK was 
the only country with 
data on some lifestyle 




However, due to high 
missing data, these 
variables were not 






history of specific 
diseases 
History of CVD 
indicator  
Although CVD risk 








medications may be 
present that have not 
been accounted for, 
leading to some 
unmeasured 
confounding.  
Channeling Bias GnRH antagonists 
to patients with 
no history of CVD 
Men with a history of 
CVD may be 
prescribed GnRH 
antagonists 




patients who may 
have been at risk of a 
CVD leading to a 
channeling bias. This 
must be considered 
when interpreting the 
results of this study. 
Classification bias Uniform coding 





drugcodes for UK and 
ATC codes & ICD 
codes for Scotland, 
Belgium, the 
Netherlands, France 
and Canada   
It was difficult to 
homogenise the 
coding system fully 
across the six 
countries in this study, 
due to heterogeneity 










in the UK. Dispensing 
database in Scotland, 
Belgium, the 
Prescription databases 
usually do not hold 
information on 
whether the patient 
has adhered to their 





For example, a man 
with PCa may be 
prescribed GnRH 
antagonists on 1st 
November but may 
not visit their health 
care professional on 
the same day for their 
injection. This 
introduces a lag time 
between the 
prescription date and 
dispensation or 
injection date 
resulting in an 
immortal time bias. A 
sensitivity analysis 
excluding the UK may 
have accounted for 





at hospital visits 
during the follow-
up time 
Hospital data was not 
available for the UK 
and medications from 
the in-patient 
pharmacy was not 
available for France 
and the Netherlands 
Immeasurable time 
bias can arise from the 
presence of an 
unidentified 
hospitalisation within 
a database (157). 
Records of 
medications 
administered during a 
hospital visit may not 
have been available 
during the study 
period. Data for 
unidentified 
hospitalisation was 
not available in the six 
countries. 
*BMI: Body Mass Index; CVD: cardiovascular disease; HCVDi: history of cardiovascular disease 
indicator; ATC: anatomical therapeutic chemical, ICD: international classification of diseases. 
 
Table 4 shows the study period, number of men and median follow-up time for men 
on GnRH agonists and GnRH antagonists in the UK, Scotland, Belgium, the 
Netherlands, France and Canada.  
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Table 4: Study period, number of men and median follow-up time for men on GnRH agonists and GnRH antagonists in the United Kingdom (excluding Scotland), Scotland, 










































N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
Study 
period 






118      
(0.7) 
9114    
(94.8) 




522     
(21.9) 
1187   
(92.5) 












            
Median 0.6 0.5 2.1 0.8 1.7 1.3 2.3 1.5 2.2 2.1 2.1 1.5 
Lower 
quartile 
0.2 0.1 1.1 0.6 0.8 0.9 1.5 1.2 0.7 0.8 1.2 0.8 
Upper 
quartile 
1.8 1.2 2.9 1.1 3.0 1.8 3.4 2.2 2.7 2.6 3.7 2.7 
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3.2.8.2 Patient characteristics 
Table 5 shows demographic and clinical characteristics of men with PCa on GnRH 
agonist and GnRH antagonists. As seen in the table, demographic variables and 
lifestyle factors were not available for most countries. Moreover, clinical 
characteristics of PCa were also not uniformly available in all countries. Therefore, 
these variables are reported in this thesis for descriptive purposes and no further 
analyses were conducted using these variables.  
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Demographic or Clinical 
Characteristic 
   
United Kingdom 
(excluding Scotland) 





































N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
Age, years             
Mean 75 74 73 74 73.5 72.3 71.9 72.5 74.2 73.4 74.7 74.1 
SD 9.6 10.1 8.4 9.2 9.3 9.8 8.3 9.6 8.6 9.8 8.2 9.1 
































































































Missing 5562  
(32.8) 
0 0 0 0 0       
Year of PCa diagnosis             




0 0   0 0 N/A N/A N/A N/A 
















N/A N/A N/A N/A 

































N/A N/A N/A N/A 





























N/A N/A N/A N/A 








0 0 0 0 N/A N/A N/A N/A 
Page 86 of 281 
 




0 0 0 0 0 0 N/A N/A N/A N/A 




0 0 0 0 0 0 N/A N/A N/A N/A 
Stage of PCa             
Locally Advanced 
(T3a/bT4 N0M0) 




N/A N/A N/A N/A N/A N/A 




N/A N/A N/A N/A N/A N/A 
PCa stage subgroups             




N/A N/A N/A N/A N/A N/A 




N/A N/A N/A N/A N/A N/A 




N/A N/A N/A N/A N/A N/A 




N/A N/A N/A N/A N/A N/A 




N/A N/A N/A N/A N/A N/A 




N/A N/A N/A N/A 




N/A N/A N/A N/A 




N/A N/A N/A N/A 
Total Gleason Score             








N/A N/A N/A N/A 








N/A N/A N/A N/A 








N/A N/A N/A N/A 








N/A N/A N/A N/A 








N/A N/A N/A N/A 
PSA             
Page 87 of 281 
 




N/A N/A N/A N/A 




N/A N/A N/A N/A 




N/A N/A N/A N/A 




N/A N/A N/A N/A 




N/A N/A N/A N/A 
Any prior PCa 
treatment 
            























Radical prostatectomy + 
Adjuvant/Salvage 
Radiotherapy 


























Radiotherapy ≤ 6 
months prior to ADT 
initiation 





Radiotherapy > 6 
months prior to ADT 
initiation 











N/A N/A N/A N/A N/A N/A 
Long course external 
beam radiotherapy +/- 
brachytherapy 




N/A N/A N/A N/A N/A N/A 

















N/A N/A N/A N/A 















Previous AA  9-12 
month 
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Brachytherapy N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 9  
(0.1) 
0 
















ADT specifics (with 
GnRH agonists) 
            


































































History of CVD indicator             
















































CVD risk factors 12 
months prior to ADT 
initiation 
            








































































Number of previous 
CVD events, 12 months 
prior to ADT initiation 

















































2 119  
(0.7) 
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Time of last previous 
CVD, 12 months prior 
to ADT initiation 
            


































4-6m 98  
(0.6) 




























BMI / obesity             




N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Underweight (<18.5) 2  
(0.01) 
0 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 




N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Obese (>30) 103 
 (0.6) 





N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Socio-economic Status             










N/A N/A N/A N/A N/A N/A N/A N/A 








N/A N/A N/A N/A N/A N/A N/A N/A 








N/A N/A N/A N/A N/A N/A N/A N/A 








N/A N/A N/A N/A N/A N/A N/A N/A 
Highest or most 









N/A N/A N/A N/A N/A N/A N/A N/A 









N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Civil Status             
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N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 




N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 




N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Smoking Status             




N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Non-smokers 78 
 (0.5) 
0 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Past Smokers 195  
(1.2) 
0 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Missing 12953 
 (76.4)  
88  
(74.6) 
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Ethnicity             




N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Black 360  
(2.1) 
0 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 









N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 




N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
*Unknown: Received anti-androgens before GnRH initiation however cannot make a distinction between flare or combined androgen blockade; N/A: Not available.
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3.2.8.3 Stage 1: Country-specific Cox proportional hazard models 
Tables 6-11 show country-specific HRs and 95% CIs for the six included countries. 
3.2.8.3.1 United Kingdom 
In the UK, 16,955 (99.3%) men with PCa were on GnRH agonists and 118 (0.7%) men 
with PCa were on GnRH antagonists (Table 4). Country-specific HRs and 95% CI from 
the UK (Table 6) showed an increased risk of developing arrhythmia in men with 
PCa on GnRH antagonists compared to GnRH agonists (HR = 4.05; 95% CI = 1.03 – 
15.9).  
 
Table 6: Hazard ratios and 95% confidence intervals from Cox proportional hazard models including 
different stratifications for any CVD, ischaemic heart disease, acute myocardial infarction, 
arrhythmia, heart failure and stroke for the United Kingdom. 
Outcome 
HR for all men 
(95% CI) 
HR for men 
with *HCVDi 
(95% CI) 
HR for men 
without HCVDi 
(95% CI) 
HR for men < 
75 years 
(95% CI) 





(0.69 – 6.84) 
1.69 
(0.47 – 6.12) 
4.02 
(0.80 – 20.12) 
1.09 
(0.25 – 4.72) 
1.85 





(0.10 – 3.62) 
0.30 
(0.03 – 2.92) 
2.17 




















(1.03 – 15.9) 
2.94 
(0.71 – 12.2) 
7.29 
(1.19 – 44.51) 
2.89 
(0.53 – 15.6) 
2.79 




(0.05 – 3.67) 
0.48 






(0.05 – 3.5) 
Stroke 
0.44 








(0.05 – 4.36) 
* HR: hazard ratio; CI: confidence interval; HCVDi: history of CVD indicator; GnRH agonists (reference 
group). The (-) indicates where analyses were not conducted due to no number of events in GnRH 
agonists or antagonist group. 
 
Page 92 of 281 
 
3.2.8.3.2 Scotland 
In Scotland, 11,929 (94.0%) men with PCa were on GnRH agonists and 768 (6.0%) 
men with PCa were on GnRH antagonists (Table 4). Results from Scotland (Table 7) 
showed an increased risk of developing any CVD (HR = 1.52; 95% CI = 1.19 – 1.94) 
and arrhythmia (HR = 2.24; 95% CI = 1.35 – 3.72) in men with PCa on GnRH 
antagonists and a previous HCVDi as compared to men on GnRH agonists. 
Moreover, there was an increased risk of developing any CVD in men with PCa on 
GnRH antagonists regardless of age, as compared to men on GnRH agonists. In men 
aged < 75 years who were on GnRH antagonists, there was also an increased risk of 
developing arrhythmia (HR = 2.10; 95% CI = 1.03 – 4.28) as compared to those on 
GnRH agonists.  
 
Table 7: Hazard ratios and 95% confidence intervals from Cox proportional hazard models including 
different stratifications for any CVD, ischaemic heart disease, acute myocardial infarction, 
arrhythmia, heart failure and stroke for Scotland. 
Outcome 
HR for all men 
(95% CI) 
HR for men 
with *HCVDi 
(95% CI) 
HR for men 
without HCVDi 
(95% CI) 
HR for men < 
75 years 
(95% CI) 





(1.25 – 1.96) 
1.52 
(1.19 – 1.94) 
1.49 
(0.85 – 2.59) 
1.64 
(1.18 – 2.27) 
1.50 





(1.00 – 2.19) 
1.42 
(0.93 – 2.16) 
1.40 
(0.44 – 4.42) 
1.28 
(0.68 – 2.40) 
1.63 





(0.83 – 2.53) 
1.24 
(0.66 – 2.33) 
2.50 
(0.78 – 8.03) 
1.40 
(0.57 – 3.42) 
1.50 
(0.74 – 3.05) 
Arrhythmia 
1.89 
(1.14 – 3.12) 
2.24 




(1.03 – 4.28) 
1.69 




(0.88 – 3.37) 
1.75 




(0.13 – 6.97) 
1.85 
(0.90 – 3.79) 




(0.35 – 1.55) 
0.63 
(0.26 – 1.55) 
1.1 
(0.27 – 4.52) 
0.27 
(0.04 – 1.96) 
1.03 
(0.46 – 2.34) 
* HR: hazard ratio; CI: confidence interval; HCVDi: history of CVD indicator; GnRH agonists (reference 




1,860 (78.1%) men with PCa were on GnRH agonists and 522 (21.9%) men with PCa 
were on GnRH antagonists in Belgium (Table 4). Results from Belgium (Table 8) 
showed an increased risk of developing any CVD in men on GnRH antagonists with a 
HCVDi (HR = 1.37; 95% CI = 1.07 – 1.76) as compared to men on GnRH agonists. 
There was also an increased risk of developing AMI in men on GnRH antagonists 
with a HCVDi (HR = 2.19; 95% CI = 1.16 – 4.16) and those aged < 75 years (HR = 2.99; 
95% CI = 1.24 – 7.19) as compared to men on GnRH agonists.  
 
Table 8: Hazard ratios and 95% confidence intervals from Cox proportional hazard models including 
different stratifications for any CVD, ischaemic heart disease, acute myocardial infarction, 
arrhythmia, heart failure and stroke for Belgium. 
Outcome 
HR for all men 
(95% CI) 
HR for men 
with *HCVDi 
(95% CI) 
HR for men 
without HCVDi 
(95% CI) 
HR for men < 
75 years 
(95% CI) 





(1.00 – 1.62) 
1.37 
(1.07 – 1.76) 
1.26 
(0.47 – 3.40) 
1.40 
(0.99 – 1.97) 
1.13 





(0.88 – 2.08) 
1.42 
(0.91 – 2.23) 
2.15 
(0.40 – 11.57) 
1.30 
(0.70 – 2.40) 
1.36 





(1.07 – 3.84) 
2.19 




(1.24 – 7.19) 
1.30 
(0.49 – 3.44) 
Arrhythmia 
1.57 
(0.96 – 2.55) 
1.65 
(1.00 – 2.73) 
3.11 
(0.28 – 35.25) 
1.47 
(0.66 – 3.26) 
1.56 




(0.62 – 2.05) 
1.17 
(0.63 – 2.17) 
2.72 
(0.24 – 30.96) 
1.09 
(0.41 – 2.87) 
1.08 
(0.51 – 2.31) 




(0.64 – 2.23) 
1.21 
(0.62 – 2.39) 
1.81 
(0.36 – 9.09) 
1.52 
(0.56 – 4.14) 
1.01 
(0.45 – 2.26) 
* HR: hazard ratio; CI: confidence interval; HCVDi: history of CVD indicator; GnRH agonists (reference 
group). The (-) indicates where analyses were not conducted due to no number of events in GnRH 
agonists/antagonist group. 
 
3.2.8.3.4 The Netherlands 
In the Netherlands, there were 1,187 (92.5%) men with PCa were on GnRH agonists 
and 97 (7.6%) men with PCa were on GnRH antagonists (Table 4). Country-specific 
HRs and 95% Cis from the Netherlands (Table 9) showed no significant risks for any 
CVD or CVD subtypes in both comparison groups. 
 
Table 9: Hazard ratios and 95% confidence intervals from Cox proportional hazard models including 
different stratifications for any CVD, ischaemic heart disease, acute myocardial infarction, 
arrhythmia, heart failure and stroke for the Netherlands. 
Outcome 
HR for all men 
(95% CI) 
HR for men 
with *HCVDi 
(95% CI) 
HR for men 
without HCVDi 
(95% CI) 
HR for men < 
75 years 
(95% CI) 





(0.62 – 2.10) 
1.61 
(0.70 – 3.71) 
0.75 
(0.23 – 2.44) 
1.01 
(0.38 – 2.71) 
1.03 









(0.14 – 18.31) 
0.60 


















(0.21 – 11.70) 
1.41 


















(0.21 – 11.70) 
Stroke 
0.73 








(0.08 – 7.08) 
* HR: hazard ratio; CI: confidence interval; HCVDi: history of CVD indicator; GnRH agonists (reference 
group). The (-) indicates where analyses were not conducted due to no number of events in GnRH 
agonists/antagonist group. 




19,641 (83.9%) men with PCa were on GnRH agonists and 912 (3.9%) men with PCa 
were on GnRH antagonists in Belgium (Table 4). Results from France (Table 10) 
showed a decreased risk of developing IHD in men with PCa on GnRH antagonists 
and aged ≥ 75 years as compared to those on GnRH agonists (HR = 0.86; 95% CI = 
1.73 – 4.43). 
 
Table 10: Hazard ratios and 95% confidence intervals from Cox proportional hazard models including 
different stratifications for any CVD, ischaemic heart disease, acute myocardial infarction, 
arrhythmia, heart failure and stroke for France. 
Outcome 
HR for all men 
(95% CI) 
HR for men 
with *HCVDi 
(95% CI) 
HR for men 
without HCVDi 
(95% CI) 
HR for men < 
75 years 
(95% CI) 





(0.70 – 1.16) 
0.95 
(0.72 – 1.25) 
1.84 
(0.47 – 1.15) 
0.92 
(0.62 – 1.36) 
0.90 





(0.57 – 1.54) 
0.78 
(0.43 – 1.41) 
2.09 
(0.84 – 5.20) 
1.02 
(0.50 – 2.07) 
0.86 





(0.62 – 3.19) 
1.57 
(0.64 – 3.86) 
1.13 
(0.15 – 8.42) 
2.42 
(0.87 – 6.56) 
0.77 
(0.19 – 3.12) 
Arrhythmia 
1.02 
(0.60 – 1.74) 
1.30 




(0.35 – 2.53) 
1.06 




(0.85 – 2.52) 
1.30 
(0.76 – 2.22) 
2.39 
(0.74 – 7.74) 
2.58 
(1.19 – 5.57) 
1.04 
(0.55 – 1.95) 
Stroke 
0.78 
(0.39 – 1.57) 
0.64 
(0.26 – 1.55) 
1.25 
(0.40 – 3.98) 
0.57 
(0.14 – 2.30) 
0.89 
(0.40 – 2.01) 
* HR: hazard ratio; CI: confidence interval; HCVDi: history of CVD indicator; GnRH agonists (reference 
group). The (-) indicates where analyses were not conducted due to no number of events in GnRH 
agonists/antagonist group. 
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3.2.8.3.6 Canada 
10,201 (94.6%) men with PCa were on GnRH agonists and 584 (5.4%) men with PCa 
were on GnRH antagonists in Canada (Table 4). In Canada (Table 11), there was 
increased risk of developing all CVD outcomes regardless of HCVDi. For men with a 
HCVDi there was an increased risk of developing any CVD (HR = 1.04; 95% CI = 1.03 
– 1.04), IHD (HR = 1.03; 95% CI = 1.02 – 1.03), AMI CVD (HR = 1.05; 95% CI = 1.04 – 
1.06), arrhythmia (HR = 1.05; 95% CI = 1.04 – 1.05), HF (HR = 1.06; 95% CI = 1.05 – 
1.07) and stroke (HR = 1.04; 95% CI = 1.03 – 1.05) in men on GnRH antagonists with 
a HCVDi as compared to men on GnRH agonists. Moreover, there was increased risk 
of developing any CVD (HR = 1.39; 95% CI = 1.18 – 1.64), arrhythmia (HR = 1.43; 95% 
CI = 1.15 – 1.79), HF (HR = 1.48; 95% CI = 1.14 – 1.92) and stroke (HR = 1.46; 95% CI 
= 1.01 – 2.13) in men aged ≥ 75 years and on GnRH antagonists as compared to men 
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Table 11: Hazard ratios and 95% confidence intervals from Cox proportional hazard models including 
different stratifications for any CVD, ischaemic heart disease, acute myocardial infarction, 
arrhythmia, heart failure and stroke for Canada. 
Outcome 
HR for all men 
(95% CI) 
HR for men 
with *HCVDi 
(95% CI) 
HR for men 
without HCVDi 
(95% CI) 
HR for men < 
75 years 
(95% CI) 





(1.04 – 1.33) 
1.04 
(1.03 – 1.04) 
1.04 
(1.03 – 1.05) 
1.08 
(0.90 – 1.30) 
1.39 





(0.92 – 1.25) 
1.03 
(1.02 – 1.03) 
1.02 
(1.01 – 1.04) 
1.03 
(0.82 – 1.29) 
1.19 





(0.68 – 1.58) 
1.05 
(1.04 – 1.06) 
1.06 
(1.02 – 1.10) 
0.87 
(0.43 – 1.76) 
1.25 
(0.74 – 2.09) 
Arrhythmia 
1.27 
(1.07 – 1.51) 
1.05 
(1.04 – 1.05) 
1.06 
(1.04 – 1.08) 
1.21 
(0.91 – 1.60) 
1.43 




(1.08 – 1.63) 
1.06 
(1.05 – 1.07) 
1.06 
(1.03 – 1.09) 
1.26 
(0.90 – 1.78) 
1.48 
(1.14 – 1.92) 
Stroke 
1.37 
(1.03 – 1.82) 
1.04 
(1.03 – 1.05) 
1.05 
(1.02 – 1.07) 
1.34 
(0.86 – 2.09) 
1.46 
(1.01 – 2.13) 
* HR: hazard ratio; CI: confidence interval; HCVDi: history of CVD indicator; GnRH agonists (reference 
group). The (-) indicates where analyses were not conducted due to no number of events in GnRH 
agonists/antagonist group. 
 
Stage 2: Meta-analysis 
Table 12 shows pooled HRs from UK, Scotland, Belgium, the Netherlands, France 
and Canada, including stratifications to evaluate the use of GnRH agonists 
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Table 12: Hazard ratios from random-effects meta-analytical models including different stratification 
for any CVD, ischaemic heart disease, acute myocardial infarction, arrhythmia, heart failure and 
stroke for six included countries. 
Outcome 
HR for all men 
(95% CI) 
HR for men 
with *HCVDi 
(95% CI) 
HR for men 
without HCVDi 
(95% CI) 
HR for men < 
75 years 
(95% CI) 





(1.03 – 1.45) 
1.21 
(1.00 – 1.46) 
1.05 
(0.91 – 1.23) 
1.21 







(0.98 – 1.28) 
1.10 
(0.89 – 1.36) 
1.02 
(1.01 – 1.04) 
1.07*1 
(0.88 – 1.29) 
1.22*2 





(1.00 – 1.78) 
1.31*3 
(0.92 – 1.86) 
1.09*4 
(0.89 – 1.33) 
1.63*3 
(0.91 – 2.94) 
1.28*3 
(0.88 – 1.85) 
Arrhythmia 
1.39 
(1.13 – 1.72) 
1.48 
(1.03 – 2.13) 
2.19*5 
(0.58 – 8.26) 
1.32 
(1.04 – 1.67) 
1.43*2 




(1.12 – 1.58) 
1.06*2 
(1.05 – 1.07) 
1.21*6 
(0.77 – 1.89) 
1.39*3 
(1.01 – 1.91) 
1.39 
(1.12 – 1.73) 
Stroke 
1.17 
(0.93 – 1.47) 
1.04*3 
(1.03 – 1.05) 
1.05*2 
(1.03 – 1.08) 
1.11*3 
(0.65 – 1.88) 
1.22 
(0.91 – 1.62) 
* HR: hazard ratio; CI: confidence interval; HCVDi: history of CVD indicator; GnRH agonists (reference 
group). History of CVD indicator was defined as any of the following 12 months prior to entering the 
cohort: any CVD event, hypertension, dyslipidaemia or diabetes. 
*1 UK was excluded due to low number of events for country-specific analysis. 
*2 Netherlands was excluded due to low number of events for country-specific analysis. 
*3 UK and the Netherlands were excluded due to low number of events for country-specific analysis. 
*4 UK, Belgium and the Netherlands were excluded due to low number of events for country-specific 
analysis. 
*5 Scotland, the Netherlands and France were excluded due to low number of events for country-
specific analysis. 
*6 UK, Scotland and the Netherlands were excluded due to low number of events for country-specific 
analysis. 
 
Men with PCa on GnRH antagonists had an increased risk of developing any CVD 
(HR = 1.22; 95% CI = 1.03-1.45), arrhythmia (HR = 1.39; 95% CI = 1.13-1.72) and HF 
(HR = 1.33; 95% CI = 1.12-1.58) compared to men on GnRH agonists. Stratification 
by HCVDi also showed an increased risk of developing arrhythmia (HR = 1.48; 95% CI 
= 1.03-2.13; Figure 13 (a)), HF (HR = 1.06; 95% CI = 1.05-1.07; Figure 13 (b)) and 
stroke (HR = 1.04; 95% CI = 1.03-1.05; Figure 13 (c)) for men on GnRH antagonists 
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with a HCVDi. For men who were on GnRH antagonists without a HCVDi, there was 
an increased risk of developing IHD (HR = 1.02; 95% CI = 1.01-1.04) and stroke (HR = 
1.05; 95% CI = 1.03-1.08) compared to those on GnRH agonists. 
Stratification by age showed an increased risk of developing any CVD (HR = 1.24; 
95% CI = 1.04-1.48; Figure 14 (a)), IHD (HR = 1.22; 95% CI = 1.03-1.45; Figure 14 (b)), 
arrhythmia (HR = 1.43; 95% CI = 1.19-1.73; Figure 14 (c)) and HF (HR = 1.39; 95% CI = 
1.12-1.73; Figure 14 (d)) in those aged ≥ 75 years. 
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Figure 13 (a): Pooled results from meta-analysis for PCa men with a HCVDi developing arrhythmia including UK, Scotland, Belgium, the 
Netherlands, France and Canada.  
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Figure 13 (b): Pooled results from meta-analysis for PCa men with a HCVDi developing heart failure including UK, Scotland, Belgium, 
France and Canada.  
Page 102 of 281 
 
 
Figure 13 (c): Pooled results from meta-analysis for PCa men with a HCVDi developing stroke including Scotland, Belgium, France and 
Canada. 
Page 103 of 281 
 
Figure 14 (a): Pooled results from meta-analysis for PCa men aged ≥ 75 years developing any CVD including UK, Scotland, Belgium, the 
Netherlands, France and Canada.  





Figure 14 (b): Pooled results from meta-analysis for PCa men aged ≥ 75 years developing ischaemic heart disease including UK, Scotland, Belgium, 
the Netherlands, France and Canada. 
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Figure 14 (c): Pooled results from meta-analysis for PCa men aged ≥ 75 years developing arrhythmia including UK, Scotland, Belgium, the 
Netherlands, France and Canada. 






Figure 14 (d): Pooled results from meta-analysis for PCa men aged ≥ 75 years developing heart failure including UK, Scotland, Belgium, 
the Netherlands, France and Canada. 
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3.2.8.3.7 Sensitivity analyses 
Sensitivity analyses excluding UK showed some differences (Table 13) in the results 
as compared to main analysis (Table 12). HR for all men remained similar in the 
sensitivity analysis excluding UK as compared to the main analysis. For men on 
GnRH antagonists, there was still an increased risk of developing any CVD (HR = 
1.21; 95% CI = 1.01-1.43), arrhythmia (HR = 1.32; 95% CI = 1.14-1.53), HF (HR = 1.34; 
95% CI = 1.12-1.59) and stroke (HR = 1.16; 95% CI = 0.91-1.49) as compared to men 
on GnRH agonists after excluding UK. For men on GnRH antagonists with a HCVDi, 
there was an increased risk of developing HF (HR = 1.06; 95% CI = 1.05-1.07) and 
stroke (HR = 1.04; 95% CI = 1.03-1.05) as compared to men on GnRH agonists, 
similar to the results in the main analysis. There was also an increased risk of 
developing IHD (HR = 1.02; 95% CI = 1.01-1.04) and stroke (HR = 1.05; 95% CI = 1.03-
1.08) in men on GnRH antagonists without a HCVDi as compared to men on GnRH 
agonists, similar to the results in the main analysis. However, exclusion of UK also 
showed an increased risk of developing arrhythmia (HR = 1.06; 95% CI = 1.04-1.08) 
in men on GnRH antagonists with a HCVDi as compared to men on GnRH agonists.  
In men aged < 75 years and on GnRH antagonists, there was an increased risk of 
developing arrhythmia (HR = 1.30; 95% CI = 1.01-1.65) as compared to men on 
GnRH agonists. These results were similar to the results in the main analysis. Finally, 
in men aged ≥ 75 years and on GnRH antagonists, there was an increased risk of 
developing any CVD (HR = 1.23; 95% CI = 1.01-1.48), IHD (HR = 1.22; 95% CI = 1.03-
1.46), arrhythmia (HR = 1.42; 95% CI = 1.17-1.72) and HF (HR = 1.41; 95% CI = 1.14-
1.76) as compared to men on GnRH agonists. These results were similar to the 
results in the main analysis.  
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Table 13: Hazard ratios from sensitivity analyses using random-effects meta-analytical model 
including different stratifications any CVD, ischaemic heart disease, acute myocardial infarction, 
arrhythmia, heart failure and stroke for Scotland, Belgium, the Netherlands, France and Canada. 
Outcome 
HR for all 
men 
(95% CI) 
HR for men 
with *HCVDi 
(95% CI) 
HR for men 
without HCVDi 
(95% CI) 
HR for men < 
75 years 
(95% CI) 
HR for men ≥ 
75 years 
(95% CI) 
Any CVD 1.21 
(1.01 – 1.43) 
1.20  
(0.99 – 1.46) 
1.04 
(1.03 – 1.05) 
1.21 
(0.98 – 1.50) 
1.23 





(0.97 – 1.34) 
1.11*1 
(0.90 – 1.37) 
1.02 
(1.01 – 1.04) 
1.07 
(0.88 – 1.29) 
1.22*1 





(1.00 – 1.78) 
1.31*1 
(0.92 – 1.86) 
1.09*2 
(0.89 – 1.33) 
1.63*1 
(0.91 – 2.94) 
1.28*1 
(0.88 – 1.85) 
Arrhythmia 1.32 
(1.14 – 1.53) 
1.42 
(0.99 – 2.04) 
1.06*3 
(1.04 – 1.08) 
1.30 
(1.02 – 1.65) 
1.42*1  




(1.12 – 1.59) 
1.06*1 
(1.05 – 1.07) 
1.21*4 
(0.77 – 1.89) 
1.39*1 
(1.01 – 1.91) 
1.41 
(1.14 – 1.76) 
Stroke 1.16 
(0.91 – 1.49) 
1.04*1 
(1.03 – 1.05) 
1.05*1 
(1.03 – 1.08) 
1.11*1 
(0.65 – 1.88) 
1.24 
(0.93 – 1.65) 
* HR: hazard ratio; CI: confidence interval; HCVDi: history of CVD indicator; GnRH agonists (reference 
group). History of CVD indicator was defined as any of the following 12 months prior to entering the 
cohort: any CVD event, hypertension, dyslipidaemia or diabetes 
*1 Netherlands was excluded due to low number of events for country-specific analysis. 
*2 Belgium and the Netherlands were excluded due to low number of events for country-specific 
analysis. 
*3 Scotland, the Netherlands and France were excluded due to low number of events for country-
specific analysis. 
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3.3 DISCUSSION 
This is the first study to combine real world data from the UK, Scotland, Belgium, 
Netherlands, France and Canada to compare the risk of CVD following GnRH 
agonists and GnRH antagonists in men with PCa. This study shows contradictory 
results to what has been previously reported in meta-analyses of RCTs and 
observational studies. The modified ROBINS-I tool emphasised three main forms of 
biases for the current study design: misclassification of study variables, channeling 
or indication and unmeasured confounding. Pooled results from the six countries 
showed that men with PCa given GnRH antagonists with history of CVD event or a 
CVD indication had a 48% higher chance of developing arrhythmia, 6% higher 
chance of developing HF and 4% higher chance of developing stroke compared to 
men on GnRH agonists. Age stratification showed that men on GnRH antagonists 
aged ≥ 75 years had a 24% higher chance of developing any CVD and 39% higher 
chance of developing HF compared to men on GnRH agonists. 
The methodological protocol for this study has been published already (122). The 
purpose of the methodological protocol was to reduce heterogeneity in the 
definitions for the study variables extracted from the six databases. In the protocol, 
a modified version of the ROBINS-I tool was used to assess the study design which 
emphasised three main forms of biases: misclassification of study variables, 
channeling or indication and unmeasured confounding. By following a standard 
protocol (122) to extract study variables from the different databases of the six 
countries, misclassification bias was avoided, to a certain extent.  
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Channeling bias is a term used to describe indication bias in pharmacoepidemiology 
and is one of the most common types of bias found in this setting. Channeling bias 
occurs when a physician prescribes specific drugs to patients with certain 
characteristics such as disease severity or age (158). Channeling bias was 
highlighted by the ROBINS-I tool in the study design phase of this study (Table 2).  
This means that GnRH antagonists may have been channelled to men with a prior 
CVD event or risk of CVD based on previous evidence (32). Although stratifying 
meta-analyses (stage 2) by HCVDi attempted to resolve channeling bias, it was 
impossible to fully avoid channeling bias in this study because no information for 
physician preferences for medications was available in the six countries.  
The channeling bias in this observational setting may be addressed by the 
PRONOUNCE trial which is currently recruiting to compare risk of fatal or non-fatal 
CVD in 900 men with PCa receiving degarelix or leuprolide (GnRH agonist) as 
primary treatment over a year (137). However, the follow-up period for the 
PRONOUNCE trial is limited to a year, whereas the average median follow-up time 
(for six included countries) for this real world study is more than a year, allowing for 
the detection of CVD events occurring 12 months after treatment initiation.   
The ROBINS-I tool highlighted some other evident and unavoidable biases 
associated with observational data such as uneven randomization distribution and 
unmeasured confounding (159). Unmeasured confounding occurs when certain 
factors may not be considered in analyses due to unavailability of data. For 
example, lifestyle factors are often not well-recorded in healthcare databases 
leading to an unmeasured confounding. Although the UK had data available on 
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some lifestyle (BMI, smoking status) and socio-economic (Townsend scores) factors, 
these variables were not added in the analytical models due to high percentage of 
missing data. Therefore, unmeasured confounding should be taken into 
consideration while interpreting the results of this study.  
Preliminary findings from this study which included four countries (UK, Belgium, the 
Netherlands and France) showed a decreased risk of developing any CVD in men on 
GnRH antagonists with a HCVDi compared to GnRH agonists (presented at the 
European Association of Urology (EAU), 2018, section 9.3.1.1, Appendix) (160).  The 
inconsistency in the preliminary results and the final results can be explained by the 
difference in methods used and the addition of Scotland and Canada. Whereas 
proportions of men developing a CVD event in both exposure groups were 
investigated (without including age or follow-up period in the models) in the EAU 
report (160), the current methodology pooled country-specific HRs with adjustment 
to age and follow-up period, thus accounting for the heterogeneity in study 
population and follow-up periods across the six countries.  
Moreover, the potential differences in prescription and delivery of GnRH 
antagonists between UK, Scotland, Belgium, the Netherlands, France and Canada 
may have also influenced the results of the study.  In the UK, GnRH antagonists 
were prescribed to men with advanced hormone-dependent PCa until 2016 (NICE 
CG175) (161-163). As a NICE review of GnRH antagonists was still in progress during 
the study period (2010-2016), only a few men were prescribed the new and 
expensive drug in the UK, explaining the low number of men on GnRH antagonists 
in the UK.  
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Similar non-specific guidelines on the definition of advanced stage and risk factors 
were followed by the other countries in this study (78, 164, 165). This may have left 
room for physicians to decide to prescribe GnRH antagonists to men with PCa based 
on PCa severity, risk factors for CVD and other comorbidities and previous evidence 
(32), thus introducing possible heterogeneity in prescription patterns of GnRH 
antagonists across the six countries. Stage of PCa may have also driven treatment 
decisions for men on the GnRH analogues thus influencing the results of this study. 
Since stage of PCa was not available across the six countries, it was not included in 
the analyses. In addition to these factors, adherence patterns to treatment 
regimens especially in men with a prior history of CVD may have also affected the 
results of this study because non-adherence to CVD medications is a leading risk 
factor for poor outcomes (166).   
Interpretation of results for some subtypes of CVD is limited due to the data sources 
that they were obtained from. For example, AMI is usually recorded in an acute 
setting (such as a hospital) due to the acute nature of the event (167). Whereas 
Scotland, Belgium, the Netherlands, France and Canada used hospital settings to 
extract AMI, the UK had no AMI events in the GnRH antagonists’ group which may 
be attributed to THIN’s origin from primary healthcare settings. Although sensitivity 
analysis excluding UK showed no significant findings (Table 13), further assessment 
of dedicated hospital registries may better inform clinicians on the risk of AMI in 
PCa men on GnRH analogues.  
One strength of this large prospective study cohort was the use of different types of 
databases (primary healthcare, secondary healthcare and claims databases) which 
ensured the inclusion of rare, adverse events that may not have been identified in a 
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RCT. However, it was difficult to fully homogenise study variables. Although a 
standard protocol eliminated some possible heterogeneity, the use of varied data 
sources from the six countries made it difficult to fully homogenise definitions for 
the study variables. For example, exclusive derivation of data from primary health 
care settings made the UK THIN database the most distinctive (i.e. use of readcodes 
instead of ICD-codes) of the six databases.  
The potential for real world evidence is very large in the healthcare setting. 
Reconfiguration of data from different healthcare settings with regulatory 
supervision is required for real world data to achieve its full potential (168). 
Addressing heterogeneity across different institutional data is an issue at the centre 
of many Innovative Medicines Initiative 2 (IMI)’s ongoing collaborative projects such 
as the GetReal Initiative (11) and Prostate cancer dIagnOsis and treatmeNt 
Enhancement through the power of big data in EuRope (PIONEER) (169), which are 
part of the Big Data for Better Outcomes (BD4BO) (170). The collective aims of 
these projects are to combine and analyse ‘big data’ from databases across 
different institutions and countries into a single data platform using novel data 
analytical techniques. This would ensure the use of big data for research focused on 
disease-related and health-economic outcomes across different healthcare systems 
in a move towards standardising healthcare pathways across Europe (11, 169, 170). 
As a result, the current study was useful in understanding the challenges involved in 
the process of obtaining access to different data sources in different countries, 
homogenising study variables and developing methodologies that are most 
appropriate for the data available in the real world setting.  




This large-scale real world study suggests that GnRH antagonists are also associated 
with an increased risk of CVD. However, results from the PRONOUNCE RCT may 
address the potential of indication bias in this observational setting even though the 
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4. CHAPTER IV – ADHERENCE TO GNRH AGONISTS IN 
PROSTATE CANCER IN SWEDEN 
Chapter IV introduces the concept of medication adherence and investigates 
patterns of adherence to GnRH agonists in men with PCa in Sweden. Adherence 
means the resolve a patient requires to follow their course of therapy and 
adherence to a treatment regimen is the primary determinant of the success of that 
treatment. The loss of adherence to medication is a global concern that has medical 
and economic consequences which makes it an important area of research, 
particularly to improve clinical outcomes of a treatment (107-109). 
 
4.1 BACKGROUND 
ADT is the standard form of treatment for men with advanced PCa. Considering that 
a large proportion of men diagnosed with PCa may remain on ADT for the rest of 
their PCa treatment, there is a need to understand factors related to adherence to 
ADT (6). No study has fully investigated patterns of adherence to GnRH agonists, the 
most common ADT in men with PCa. We assessed this using data from PCBaSeTraject 
version 4.0 (171). 
Previous studies in breast cancer have reported side-effects to be a major cause for 
non-adherence to ADT. 46% women who underwent hormonal therapy for breast 
cancer withdrew from their treatment due to unwanted side-effects associated with 
the hormonal therapy (172). Side-effects associated with prolonged use of GnRH 
agonists such as; fatigue, hot flushes, low bone density (leading to increased risk of 
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fractures) and even psychological issues may also be a factor contributing to non-
adherence for men on hormone therapy for PCa (114, 115).  
Intermittent GnRH agonists may be given to some men with PCa to minimise the 
side-effects attributed to the medication while maintaining anti-tumour efficacy 
(173, 174). Active treatment periods during an intermittent regimen may be 
separated by periods without any form of treatment. These active treatment 
periods by GnRH agonists may last for 6-9 months or until a PSA nadir of < 4 g/ml 
has been reached (175).  
Although one study has highlighted that there is an issue of non-adherence to GnRH 
agonists in men with PCa (176), no studies in the literature have fully investigated 
patterns of adherence to GnRH agonists in PCa. Therefore, the aim of this study was 
to identify patterns influencing adherence to GnRH agonists in men with PCa over 3 
years in PCBaSeTraject. 
 
4.2  METHODS 
 Study population 
The National Quality Register on Prostate Cancer of Sweden (NPCR) is linked to 
other healthcare registries and demographic databases by PCBaSe (177, 178). 
Healthcare registries such as the Swedish Cancer Registry, the Cause of Death 
Register, the Prescribed Drug Register and the National Patient Register are linked 
to NPCR by PCBaSe using the unique Swedish Personal Identity Number (171). NPCR 
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includes information on tumour stage, Gleason grading, serum level PSA and 
primary treatment for PCa (177). 
PCBaSe has undergone a number of extensions with more cases, longer follow-up, 
family history of PCa and a selection of men free of PCa at the time of sampling 
(PCBaSe 2.0), with the latest version (PCBaSeTraject, version 4.0) including men 
diagnosed with between 1998-2016 (177, 178). This study included men with PCa 
who initiated GnRH agonists between 2006-2013. 
Recommendations for PCa treatment during this study period were set by regional 
clinical care guidelines based on national recommendations from the National 
Board of Health and Welfare in Sweden. The guidelines stated that once castration 
by ADT is initiated, it should not be discontinued (119).   
 Exposures 
Men with PCa who started GnRH agonists between 2006-2013 were included in the 
study. Men with PCa on GnRH agonists were divided into two treatment groups: 
primary and secondary. Primary GnRH agonists was defined as the first form of PCa 
treatment. Secondary GnRH agonists was defined as men who received other forms 
of PCa treatments prior to GnRH agonists. Men entered the study 45 days (run-in 
period) following initiation of GnRH agonists and exited at 3 years (and 6 years for 
sensitivity analysis). 45 days was used as a run-in period to avoid overestimating 
adherence 90 days’ injection interval was the most commonly prescribed GnRH 
agonists (11.25 mg) in PCBaSeTraject. Only men who had at least a 3-year follow-up 
were considered because men with shorter follow-up may show better adherence 
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to GnRH agonists, thus overestimating adherence in this group of men. A detailed 
description of the inclusion and exclusion criteria can be found in Figure 15. 
 
Figure 15: Consort diagram showing the inclusion and exclusion criteria used to select men with PCa 
on GnRH agonists from PCBaSe. 
 
 Outcomes 
A binary outcome of adherent versus non-adherent was quantified by MPR (179), 
with a MPR of ≥ 80% defined as adherent and < 80% as non-adherent. MPR was 





Days of prescribed/dispensed supply  
          Number of days in the study period 
X   100 % 
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 Other study variables 
In addition to the exposures and the outcomes, age, injection intervals, risk group at 
diagnosis, change in Charlson Comorbidity Index (CCI) since diagnosis, year of GnRH 
agonists’ initiation, prior PCa treatment and civil status were extracted from PCBaSe 
(Table 14). 
Table 14: Detailed definitions for other study variables extracted from PCBaSeTraject for this study. 
Study Variables Data Extraction in PCBaSeTraject 
Age Age was calculated using date of births for men on GnRH 
agonists. The age categories used were:  ≤ 65 years, 66-74 
years, 75-84 years and ≥ 85 years.  
Injection 
Intervals 
Injection intervals was defined as 90 days, 180 days, 365 
days and mixed. The dosages were defined by the defined 
daily dose (DDD) number in PCBaSeTraject. The DDD is 
defined as the average maintenance dose per day assumed 
for a drug for its indicated use (180). For DDD < 55, the 
injection interval was defined as 30 days, DDD of 55-99 was 
defined as 90 days, 100-199 was defined as 180 days and 
DDD ≥ 200 was defined as 365 days. Low number of men in 
the 30 days’ injection interval group (primary GnRH 
agonists = 23; secondary GnRH agonists = 19) resulted in 
merging the 30 days’ injection interval group with the 90 
days’ injection interval group. The mixed group included 
men who started GnRH agonists therapy at a ‘short-acting 
depot’ and proceeded to a ‘long-acting depot’ over the 
course of three years. 
Risk Group at 
Diagnosis 
Risk group at diagnosis in PCBaSeTraject was defined as low 
risk, medium or intermediate risk, high risk, regionally 





Charlson Comorbidity Index (CCI) was first developed in the 
1980’s as a weighted index accounting for the number and 
seriousness of comorbidities  and classifying them to 
estimate risk of death from these comorbidities in 
longitudinal studies (181). Change in CCI for this study was 
calculated as a difference between CCI at diagnosis and CCI 
at 3 years following GnRH agonists. It was defined as no 
change, change by 1, change by 2, change by 3 and change 
by ≥ 4. 
Year of GnRH 
agonists’ 
Initiation 
Year of GnRH agonists’ initiation was defined from date of 
first prescription of GnRH agonists for men with PCa in 
PCBaSeTraject. 




Prior PCa treatment was defined as those who had received 
PCa treatments such as deferred treatment, anti-
androgens, radical prostatectomy only (i.e. without 
radiotherapy), radiotherapy < 1 year after radical 
prostatectomy and radiotherapy ≥ 1 years after radical 




Prior PCa treatment was used to differentiate between men 
who received GnRH agonists as primary for their PCa 
treatment and those who had received GnRH agonists as 
secondary treatment. Secondary treatment also included 
men who had received more than one form of PCa 
treatment prior to GnRH agonists’ initiation. All analyses 
were conducted separately for primary and secondary 
GnRH agonists. 
Civil Status Civil status was available for all men included in the study 
and was defined as those who were single and married at 
study entry. 
* ATC: Anatomical Therapeutic Chemical; DDD: Defined Daily Dose; CCI: Charlson Comorbidity Index. 
 
4.3  ANALYSIS 
 Main analysis 
Multivariable logistic regression analyses were conducted separately for men with 
PCa receiving primary and secondary GnRH agonists with the odds in the regression 
models expressing the odds of being adherent. A MPR of ≥ 80% was defined as 
adherent and < 80% defined as non-adherent. Models for primary GnRH agonists 
included: age, injection intervals, risk group at diagnosis, change in CCI since 
diagnosis, year of GnRH agonists’ initiation and civil status. For secondary GnRH 
agonists the following variables were included: age, change in CCI since diagnosis, 
prior PCa treatment and civil status. Adherence was defined over 3 years following 
GnRH agonists.  
The distinction between flare protection and CAB (defined in chapter III) was 
difficult to make in PCBaSeTraject because anti-androgens were only recorded 
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intermittently in the database and no precise definition could be made. Therefore, 
flare-protection and CAB were combined as anti-androgens given to men with PCa 
as prior PCa treatment.  
 Sensitivity analyses 
Adherence over a longer follow-up (6 years) was also calculated for men with PCa 
who were on GnRH agonists for 6 years in PCBaSeTraject, thus including a higher 
proportion of long-time survivors on GnRH agonists. Multivariable logistic 
regression was conducted with a MPR of ≥ 80% being adherent and < 80% being 
non-adherent.  
The chance of non-adherent men with a MPR of < 80% being on an intermittent 
regimen for GnRH agonists was explored in a sensitivity analysis. The reason for low 
MPR observed in these men may be due to an intermittent treatment regimen 
(common in men treated with GnRH agonists) or their decision to quit the 
treatment for various reasons. An intermittent treatment regimen for GnRH 
agonists was determined as a gap of < 9 months between the last and second last 
prescriptions in PCBaSeTraject (174).  Men on GnRH agonists with ≥ 9 months’ gap 
were defined as having ended their treatment and classed as non-adherent. Once 
the outcomes (adherent vs non-adherent) were reclassified after considering the 
intermittent treatment regimen, the logistic regression models were repeated for 
primary and secondary GnRH agonists, with a MPR of ≥ 80% being adherent and < 
80% being non-adherent. 
Evidence suggests that testosterone levels may remain suppressed for a longer 
period of time after treatment with GnRH agonists than previously thought (182). 
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To account for this evidence, a sensitivity analysis was conducted by running the 
logistic regression models again using redefined outcomes. The redefined outcomes 
used a MPR of ≥ 50% for being adherent and < 50% for being non-adherent.  
 
4.4  RESULTS 
 Main analysis 
8,105 men with PCa starting on primary GnRH agonists and 4,738 men with PCa 
starting on secondary GnRH agonists between 2006 and 2013 from PCBaSe were 
determined to be eligible for the study (Figure 15). 
Table 15 shows patient characteristics for the study after 3 years on GnRH agonists. 
79% were adherent on primary GnRH agonists after 3 years. 71% were adherent on 
secondary treatment after 3 years. The mean age was similar for primary (adherent 
= 77, SD = 7.8; non-adherent = 76, SD = 8.4) and secondary (adherent = 76, SD = 7.8; 
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Primary GnRH agonists Secondary GnRH agonists 
Adherent (%) Non-adherent (%) Adherent (%) Non-adherent (%) 
n 6432 (79.4) 1673 (20.6) 3376 (71.3) 1362 (28.8) 
     
Age (Years)     
Mean 76.5 75.9 76.0 75.1 
SD 7.8 8.4 7.8 8.0 
     
Age Groups (Years)     
≤ 65 612 (9.5) 190 (11.4) 348 (10.3) 185 (13.6) 
66-74 1719 (26.7) 465 (27.8) 999 (29.6) 419 (30.8) 
75-84 3169 (49.3) 762 (45.6) 1580 (46.8) 599 (44.0) 
≥ 85 932 (14.5) 256 (15.3) 449 (13.3) 159 (11.7) 
     
*Injection Interval 
(Days) 
    
90 4519 (70.3) 1404 (83.9) 2388 (70.7) 1135 (83.3) 
180 374 (5.8) 46 (2.8) 203 (6.0) 33 (2.4) 
365 (Implant) 648 (10.1) 66 (4.0) 347 (10.3) 62 (4.6) 
Mixed 891 (13.9) 149 (8.9) 438 (13.0) 116 (8.5) 
Missing 0 8 (0.5) 0 16 (1.2) 
     
Risk Groups at 
Diagnosis 
    
Low Risk 98 (1.5) 65 (3.9) 437 (12.9) 244 (17.9) 
Medium Risk 695 (10.8) 226 (13.5) 1003 (29.7) 404 (29.7) 
High Risk 2305 (35.8) 638 (38.1) 1332 (39.5) 503 (36.9) 
Regional Metastasis 1064 (16.5) 273 (16.3) 402 (11.9) 135 (9.9) 
Distant Metastasis 2235 (34.8) 457 (27.3) 164 (4.9) 56 (4.1) 
Missing 35 (0.5) 14 (0.8) 39 (1.1) 20 (1.5) 
     
Prior PCa Treatment     
*Deferred Treatment N/A N/A 1509 (44.7) 641 (47.1) 
Anti-androgens N/A N/A 649 (19.2) 198 (14.5) 
Radical Prostatectomy 
only 
N/A N/A 269 (8.0) 148 (10.9) 
Radiotherapy N/A N/A 719 (21.3) 279 (20.5) 
Radiotherapy after 
Radical Prostatectomy 
    
< 1 year N/A N/A 109 (3.2) 54 (4.0) 
≥ 1 year N/A N/A 121 (3.6) 42 (3.1) 
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Change in *CCI since 
CCI at diagnosis 
    
No change 4636 (72.1) 1244 (74.4) 2485 (73.6) 1014 (74.5) 
Change by 1 920 (14.3) 223 (13.3) 439 (13.0) 170 (12.5) 
Change by 2 533 (8.3) 132 (7.9) 288 (8.5) 115 (8.4) 
Change by 3 215 (3.3) 47 (2.8) 102 (3.0) 35 (2.6) 
Change by ≥ 4 128 (2.0) 27 (1.6) 62 (1.8) 28 (2.1) 
     
Civil Status     
Single 2374 (36.9) 649 (38.8) 1061 (31.4) 472 (34.7) 
Married 4058 (63.1) 1023 (61.2) 2315 (68.6) 890 (65.4) 
Missing 0 1 (0.1) 0 0 
     
Year of GnRH 
agonists’ Initiation 
    
2006-2007 2026 (31.5) 558 (33.4) 842 (24.9) 344 (25.3) 
2008-2009 1747 (27.2) 471 (28.2) 869 (25.7) 336 (24.7) 
2010-2011 1474 (22.9) 362 (21.6) 894 (26.5) 328 (24.1) 
2012-2013 1185 (18.4) 282 (16.9) 771 (22.8) 354 (26.0) 
* Deferred treatment includes men who underwent active surveillance and watchful waiting; N/A: 
Not applicable; CCI: Charlson Comorbidity Index; Injection interval at 90 days included 7 adherents 
(primary = 6, secondary = 1) and 35 non-adherent (primary = 17, secondary = 18) PCa men given 30 
days dosages due to low number in the 30 days group. 
 
 
4.4.1.1 Primary GnRH agonists 
Table 16 outlines the results of a logistic regression on primary GnRH agonists. 
Increased adherence was observed in the age-groups 66-74 (OR = 1.27; 95% CI = 
1.04-1.54) and 75-84 (OR = 1.49; 95% CI = 1.23-1.81) compared to group ≤ 65 years. 
Men with PCa on the 365 days’ hydrogel implant were three times more likely to be 
adherent than men on 90 days’ injection interval (OR = 3.29; 95% CI = 2.52-4.30). 
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Table 16: Logistic regression analyses showing odds ratios (OR) and 95% confidence intervals (CI) for 





OR 95% CI OR 95% CI 
Age Groups (Years)     
≤ 65 1.00 Ref. 1.00 Ref. 
66-74 1.15 0.95-1.39 1.27 1.04-1.54 
75-84 1.29 1.08-1.55 1.49 1.23-1.81 
≥ 85 1.13 0.91-1.40 1.24 0.99-1.56 
     
*Injection interval (Days)     
90 1.00 Ref. 1.00 Ref. 
180 2.53 1.85-3.45 2.61 1.89-3.59 
365 (Implant) 3.05 2.35-3.96 3.29 2.52-4.30 
Mixed 1.86 1.55-2.23 1.93 1.60-2.32 
     
Risk Groups at Diagnosis     
Low Risk 1.00 Ref. 1.00 Ref. 
Medium Risk 2.04 1.44-2.89 1.88 1.32-2.69 
High Risk 2.40 1.73-3.32 2.34 1.68-3.26 
Regional Metastasis 2.59 1.84-3.63 2.69 1.90-3.82 
Distant Metastasis 3.24 2.33-4.51 3.56 2.54-5.00 
     
Change in *CCI since CCI at 
diagnosis 
    
No change 1.00 Ref. 1.00 Ref. 
Change by 1 1.11 0.94-1.30 1.12 0.95-1.33 
Change by 2 1.08 0.89-1.32 1.12 0.91-1.38 
Change by 3 1.23 0.89-1.69 1.19 0.86-1.66 
Change by ≥ 4 1.27 0.84-1.94 1.21 0.79-1.86 
     
Civil Status     
Single 1.00 Ref. 1.00 Ref. 
Married 1.08 0.97-1.21 1.08 0.97-1.21 
     
Year of GnRH agonists’ 
initiation 
    
2006-2007 1.00 Ref. 1.00 Ref. 
2008-2009 1.02 0.89-1.17 0.86 0.75-1.00 
2010-2011 1.12 0.97-1.30 0.88 0.75-1.03 
2012-2013 1.16 0.99-1.36 0.85 0.72-1.01 
* OR: Odds ratio; CI: Confidence interval; Non-adherent (reference group); CCI: Charlson 
Comorbidity Index; Injection interval at 90 days included 7 adherents (primary = 6, secondary = 1) 
and 35 non-adherent (primary = 17, secondary = 18) PCa men given 30 days’ dosages due to low 
number in the 30 days’ group. 
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4.4.1.2 Secondary GnRH agonists 
Table 17 shows the results of a logistic regression for secondary GnRH agonists. 
Increased age was associated with increased adherence in men who were given 
GnRH agonists as a secondary treatment for their PCa with the most adherent in 
men aged ≥ 85 years (OR = 1.65; 95% CI = 1.23-2.22). An increased adherence was 
observed in men who were given anti-androgens (OR = 1.50; 95% CI = 1.23-1.82) 
and radiotherapy (OR = 1.35; 95% CI =1.11-1.64) as primary treatment prior to 
GnRH agonists’ initiation compared to deferred treatment. Men who were given 
radiotherapy ≥ 1 year after undergoing radical prostatectomy were also more likely 
to be adherent to secondary GnRH agonists compared to no radiotherapy (OR = 
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Table 17: Univariate and multivariable logistic regression analyses showing odds ratios (OR) and 95% 





OR 95% CI OR 95% CI 
Age Groups (Years)     
≤ 65 1.00 Ref. 1.00 Ref. 
66-74 1.27 1.03-1.57 1.27 1.02-1.58 
75-84 1.40 1.15-1.72 1.46 1.16-1.84 
≥ 85 1.50 1.16-1.94 1.65 1.23-2.22 
     
Injection Interval (Days)     
90 1.00 Ref. 1.00 Ref. 
80 2.92 2.01-4.25 2.83 1.95-4.13 
365 (Implant) 2.66 2.01-3.52 2.65 2.00-3.51 
Mixed 1.79 1.45-2.23 1.82 1.46-2.26 
     
Change in *CCI since CCI at 
diagnosis 
    
No change 1.00 Ref. 1.00 Ref. 
Change by 1 1.05 0.87-1.28 1.05 0.86-1.27 
Change by 2 1.02 0.81-1.28 0.99 0.78-1.25 
Change by 3 1.19 0.80-1.76 1.15 0.77-1.71 
Change by ≥ 4 0.90 0.57-1.42 0.84 0.53-1.34 
     
Civil Status     
Single 1.00 Ref. 1.00 Ref. 
Married 1.16 1.01-1.32 1.15 1.00-1.32 
     
Prior PCa Treatment     
*Deferred Treatment 1.00 Ref. 1.00 Ref. 
Anti-androgens 1.39 1.16-1.67 1.50 1.23-1.82 
Radical Prostatectomy only 0.77 0.62-0.96 0.91 0.71-1.67 
Radiotherapy 1.09 0.93-1.29 1.35 1.11-1.64 
Radiotherapy < 1 year after 
Radical Prostatectomy 
0.86 0.61-1.20 1.17 0.81-1.71 
Radiotherapy ≥ 1 year after 
Radical Prostatectomy 
1.22 0.85-1.76 1.54 1.04-2.28 
* OR: Odds ratio; CI: Confidence interval; Non-adherent (reference group); Deferred treatment 
includes men who underwent active surveillance and watchful waiting; CCI: Charlson Comorbidity 
Index; Injection interval at 90 days included 7 adherent (primary = 6, secondary = 1) and 35 non-
adherent (primary = 17, secondary = 18) PCa men given 30 days dosages due to low number in the 
30 days group. 
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 Sensitivity analyses 
4.4.2.1 Longer Study Period 
After 6 years on GnRH agonists, 3,611 men with PCa were on primary treatment 
and 1,967 were on secondary treatment (Table 18).  
 





Primary GnRH Agonists Secondary GnRH agonists 
Adherent (%) Non-adherent (%) Adherent (%) Non-adherent (%) 
n 2636 (73.0) 975 (27.0) 1232 (62.6) 735 (37.4) 
     
Age (Years)     
Mean 75.5 74.8 75.2 74.0 
SD 7.2 7.9 7.3 7.7 
     
Age Groups 
(Years) 
    
≤ 65 254 (9.6) 132 (13.5) 139 (11.3) 115 (15.7) 
66-74 797 (30.2) 296 (30.4) 389 (31.6) 245 (33.3) 
75-84 1342 (50.9) 444 (45.5) 598 (48.5) 325 (44.2) 
≥ 85 243 (9.2) 103 (10.6) 106 (8.6) 50 (6.8) 
     
*Injection 
Interval (Days) 
    
90 1752 (66.5) 797 (81.7) 832 (67.5) 606 (82.5) 
180 88 (3.3) 18 (1.9) 50 (4.1) 8 (1.1) 
365 (Implant) 233 (8.8) 38 (3.9) 92 (7.5) 38 (5.2) 
Mixed 563 (21.4) 118 (12.1) 258 (20.9) 77 (10.5) 
Missing 0 4 (0.4) 0 6 (0.8) 
     
Risk Groups at 
Diagnosis 
    
Low Risk 61 (2.3) 53 (5.4) 172 (13.9) 134 (18.2) 
Medium Risk 382 (14.5) 170 (17.4) 394 (32.0) 200 (27.2) 
High Risk 1003 (38.1) 382 (39.2) 466 (37.8) 286 (38.9) 
Regional 
Metastasis 
449 (17.0) 163 (16.7) 133 (10.8) 81 (11.0) 
Distant 
Metastasis 
724 (27.5) 201 (20.6) 53 (4.3) 24 (3.3) 
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Missing 17 (0.6) 6 (0.6)   
     
Prior PCa 
Treatment 
    
*Deferred 
Treatment 
N/A N/A 615 (49.9) 343 (46.7) 
Anti-
androgens 




N/A N/A 108 (8.8) 77 (10.5) 
Radiotherapy N/A N/A 218 (17.7) 185 (25.2) 
Radiotherapy 
< 1 year after 
Radical 
Prostatectomy 
N/A N/A 41 (3.3) 36 (4.9) 
Radiotherapy 
≥ 1 year after 
Radical 
Prostatectomy 
N/A N/A 37 (3.0) 21 (2.9) 
     
Change in 
*CCI since CCI 
at diagnosis 
    
No change 1536 (58.3) 577 (59.2) 733 (59.5) 454 (61.8) 
Change by 1 522 (19.8) 166 (17.0) 211 (17.1) 140 (19.1) 
Change by 2 322 (12.2) 129 (13.2) 150 (12.2) 75 (10.2) 
Change by 3 146 (5.5) 56 (5.7) 82 (6.7) 39 (5.3) 
Change by ≥ 4 110 (4.2) 47 (4.8) 56 (4.6) 27 (3.7) 
     
Civil Status     
Single 903 (34.3) 365 (37.4) 352 (28.6) 240 (32.7) 
Married 1733 (65.7) 610 (62.6) 880 (71.4) 495 (67.4) 
 
 
     
Year of GnRH 
agonists’ 
initiation 
    
2006-2007 1056 (40.1) 433 (44.4) 456 (37.0) 272 (37.0) 
2008-2009 851 (32.3) 283 (29.0) 403 (32.7) 232 (31.6) 
2010-2011 729 (27.7) 259 (26.6) 373 (30.3) 231 (31.4) 
2012-2013 0 0 0 0 
* OR: Odds ratio; CI: Confidence interval; Non-adherent (reference group); Deferred treatment 
includes men who underwent active surveillance and watchful waiting; N/A: Not applicable; CCI: 
Charlson Comorbidity Index; Injection interval at 90 days included PCa men given 30 days dosages 
due to low number in the 30 days group. 
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4.4.2.1.1 Primary GnRH agonists 
After 6 years on GnRH agonists, men with PCa aged 66-74 (OR = 1.60; 95% CI = 1.23-
2.07) and 75-84 (OR = 1.88; 95% CI = 1.45-2.42) showed an increased adherence 
compared to men with PCa aged ≤ 65 years (Table 19). Increased adherence was 
also observed with increased injection intervals (180 days OR = 2.18; 95% CI = 1.30-
3.67; 365 days OR = 2.94; 95% CI = 2.03-4.25 and mixed OR = 2.27; 1.82-2.83, as 
compared to 90 days’ injection intervals), increased risk groups at diagnosis and 
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Table 19: Univariate and multivariable logistic regression analyses showing odds ratios (OR) and 95% 





OR 95% CI OR 95% CI 
Age Groups (Years)     
≤ 65 1.00 Ref. 1.00 Ref. 
66-74 1.40 1.09-1.80 1.60 1.23-2.07 
75-84 1.57 1.24-1.99 1.88 1.45-2.42 
≥ 85 1.23 0.90-1.67 1.37 0.98-1.91 
     
*Injection interval 
(Days) 
    
90 1.00 Ref. 1.00 Ref. 
180 2.22 1.33-3.72 2.18 1.30-3.67 
365 2.79 1.96-3.97 2.94 2.03-4.25 
Mixed 2.17 1.75-2.69 2.27 1.82-2.83 
     
Risk Groups at 
Diagnosis 
    
Low Risk 1.00 Ref. 1.00 Ref. 
Medium Risk 1.95 1.30-2.94 1.90 1.24-2.90 
High Risk 2.28 1.55-3.36 2.44 1.63-3.64 
Regional Metastasis 2.39 1.59-3.60 2.77 1.81-4.23 
Distant Metastasis 3.13 2.10-4.67 3.85 2.53-5.84 
     
Change in *CCI since 
CCI at diagnosis 
    
No change 1.00 Ref. 1.00 Ref. 
Change by 1 1.18 0.97-1.44 1.23 1.00-1.52 
Change by 2 0.94 0.75-1.17 0.95 0.75-1.21 
Change by 3 0.98 0.71-1.35 0.93 0.67-1.29 
Change by ≥ 4 0.88 0.62-1.25 0.89 0.61-1.28 
     
Civil Status     
Single 1.00 Ref. 1.00 Ref. 
Married 1.15 0.99-1.34 1.12 0.96-1.31 
     
Year of GnRH agonists’ 
initiation 
    
2006-2007 1.00 Ref. 1.00 Ref. 
2008-2009 1.23 1.04-1.47 1.07 0.90-1.29 
2010-2011 1.15 0.96-1.38 0.91 0.75-1.10 
2012-2013 N/A N/A N/A N/A 
* OR: Odds ratio; CI: Confidence interval; Non-adherent (reference group); CCI: Charlson 
Comorbidity Index; Injection interval at 90 days included PCa men given 30 days’ dosages due to low 
number in the 30 days’ group. 
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4.4.2.1.2 Secondary GnRH agonists 
In comparison to deferred treatment, increased adherence was observed in men 
who were given anti-androgens (OR = 1.67; 95% CI = 1.22-2.29) as prior PCa 
treatment, whereas decreased adherence was observed in men who underwent 
radiotherapy (OR = 0.73; 95% CI = 0.56-0.97) (Table 20).  
 
Table 20: Univariate and multivariable logistic regression analyses showing odds ratios (OR) and 95% 





OR 95% CI OR 95% CI 
Age Groups (Years)     
≤ 65 1.00 Ref. 1.00 Ref. 
66-74 1.31 0.98-1.76 1.23 0.90-1.68 
75-84 1.52 1.15-2.02 1.32 0.94-1.84 
≥ 85 1.75 1.16-2.66 1.55 0.96-2.49 
     
*Injection Interval (Days)     
90 1.00 Ref. 1.00 Ref. 
80 4.55 2.14-9.67 4.83 2.26-10.35 
365 (Implant) 1.76 1.19-2.61 1.69 1.13-2.51 
Mixed 2.44 1.85-3.21 2.40 1.81-3.17 
     
Change in *CCI since CCI 
at diagnosis 
    
No change 1.00 Ref. 1.00 Ref. 
Change by 1 0.93 0.73-1.19 0.90 0.70-1.16 
Change by 2 1.24 0.92-1.67 1.25 0.92-1.71 
Change by 3 1.30 0.87-1.94 1.27 0.84-1.92 
Change by ≥ 4 1.28 0.80-2.06 1.24 0.76-2.01 
     
Civil Status     
Single 1.00 Ref. 1.00 Ref. 
Married 1.21 0.99-1.48 1.22 1.00-1.50 
     
Prior PCa Treatment     
*Deferred Treatment 1.00 Ref. 1.00 Ref. 
Anti-androgens 1.63 1.21-2.19 1.67 1.22-2.29 




0.78 0.57-1.08 0.86 0.60-1.23 
Radiotherapy 0.66 0.52-0.83 0.73 0.56-0.97 
Radiotherapy < 1 year 
after Radical 
Prostatectomy 
0.64 0.40-1.01 0.76 0.45-1.27 
Radiotherapy ≥ 1 year 
after Radical 
Prostatectomy 
0.98 0.57-1.71 1.08 0.59-1.97 
* OR: Odds ratio; CI: Confidence interval; Non-adherent (reference group); Deferred treatment 
includes men who underwent active surveillance and watchful waiting; CCI: Charlson Comorbidity 
Index; Injection interval at 90 days included PCa men given 30 days’ dosages due to low number in 
the 30 days’ group. 
 
4.4.2.2 Reclassification of Outcomes 
In this analysis, outcomes were reclassified according to men who received 
intermittent GnRH agonists or who discontinued treatment. As discussed above, an 
intermittent treatment regimen for GnRH agonists was determined as a gap of < 9 
months between the last and second last prescriptions in PCBaSeTraject. Following 
reclassification, 89% (7,227/8,105) men with PCa on primary GnRH agonists were 
adherent and 11% (878/8,105) were non-adherent. 86% (4,049/4,738) men with 
PCa on secondary GnRH agonists were adherent and 15% (689/4,738) were non-
adherent (Appendix Table 1, Appendix). 
4.4.2.2.1 Primary GnRH agonists 
Table 21 shows odds ratios and 95% Cis estimated using logistic regression models 
on the reclassified outcomes. Increased age, injection interval and risk groups 
showed an increased adherence in men on primary GnRH agonists. Reclassification 
of outcomes in the primary GnRH agonists’ group showed that change in CCI by 3 
compared to no change in CCI (OR = 1.95; 95% CI = 1.15-3.33) was also statistically 
significant which was not observed in the original analysis.  
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Table 21: Univariate and multivariable logistic regression analyses showing odds ratios (OR) and 95% 
confidence intervals (CI) for men with PCa after 3 years on primary GnRH agonists, following 





OR 95% CI OR 95% CI 
Age Groups (Years)     
≤ 65 1.00 Ref. 1.00 Ref. 
66-74 1.39 1.10-1.75 1.71 1.34-2.18 
75-84 1.64 1.31-2.04 2.26 1.78-2.88 
≥ 85 1.52 1.17-1.99 1.94 1.46-2.58 
     
*Injection Interval (Days)     
90 1.00 Ref. 1.00 Ref. 
180 1.45 1.02-2.04 1.43 1.00-2.05 
365 (Implant) 1.74 1.30-2.33 1.81 1.34-2.45 
Mixed 2.55 1.92-3.39 2.65 1.99-3.54 
     
Risk Groups at Diagnosis     
Low Risk 1.00 Ref. 1.00 Ref. 
Medium Risk 2.39 1.64-3.48 2.20 1.49-3.24 
High Risk 3.29 2.31-4.67 3.16 2.20-4.53 
Regional Metastasis 4.33 2.96-6.33 4.70 3.18-6.96 
Distant Metastasis 5.45 3.80-7.84 6.49 4.45-9.47 
     
Change in *CCI since CCI at 
diagnosis 
    
No change 1.00 Ref. 1.00 Ref. 
Change by 1 1.09 0.89-1.34 1.07 0.86-1.32 
Change by 2 1.09 0.84-1.42 1.12 0.86-1.47 
Change by 3 2.08 1.23-3.53 1.95 1.15-3.33 
Change by ≥ 4 1.18 0.69-2.02 1.13 0.65-1.96 
     
Civil Status     
Single 1.00 Ref. 1.00 Ref. 
Married 0.92 0.80-1.07 0.93 0.80-1.08 
     
Year of GnRH agonists’ 
initiation 
    
2006-2007 1.00 Ref. 1.00 Ref. 
2008-2009 1.26 1.05-1.51 1.11 0.92-1.35 
2010-2011 1.11 0.92-1.34 0.91 0.75-1.11 
2012-2013 1.30 1.05-1.60 0.98 0.79-1.22 
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* OR: Odds ratio; CI: Confidence interval; Non-adherent (reference group); CCI: Charlson 
Comorbidity Index; Injection interval at 90 days included PCa men given 30 days’ dosages due to low 
number in the 30 days’ group. 
 
4.4.2.2.2 Secondary GnRH agonists 
For the men on secondary GnRH agonists (Table 22), similar patterns as the original 
analysis was observed with age, injection intervals and prior PCa treatments (anti-
androgens, radiotherapy and radiotherapy ≥ 1 year after radical prostatectomy) 
affecting adherence patterns. 
Table 22: Univariate and multivariable logistic regression analyses showing odds ratios (OR) and 95% 
confidence intervals (CI) for PCa men after 3 years on secondary GnRH agonists, following 





OR 95% CI OR 95% CI 
Age Groups (Years)     
≤ 65 1.00 Ref. 1.00 Ref. 
66-74 1.11 0.86-1.45 1.14 0.86-1.51 
75-84 1.31 1.02-1.69 1.49 1.10-2.01 
≥ 85 1.68 1.20-2.35 2.10 1.42-3.09 
     
*Injection Interval (Days)     
90 1.00 Ref. 1.00 Ref. 
180 1.98 1.25-3.11 1.87 1.18-2.96 
365 (Implant) 1.35 0.99-1.83 1.34 0.98-1.83 
Mixed 3.03 2.11-4.36 3.18 2.20-4.58 
     
Change in *CCI since CCI at 
diagnosis 
    
No change 1.00 Ref. 1.00 Ref. 
Change by 1 1.17 0.91-1.51 1.15 0.89-1.49 
Change by 2 1.10 0.82-1.48 1.06 0.78-1.43 
Change by 3 1.69 0.95-3.02 1.62 0.90-2.90 
Change by ≥ 4 1.05 0.58-1.90 1.01 0.55-1.84 
     
Civil Status     
Single 1.00 Ref. 1.00 Ref. 
Married 1.08 0.91-1.28 1.08 0.90-1.28 
     
Prior PCa Treatment     
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*Deferred Treatment 1.00 Ref. 1.00 Ref. 
Anti-androgens 1.71 1.32-2.20 1.92 1.47-2.50 
Radical Prostatectomy only 0.65 0.50-0.83 0.81 0.60-1.08 
Radiotherapy 1.34 1.07-1.67 1.84 1.42-2.38 
Radiotherapy < 1 year after 
Radical Prostatectomy 
0.95 0.62-1.45 1.50 0.93-2.44 
Radiotherapy ≥ 1 year after 
Radical Prostatectomy 
1.27 0.79-2.04 1.88 1.11-3.18 
* OR: Odds ratio; CI: Confidence interval; Non-adherent (reference group); Deferred treatment 
includes men who underwent active surveillance and watchful waiting; CCI: Charlson Comorbidity 
Index; Injection interval at 90 days included PCa men given 30 days’ dosages due to low number in 
the 30 days’ group. 
 
4.4.2.3 Redefinition of Outcomes 
Tables 23 and 24 show odds ratios and 95% confidence intervals after 3 years on 
GnRH agonists, following redefinition of adherent and non-adherent. In this 
analysis, a MPR of ≥ 50% was considered as adherent and a MPR of < 50% was 
considered as adherent to GnRH agonists.  
4.4.2.3.1 Primary GnRH agonists 
Following redefinition of outcomes, 88% (7,140/8,105) men on primary GnRH 
agonists were adherent and 12% (965/8,105) were non-adherent (Appendix Table 2, 
Appendix). Increased age, longer injection interval and higher risk groups showed 
an increased adherence in men on primary GnRH agonists (Table 22). 
 
Table 23: Univariate and multivariable logistic regression analyses showing odds ratio (OR) and 95% 
confidence intervals (CI) for men with PCa after 3 years on primary GnRH agonists, following 





OR 95% CI OR 95% CI 
Age Groups (Years)     
≤ 65 1.00 Ref. 1.00 Ref. 
66-74 1.20 0.96-1.50 1.43 1.13-1.82 
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75-84 1.62 1.31-2.01 2.12 1.68-2.68 
≥ 85 1.49 1.15-1.94 1.82 1.38-2.40 
     
*Injection Interval (Days)     
90 1.00 Ref. 1.00 Ref. 
180 1.97 1.36-2.85 2.01 1.37-2.94 
365 (Implant) 3.35 2.35-4.79 3.44 2.39-4.95 
Mixed 2.48 1.90-3.22 2.60 1.99-3.39 
     
Risk Groups at Diagnosis     
Low Risk 1.00 Ref. 1.00 Ref. 
Medium Risk 2.52 1.73-3.65 2.28 1.56-3.35 
High Risk 3.31 2.34-4.67 3.16 2.21-4.51 
Regional Metastasis 3.60 2.49-5.19 3.91 2.67-5.71 
Distant Metastasis 5.33 3.74-7.61 6.41 4.42-9.29 
     
Change in *CCI since CCI at 
diagnosis 
    
No change 1.00 Ref. 1.00 Ref. 
Change by 1 1.11 0.91-1.36 1.08 0.88-1.32 
Change by 2 1.20 0.93-1.56 1.22 0.93-1.59 
Change by 3 1.54 0.99-2.41 1.44 0.92-2.26 
Change by ≥ 4 1.32 0.77-2.26 1.24 0.72-2.14 
     
Civil Status     
Single 1.00 Ref. 1.00 Ref. 
Married 1.08 0.94-1.24 1.10 0.95-1.26 
     
Year of GnRH agonists’ initiation     
2006-2007 1.00 Ref. 1.00 Ref. 
2008-2009 1.26 1.06-1.50 1.06 0.88-1.27 
2010-2011 1.23 1.02-1.48 0.94 0.78-1.14 
2012-2013 1.24 1.02-1.51 0.87 0.71-1.07 
* OR: Odds ratio; CI: Confidence interval; Non-adherent (reference group); CCI: Charlson 
Comorbidity Index; Injection interval at 90 days included PCa men given 30 days’ dosages due to low 
number in the 30 days’ group. 
 
 
4.4.2.3.2 Secondary GnRH agonists 
84% (3,959/4,738) men on secondary GnRH agonists were adherent and 16% 
(779/4,738) were non-adherent (Appendix Table 2, Appendix). For men on 
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secondary GnRH agonists (Table 24), increased adherence was observed with 
increased age, injection intervals and those who were given anti-androgens or 
radiotherapy as PCa treatment before GnRH agonists.  
 
Table 24: Univariate and multivariable logistic regression analyses showing odds ratio (OR) and 95% 
confidence intervals (CI) for PCa men after 3 years on secondary GnRH agonists, following 






OR 95% CI OR 95% CI 
Age Groups (Years)     
≤ 65 1.00 Ref. 1.00 Ref. 
66-74 1.25 0.97-1.60 1.24 0.96-1.62 
75-84 1.42 1.12-1.81 1.53 1.15-2.02 
≥ 85 1.56 1.14-2.12 1.81 1.27-2.59 
     
*Injection Interval 
(Days) 
    
90 1.00 Ref. 1.00 Ref. 
180 2.45 1.54-3.91 2.39 1.49-3.81 
365 (Implant) 2.43 1.70-3.47 2.44 1.71-3.50 
Mixed 2.02 1.51-2.70 2.09 1.56-2.80 
     
Change in *CCI since 
CCI at diagnosis 
    
No change 1.00 Ref. 1.00 Ref. 
Change by 1 1.15 0.91-1.46 1.14 0.89-1.46 
Change by 2 1.13 0.85-1.50 1.08 0.80-1.44 
Change by 3 1.55 0.91-2.63 1.49 0.87-2.55 
Change by ≥ 4 1.11 0.62-1.98 1.05 0.59-1.89 
     
  Civil Status     
Single 1.00 Ref. 1.00 Ref. 
Married 1.16 0.99-1.37 1.15 0.97-1.36 
     
Prior PCa Treatment     
*Deferred Treatment 1.00 Ref. 1.00 Ref. 
Anti-androgens 1.36 1.08-1.70 1.50 1.18-1.90 
Radical Prostatectomy 
only 
0.70 0.54-0.90 0.87 0.65-1.15 
Radiotherapy 1.42 1.15-1.77 1.90 1.48-2.45 
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Radiotherapy < 1 year 
after Radical 
Prostatectomy 
0.77 0.52-1.14 1.16 0.75-1.80 
Radiotherapy ≥ 1 year 
after Radical 
Prostatectomy 
0.98 0.64-1.48 1.34 0.85-2.11 
* OR: Odds ratio; CI: Confidence interval; Non-adherent (reference group); Deferred treatment 
includes men who underwent active surveillance and watchful waiting; CCI: Charlson Comorbidity 
Index; Injection interval at 90 days included PCa men given 30 days’ dosages due to low number in 




4.5  DISCUSSION 
This population-based register study was the first to investigate patterns of 
adherence to GnRH agonists in men with PCa in Sweden. Increased adherence to 
primary GnRH agonists was observed with increased age, a longer injection interval 
and a diagnosis of high risk or metastatic PCa after 3 years. Adherence to secondary 
GnRH agonists was stronger with increased age and prior use of anti-androgens and 
radiotherapy. Reclassification and redefinition of outcomes showed similar patterns 
as above and no remarkable differences in associations were observed with a longer 
study period of 6 years. 
An increased age was associated with increased adherence to GnRH agonists in this 
study. Several studies (183, 184) on heart failure medication support the findings of 
the current study. Individuals who were older with chronic illnesses were shown to 
have an increased adherence to heart failure medications than their younger 
counterparts. In the current study, older men with PCa showed an increased 
adherence regardless of whether they received primary or secondary GnRH 
agonists. Older men may be able to cope better with side-effects such as erectile 
dysfunction than their younger counterparts. A review (185) on the experiences of 
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men after PCa treatment has shown that side-effects such as erectile dysfunction 
had minimal impact in older men because they had already experienced sexual 
dysfunction due to another chronic or co-morbid disease. Moreover, erectile 
dysfunction was an “ill-effect’ that older men could live with and had minimal 
impact on their masculinity.    
Men with PCa with 365 days (50mg) intervals between their GnRH agonists 
injections showed three times increased adherence as compared to men receiving 
the injection with 90 days’ interval. This can be attributed to the reduced number of 
visits required to deliver the injections at higher doses, which means that men on 
the longer injection intervals may simply be more receptive to the less frequent and 
more convenient injection schedules (113). This warrants further discussion among 
clinicians into 365 days’ implants to be offered as an alternative to men 
encountering difficulties organising appointments at set intervals for injection 
administration. 
A three-fold increased adherence was observed in men with metastatic PCa at 
diagnosis compared to men diagnosed with low risk PCa. One reason for this 
increase may be that men with metastatic PCa were more likely to adhere to their 
cancer treatment in order to relieve disease symptoms such as bone pain, since 
disease severity is most often associated with more severe symptoms (186). 
However, the predominant reason for this increase may be due to the influence of 
stage-specific treatment guidelines in Sweden. For example, some men with low 
risk PCa may be on GnRH agonists with an elective intent (i.e. men with low risk PCa 
may be given treatment instead of no treatment) leading to the low adherence 
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observed this group (187). Moreover, this study did not account for oestrogens as it 
was extremely uncommon in the dataset although guidelines (187) in Sweden 
suggested the use of oestrogens for metastatic PCa because of similar effects to 
GnRH agonists at a lower cost. 
An increased adherence was also observed in men who had received radiotherapy 
prior to GnRH agonists’ initiation compared to those who were on deferred 
treatment. In men who had undergone radiotherapy for PCa, having radiotherapy ≥ 
1 year after their radical prostatectomy improved adherence to GnRH agonists 
which may reflect the treatment regimen for an advanced or recurrent PCa. 
Recommended therapies for localised PCa in Sweden include: radical 
prostatectomy, radiation therapy (188), anti-androgen monotherapy (189) or a 
combination of any of these based on cancer risk category and life expectancy. 
GnRH agonists can be given after a radical prostatectomy to reduce the risk of 
recurrence and to men who have a PSA relapse. In some of these cases, once PSA is 
under control, physicians may decide to discontinue GnRH agonists (190). 
Differences in the radiotherapy regimens between localised and advanced or 
recurrent PCa therefore explain the adherence patterns discussed above.  
Men given anti-androgens prior to their GnRH agonists were also more adherent 
than those on deferred treatment. Although some men can continue anti-
androgens in combination with GnRH agonists (for one month or longer) because it 
can help relieve the side-effects caused by GnRH agonists (191), further research is 
required to understand how patterns of adherence to GnRH agonists is related to 
different anti-androgen regimens in men with PCa.   
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No remarkable differences to adherence patterns were observed following 
reclassification of outcomes suggesting that adherence in men on primary or 
secondary GnRH agonists was not affected by whether they were on intermittent 
therapy (Tables 21-22). In order to minimise (or reduce) the risk of side-effects due 
to GnRH agonists, men on GnRH agonists may be placed on an intermittent 
treatment regimen all the while maintaining anti-tumour efficacy (173, 174). These 
men may have lower adherence to GnRH agonists due to a longer gap in their 
treatment regimen. Therefore, it was important to conduct a sensitivity analysis 
using reclassified outcomes accounting for the possibility of an intermittent 
treatment. However, the lack of a standard definition for intermittent therapy for 
men on GnRH agonists means that the 9 months’ gap explored in this study 
warrants further research. 
Redefining adherence to a MPR of 50% cut-off (Tables 23-24) showed no 
remarkable differences compared to the original analysis (Tables 16-17). 
Nevertheless, it was important to investigate Pettersson et al.’s (2006) report on 
the longer-lasting effects of testosterone suppression by GnRH agonists than 
previously documented in this study (182).  
The possibility of a switch in treatment regimens from GnRH agonists to other forms 
of ADT was not explored in this study since very few men switched treatments in 
the dataset. One could argue about the generalisability of the study population in 
PCBaSeTraject being limited to a single country as differences in healthcare settings 
exist in different countries, especially limited by its ethnic diversity. However, 
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treatment with GnRH agonists may not differ significantly among men with PCa 
globally and therefore the results of this study may be applicable globally.  
Future research assessing predictive factors once men stop adhering to the 
treatment may also offer explanations to the patterns observed in PCBaSeTraject. 
Factors that are patient-related were not explored in this study because this was 
beyond the information available in PCBaSeTraject. Patient-related factors such as 
forgetfulness, side-effects of GnRH agonists and ‘white-coat compliance’ may also 
contribute to the adherence patterns in men on GnRH agonists (82). Therefore, this 
thesis also comprises of a qualitative study (chapter VI) exploring the reasons 
contributing to non-adherence to GnRH agonists, both from a patient’s and 
clinician’s perspective to better understand overall adherence in men with PCa on 
long-term GnRH agonists. 
 
4.6  CONCLUSION 
This study identified increased age, advanced cancer stage at diagnosis, longer 
injection intervals and prior PCa treatment as patterns contributing to increased 
adherence to GnRH agonists in men with PCa. The patterns observed in this study 
provides evidence for some common factors already known from other disease 
settings that can contribute to adherence in men on GnRH agonists. Further 
research on data from other countries (chapter V) and qualitative research (chapter 
VI) are needed to reinforce the findings of this study. 
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5. CHAPTER V – ADHERENCE TO GNRH AGONISTS IN 
PROSTATE CANCER IN THE UNITED KINGDOM 
Chapter IV introduced the concept of adherence and explored patterns of 
adherence to GnRH agonists in men with PCa in Sweden. This chapter will employ 
the same methods to investigate this in the UK population and briefly explore the 
differences or similarities in the patterns identified between the Swedish and UK 
populations.  
 
5.1  BACKGROUND 
Patterns of adherence to GnRH agonists have not been investigated previously in 
the UK. Considering that a large proportion of men with PCa are on GnRH agonists 
or some form of ADT, possibly for the rest of their lives, it is important to better 
understand adherence patterns in this population (6).  
In the UK, ADT is offered to men with locally advanced and advanced PCa (NICE 
NG131) (120). Furthermore it is recommended that men continue with GnRH 
agonists treatment along with Docetaxel chemotherapy in castrate-resistant PCa 
(NICE 1.5.12, NG131) (120) because GnRH agonists increases the expression of the 
pro-apoptotic protein, Bax, which leads to re-sensitising castrate-resistant PCa cells 
to the cytotoxic activity of Docetaxel (192). 
As mentioned in chapter IV, side-effects associated with prolonged use of ADT have 
shown to be a major cause of non-adherence to ADT in previous breast cancer 
studies (172). Some side-effects reported to be associated with ADT include: 
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fatigue, hot flushes, low bone density (leading to increased risk of fractures) and 
even psychological issues (114, 115). These may also affect adherence to treatment 
among men with PCa. 
Other factors identified from the literature that may be associated with medication 
adherence and have not already been discussed in chapter IV include; socio-
demographic information and lifestyle factors of an individual such as ethnicity, 
socio-economic status, smoking status and alcohol intake (117, 193). These factors 
are explored in more detail below.   
Several studies have reported ethnicity to be an important factor contributing to 
the adherence status of an individual. A literature review (82) identified 16 studies 
that included ethnicity as a factor contributing to medication adherence. The results 
of this review showed Caucasians to have an increased adherence to medication 
compared to other ethnic minorities. This was attributed to the plausible 
explanation of language barriers and lower socio-economic statuses of the 
minorities included in the countries studied (82). Ethnicity was not investigated in 
PCBaSeTraject (chapter IV) because more than 90% of population in PCBaSeTraject had a 
Caucasian origin (194).  
Adherence to medication has also been shown to be associated with lifestyle 
factors such as smoking status and alcohol intake. Individuals who smoked or had 
an increased alcohol intake were more likely to be non-adherent to medication 
(117, 193). Smoking status was not available in PCBaSeTraject and was not 
investigated in chapter IV. The introduction of the April 2004 contract for UK GPs 
resulted in a substantial increase in GPs recording the smoking status of patients 
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attending general practices across UK (195). Although this raises the possibility of 
investigating smoking status as a non-adherent factor in the UK THIN database 
(141), detailed investigation of smoking status in chapter III has already shown a 
high percentage of missing data for this variable in the THIN database.   
Although issues surrounding non-adherence to GnRH agonists in men with PCa in 
Sweden has been explored in chapter IV of this thesis, country-specific factors such 
as treatment guidelines may influence the patterns observed in chapter IV. This 
study will therefore aim to investigate patterns of adherence to GnRH agonists in 
PCa in the UK population using the primary healthcare database, THIN (141). 
 
5.2  METHODS 
 Study Population 
Men with PCa on GnRH agonists were identified from the THIN database using 
drugcodes for GnRH agonists. Detailed structure of the THIN database has been 
discussed in chapter III. The THIN (141) database covers more than 500 GP practices 
across UK representing prescription patterns relevant to the UK population. In 
addition to the prescription data; the database comprises other relevant data 
elements such as: age, frequency of prescriptions, combination treatment 
modalities, civil status, smoking status, BMI, ethnicity and social deprivation index 
(Townsend scores) (141). This study included men starting on GnRH agonists 
between 1990-2013. 
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 Exposure 
Men with PCa on GnRH agonists entered the cohort 45 days after GnRH agonists’ 
initiation date. In order to avoid overestimating adherence in men with a shorter 
follow-up, only men with a minimum of 3 years on GnRH agonists were considered 
for the study. Men in the study were divided into two groups: those who had 
received GnRH agonists as the first-line treatment for their PCa were grouped as 
primary GnRH agonists and those who had received GnRH agonists following other 
PCa treatments were grouped as secondary GnRH agonists. The distinction between 
primary and secondary GnRH agonists in the THIN database was made using the 
variable, prior PCa treatment. Prior PCa treatment was created using readcodes 
(146)  for curative treatments such as radical prostatectomy and radiotherapy and 
drugcodes (chapter III) for anti-androgens.  
 Outcome 
Similarly to the study using PCBaSeTraject in chapter IV, the outcome was defined as 
adherent and non-adherent using the MPR (179). MPR was used to quantify 
adherence by using the following equation: 
 
 
A MPR of ≥ 80% was classified as adherent and a MPR of < 80% as non-adherent. 
 Analysis 
5.2.4.1 Main analysis 
The frequency of patterns for GnRH agonists’ use in PCa men was analysed 
separately depending on whether men with PCa were given primary or secondary 
Days of prescribed/dispensed supply  
          Number of days in the study period 
X   100 % 
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GnRH agonists. Logistic regression analyses were conducted in both groups to 
estimate ORs and 95% CIs of adherence to GnRH agonists. The regression models 
for primary GnRH agonists included age groups and injection intervals. For 
secondary GnRH agonists, the regression models included age groups, injection 
intervals and prior PCa treatment. Study variables civil status, smoking status, 
ethnicity, SES and BMI were not included in the regression models due to a high 
percentage of missing information.  
5.2.4.2 Sensitivity analyses 
The sensitivity analyses conducted for this study were also similar to chapter IV 
which included a longer follow-up period of six years, reclassification and 
redefinition of outcomes. Multivariable logistic regression was conducted with a 
MPR of ≥ 80% being adherent and < 80% being non-adherent was conducted for 
men who were on GnRH agonists for six years in THIN.  
In a further sensitivity analysis, logistic regression models were repeated for 
primary and secondary GnRH agonists following reclassification of outcomes. This 
sensitivity analysis was conducted to determine whether an intermittent regimen 
resulted in low MPR in some men on GnRH agonists. A gap of < 9 months between 
the last and second last prescriptions in THIN was defined as intermittent 
medication in THIN (174).   
Finally, logistic regression models for primary and secondary GnRH agonists were 
also repeated using redefined outcomes (MPR of ≥ 50% for being adherent and < 
50% for being non-adherent). As mentioned in chapter IV, the rationale behind this 
sensitivity analysis was to account for evidence that suggests that testosterone 
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levels may remain suppressed for a longer period of time after treatment with 
GnRH agonists than previously thought (182).  
 
5.3 RESULTS 
 Main Analysis 
4,923 men with PCa starting on primary GnRH agonists and 423 men with PCa 
starting on secondary GnRH agonists between 1990 and 2013 were extracted from 
THIN. Table 25 shows patient characteristics after 3 years on GnRH agonists. 75% 
were adherent on primary GnRH agonists and 70% were adherent on secondary 
treatment after 3 years. The mean age was similar for primary (adherent = 76, SD = 
8.0; non-adherent = 75, SD = 8.2) and secondary (adherent = 74, SD = 8.3; non-
adherent = 71, SD = 8.2) GnRH agonists.  





Primary GnRH Agonists Secondary GnRH Agonists 
Adherent (%) Non-adherent (%) Adherent (%) Non-adherent (%) 
n 3712 (75.4) 1211 (24.6) 295 (69.7) 128 (30.3) 
     
Age (Years)     
Mean (SD) 76  75  74  71  
SD 8.0 8.2 8.3 8.2 
     
Age Groups (Years)     
≤ 65 368 (9.9) 147 (12.1) 57 (19.3) 33 (25.8) 
66-74 1003 (27.0) 310 (25.6) 87 (29.5) 58 (45.3) 
75-84 1759 (47.4) 438 (36.2) 123 (41.7) 29 (22.7) 
≥ 85 442 (11.9) 107 (8.8) 28 (9.5) 8 (6.3) 
Missing 140 (3.8) 209 (17.3) 0 0 
     
Injection Interval 
(Days) 
    
28 920 (24.8) 547 (45.2) 62 (21.0) 34 (26.6) 
90 2641 (71.2) 649 (53.6) 224 (75.9) 90 (70.3) 
180 151 (4.1) 15 (1.2) 9 (3.1) 4 (3.1) 
     




    
Radical 
prostatectomy 
N/A N/A 95 (32.2) 51 (39.8) 
Radiotherapy N/A N/A 148 (50.2) 64 (50.0) 
Anti-androgens N/A N/A 52 (17.6) 13 (10.2) 
     
Civil Status     
Single 17 (0.5) 3 (0.3) 4 (1.4) 0 
Married 39 (1.1) 6 (0.5) 6 (2.0) 2 (1.6) 
Missing 3656 (98.5) 1202 (99.3) 285 (96.6) 126 (98.4) 
     
Smoking Status     
Current Smokers 634 (17.1) 205 (16.9) 43 (14.6) 15 (11.7) 
Non-Smokers 22 (0.6) 8 (0.7) 2 (0.7) 3 (2.3) 
Past Smokers 48 (1.3) 12 (1.0) 6 (2.0) 4 (3.1) 
Missing 3008 (81.0) 986 (81.4) 244 (82.7) 106 (82.8) 
     
Ethnicity     
Caucasian 1279 (34.5) 382 (31.5) 105 (35.6) 41 (32.0) 
Black 34 (0.9) 9 (0.7) 1 (0.3) 0 
Asian 6 (0.2) 4 (0.3) 1 (0.3) 0 
Other 7 (0.2) 5 (0.4) 1 (0.3) 0 
Missing 2386 (64.3) 811 (67.0) 187 (63.4) 87 (68.0) 
     
Socio-economic 
Status 
    
Lowest or least 
deprived 
(Townsend 1) 
172 (4.6) 41 (3.4) 16 (5.4) 6 (4.7) 
Low (Townsend 2) 179 (4.8) 39 (3.2) 16 (5.4) 8 (6.3) 
Middle (Townsend 
3) 
139 (3.7) 26 (2.2) 7 (2.4) 1 (0.8) 
High (Townsend 4) 109 (2.9) 13 (1.1) 7 (2.4) 2 (1.6) 
Highest or most 
deprived 
(Townsend 5) 
63 (1.7) 18 (1.5) 6 (2.0) 0 
Missing 3050 (82.2) 1074 (88.7) 243 (82.4) 111 (86.7) 
     
BMI / obesity     
Normal weight 
(18.5-24) 
7 (0.2) 1 (0.1) 1 (0.3) 0 
Underweight 
(<18.5) 
0 0 0 0 
Overweight (25-30) 20 (0.5) 1 (0.1) 2 (0.7) 1 (0.8) 
Obese (>30) 7 (0.2) 2 (0.2) 0 0 
Missing 3678 (99.1) 1207 (99.7) 292 (99.0) 127 (99.2) 
* BMI: Body Mass Index; N/A: Not available. 
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5.3.1.1 Primary GnRH agonists 
Table 26 outlines the results of a logistic regression for men receiving primary GnRH 
agonists. Increased adherence was observed in the age groups 75-84 (OR = 1.47; 
95% CI = 1.18-1.83) and ≥ 85 (OR = 1.50; 95% CI = 1.13-2.00) as compared to the 
group ≤ 65 years. Men with PCa on the 90 days’ injection interval (OR = 1.87; 95% CI 
= 1.61-2.16) and 180 days’ injection interval (OR = 4.13; 95% CI = 2.43-7.02) were 
more likely to be adherent than men on 28 days’ injection interval. 
Table 26: Univariate and multivariable logistic analyses showing odds ratios (OR) and 95% confidence 
intervals (CI) for men with PCa after 3 years on primary GnRH agonists. 
Patient Characteristics Univariate Multivariable 
OR 95% CI OR 95% CI 
Age Groups (Years)     
≤ 65 1.00 Ref. 1.00 Ref. 
66-74 1.29 1.03-1.63 1.23 0.97-1.55 
     
75-84 1.60 1.29-1.99 1.47 1.18-1.83 
≥ 85 1.65 1.24-2.19 1.50 1.13-2.00 
     
Injection Interval (Days)     
28 1.00 Ref. 1.00 Ref. 
90 2.43 2.12-2.79 1.87 1.61-2.16 
180 5.62 3.32-9.52 4.13 2.43-7.02 
* OR: Odds ratio; CI: Confidence interval; non-adherent (reference group). 
 
5.3.1.2 Secondary GnRH agonists 
Table 27 shows the results of a logistic regression for men on secondary GnRH 
agonists. Increased adherence was observed in men aged 75-84 (OR = 2.55; 95% CI 
= 1.41-4.61) compared to men aged ≤ 65. Injection interval and prior PCa treatment 
had no influence on adherence status. 
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Table 27: Univariate and multivariable logistic regression analyses showing odds ratios (OR) and 95% 
confidence intervals (CI) for men with PCa after 3 years on secondary GnRH agonists. 
Patient Characteristics Univariate Multivariable 
OR 95% CI OR 95% CI 
Age (Years)     
≤ 65 1.00 Ref. 1.00 Ref. 
66-74 0.87 0.50-1.49 0.86 0.49-1.47 
75-84 2.46 1.36-4.43 2.55 1.41-4.61 
≥ 85 2.03 0.83-4.96 2.21 0.88-5.51 
     
Injection Interval (Days)     
28 1.00 Ref. 1.00 Ref. 
90 1.36 0.84-2.22 1.51 0.91-2.50 
180 1.23 0.35-4.31 1.27 0.34-4.63 
     
Prior PCa Treatment     
Radical prostatectomy 1.00 Ref. 1.00 Ref. 
Radiotherapy 1.21 0.63-2.35 1.29 0.80-2.08 
Anti-androgens 1.16 0.74-1.82 1.33 0.80-2.08 
* OR: Odds ratio; CI: Confidence interval; non-adherent (reference group). 
 
 Sensitivity analyses 
5.3.2.1 Longer follow-up period 
After six years on GnRH agonists, 1,828 men with PCa were on primary treatment 
and 174 were on secondary treatment (Table 28). Mean age was 75 years (SD = 7.7) 
for adherent and 73 years (SD = 7.2) for non-adherent men on primary GnRH 
agonists. For men on secondary GnRH agonists, mean age was 72 years (SD = 7.9) 
for adherent men and 69 years (SD = 7.5) for non-adherent men. 
 






Primary GnRH Agonists Secondary GnRH Agonists 
Adherent 
(%) 
Non-adherent (%) Adherent 
(%) 
Non-adherent (%) 
n 1296 (70.9) 532 (29.1) 119 (68.4) 55 (31.6) 
     
Age (Years)     
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Mean (SD) 75  73  72  69  
SD 7.7 7.2 7.9 7.5 
     
Age Groups (Years)     
≤ 65 128 (9.9) 67 (12.6) 24 (20.2) 14 (25.5) 
66-74 446 (34.4) 172 (32.3) 48 (40.3) 30 (54.6) 
75-84 612 (47.2) 194 (36.5) 40 (33.6) 9 (16.4) 
≥ 85 88 (6.8) 21 (4.0) 7 (5.9) 2 (3.6) 
Missing 22 (1.7) 78 (14.7) 0 0 
     
Injection Intervals 
(Days) 
    
28 341 (26.3) 231 (43.4) 26 (21.9) 14 (25.5) 
90 911 (70.3) 294 (55.3) 91 (76.5) 41 (74.6) 
180 44 (3.4) 7 (1.3) 2 (1.7) 0 
     
Prior PCa Treatment     
Radical 
prostatectomy 
N/A N/A 34 (28.6) 23 (41.8) 
Radiotherapy N/A N/A 65 (54.6) 24 (43.6) 
Anti-androgens N/A N/A 20 (16.8) 8 (14.6) 
     
Civil Status     
Single 4 (0.3) 1 (0.2) 4 (3.4) 0 
Married 8 (0.6) 3 (0.6) 0 0 
Missing 1284 (99.1) 528 (99.3) 115 (96.6) 55 (100) 
     
Smoking Status     
Current Smokers 227 (17.5) 103 (19.4) 20 (16.8) 8 (14.6) 
Non-Smokers 9 (0.7) 4 (0.8) 1 (0.8) 1 (1.8) 
Past Smokers 15 (1.2) 6 (1.1) 4 (3.4) 1 (1.8) 
Missing 1045 (80.6) 419 (78.8) 94 (79.0) 45 (81.8) 
     
Ethnicity     
Caucasian 452 (34.9) 172 (32.3) 44 (37.0) 20 (36.4) 
Black 11 (0.9) 4 (0.8) 0 0 
Asian 2 (0.2) 1 (0.2) 0 0 
Other 1 (0.1) 4 (0.8) 1 (0.8) 0 
Missing 830 (64.0) 351 (66.0) 74 (62.2) 35 (63.6) 
     
Socio-economic 
Status 
    
Lowest or least 
deprived (Townsend 
1) 
17 (1.3) 7 (1.3) 1 (0.8) 1 (1.8) 
Low (Townsend 2) 23 (1.8) 8 (1.5) 1 (0.8) 0 
Middle (Townsend 3) 21 (1.6) 3(0.6) 2 (1.7) 0 
High (Townsend 4) 18 (1.4) 3 (0.6) 0 0 
Highest or most 
deprived (Townsend 
5) 
6 (0.5) 6 (1.1) 2 (1.7) 0 
Missing 1211 (93.4) 505 (94.9) 113 (95.0) 54 (98.2) 
     
BMI / obesity     
Normal weight (18.5-
24) 
3 (0.2) 1 (0.2) 1 (0.8) 0 
Underweight (<18.5) 0 0 0 0 
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Overweight (25-30) 7 (0.5) 1 (0.2) 1 (0.8) 0 
Obese (>30) 2 (0.2) 0 0 0 
Missing 1284 (99.1) 530 (99.6) 117 (98.3) 55 (100) 
* BMI: Body Mass Index; N/A: Not available. 
 
5.3.2.1.1 Primary GnRH agonists 
For men on primary GnRH agonists, increased age was associated with increased 
adherence with the most adherent age group being ≥ 85 years (OR = 2.08; 95% CI = 
1.18-3.65) compared to ≤ 65 years (Table 29). An increased adherence was also 
observed in men who were administered injections at 90 days’ intervals (OR = 1.55; 
95% CI = 1.23-1.95) and 180 days’ intervals (OR = 2.97; 95% CI = 1.31-6.77) as 
compared to 28 days. 
 
Table 29: Univariate and multivariable logistic regression analyses showing odds ratios (OR) and 95% 





OR 95% CI OR 95% CI 
Age (Years)     
≤ 65 1.00 Ref. 1.00 Ref. 
66-74 1.36 0.96-1.91 1.31 0.92-1.85 
75-84 1.65 1.18-2.31 1.53 1.09-2.15 
≥ 85 2.19 1.25-3.84 2.08 1.18-3.65 
     
Injection Interval (Days)     
28 1.00 Ref. 1.00 Ref. 
90 2.10 1.70-2.60 1.55 1.23-1.95 
180 4.26 1.89-9.62 2.97 1.31-6.77 
* OR: Odds ratio; CI: Confidence interval; non-adherent (reference group). 
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5.3.2.1.2 Secondary GnRH agonists 
For men on secondary GnRH agonists, increased adherence was observed in men 
aged 75-84 years (OR = 2.94; 95% CI = 1.08 -8.03) compared to men aged ≤ 65 years 
(Table 30). Injection interval 180 days had low number of men on GnRH agonists in 
the two outcome groups for analysis (adherent = 2; non-adherent = 0). Prior PCa 
treatment had no influence on the adherence status of men on secondary GnRH 
agonists.  
Table 30: Univariate and multivariable logistic regression analyses showing odds ratios (OR) and 95% 





OR 95% CI OR 95% CI 
Age (Years)     
≤ 65 1.00 Ref. 1.00 Ref. 
66-74 0.93 0.42-2.08 1.02 0.45-2.34 
75-84 2.59 0.97-6.90 2.94 1.08-8.03 
≥ 85 2.04 0.37-11.22 2.54 0.45-14.4 
     
Injection Interval (Days)     
28 1.00 Ref. 1.00 Ref. 
90 1.20 0.57-2.52 1.22 0.56-2.66 
180 * - - * - - 
     
Prior PCa Treatment     
Radical prostatectomy 1.00 Ref. 1.00 Ref. 
Radiotherapy 1.83 0.90-3.71 1.97 0.95-4.08 
Anti-androgens 1.69 0.64-4.49 1.44 0.52-3.97 
* * OR: Odds ratio; CI: Confidence interval; non-adherent (reference group); Injection interval 180 
days had low number of men on GnRH agonists in the two outcome groups for analysis (Adherent = 
2; Non-adherent = 0) 
 
5.3.2.2 Reclassification of outcomes 
Patient characteristics after reclassification of outcomes are provided in (Appendix 
Table 3, Appendix). Following reclassification based on intermittent GnRH agonists 
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therapy, 78% (3,833/4,923) men with PCa on primary GnRH agonists were adherent 
and 22% (1,090/4,923) were non-adherent. 72% (303/423) men with PCa on 
secondary GnRH agonists were adherent and 28% (120/423) were non-adherent. 
Mean age was similar for men on primary (adherent = 76, SD = 8.0; non-adherent = 
74, SD = 8.1) and secondary GnRH agonists (adherent = 74, SD = 8.4; non-adherent = 
70, SD = 7.8).  
5.3.2.2.1 Primary GnRH agonists 
Table 31 shows odds ratios and 95% CIs estimated using logistic regression models 
on the reclassified outcomes. Increased age and injection intervals showed an 
increased adherence in men on primary GnRH agonists.  
 
Table 31: Univariate and multivariable logistic regression analyses showing odds ratios (OR) and 95% 
confidence intervals (CI) for men with PCa after 3 years on primary GnRH agonists, following 





OR 95% CI OR 95% CI 
Age Groups (Years)     
≤ 65 1.00 Ref. 1.00 Ref. 
66-74 1.38 1.09-1.74 1.33 1.05-1.68 
75-84 1.71 1.37-2.13 1.60 1.28-2.00 
≥ 85 1.96 1.45-2.64 1.83 1.35-2.47 
     
Injection Interval (Days)     
28 1.00 Ref. 1.00 Ref. 
90 2.06 1.79-2.37 1.55 1.33-1.81 
180 4.40 2.60-7.46 3.16 1.86-5.39 
* OR: Odds ratio; CI: Confidence interval; non-adherent (reference group). 
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5.3.2.2.2 Secondary GnRH agonists 
For the men on secondary GnRH agonists (Table 32), increased age was associated 
with increased adherence with the most adherence observed in ≥ 85 year olds (OR = 
3.97; 95% CI = 1.38-11.42). Injection intervals and prior PCa treatment had no 
influence on adherence patterns in men on secondary GnRH agonists which was 
similar to the patterns observed in the original analysis (Table 27). 
 
Table 32: Univariate and multivariable logistic regression analyses showing odds ratios (OR) and 95% 
confidence intervals (CI) for men with PCa after 3 years on secondary GnRH agonists, following 





OR 95% CI OR 95% CI 
Age Groups (Years)     
≤ 65 1.00 Ref. 1.00 Ref. 
66-74 0.92 0.53-1.58 0.91 0.53-1.57 
75-84 2.81 1.54-5.12 2.88 1.57-5.28 
≥ 85 3.59 1.27-10.13 3.97 1.38-11.42 
     
Injection Interval (Days)     
28 1.00 Ref. 1.00 Ref. 
90 1.21 0.73-1.98 1.34 0.80-2.25 
180 1.02 0.29-3.59 1.05 0.29-3.87 
     
Prior PCa Treatment     
Radical prostatectomy 1.00 Ref. 1.00 Ref. 
Radiotherapy 1.13 0.71-1.79 1.34 0.82-2.17 
Anti-androgens 1.31 0.66-2.59 1.50 0.73-3.07 
* OR: Odds ratio; CI: Confidence interval; non-adherent (reference group). 
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5.3.2.3 Redefinition of outcomes 
In this analysis, a MPR of ≥ 50% was considered as adherent and a MPR of < 50% 
was considered as adherent to GnRH agonists. Appendix Table 4 (Appendix) shows 
characteristics of men following redefinition of outcomes. 86% (4,246/4,923) men 
on primary GnRH agonists were adherent and 14% (677/4,923) were non-adherent. 
83% (352/423) men on secondary GnRH agonists were adherent and 17% (71/423) 
were non-adherent. Mean age was similar for men on primary (adherent = 76, SD = 
8.0; non-adherent = 74, SD = 8.1) and secondary GnRH agonists (adherent = 74, SD = 
8.4; non-adherent = 70, SD = 7.6).  
5.3.2.3.1 Primary GnRH agonists 
Following redefinition of outcomes (Table 33), increased age and longer injection 
interval showed an increased adherence in men on primary GnRH agonists. 
 
Table 33: Univariate and multivariable logistic regression analyses showing odds ratio (OR) and 95% 
confidence intervals (CI) for men with PCa after 3 years on primary GnRH agonists, following 






OR 95% CI OR 95% CI 
Age Groups (Years)     
≤ 65 1.00 Ref. 1.00 Ref. 
66-74 1.39 1.05-1.83 1.30 0.98-1.72 
75-84 1.82 1.40-2.38 1.64 1.25-2.15 
≥ 85 2.52 1.71-3.72 2.26 1.53-3.35 
     
Injection Interval 
(Days) 
    
28 1.00 Ref. 1.00 Ref. 
90 2.90 2.45-3.42 2.11 1.76-2.53 
180 5.47 2.76-10.82 3.77 1.89-7.50 
* OR: Odds ratio; CI: Confidence interval; non-adherent (reference group). 
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5.3.2.3.2 Secondary GnRH agonists 
For men on secondary GnRH agonists (Table 34), increased adherence was observed 
with increased age and longer injection intervals. Prior PCa treatment had no 
influence on the adherence status.  
 
Table 34: Univariate and multivariable logistic regression analyses showing odds ratio (OR) and 95% 
confidence intervals (CI) for men with PCa after 3 years on secondary GnRH agonists, following 





OR 95% CI OR 95% CI 
Age Groups (Years)     
≤ 65 1.00 Ref. 1.00 Ref. 
66-74 0.66 0.34-1.25 0.65 0.34-1.24 
75-84 2.30 1.07-4.92 2.41 1.12-5.18 
≥ 85 3.96 0.87-18.11 4.17 0.89-19.45 
     
Injection Interval (Days)     
28 1.00 Ref. 1.00 Ref. 
90 1.59 0.90-2.83 1.78 0.98-3.24 
180 0.93 0.24-3.70 1.02 0.24-4.27 
     
Prior PCa Treatment     
Radical prostatectomy 1.00 Ref. 1.00 Ref. 
Radiotherapy 1.01 0.58-1.77 1.22 0.68-2.19 
Anti-androgens 1.02 0.45-2.27 1.22 0.52-2.86 
* OR: Odds ratio; CI: Confidence interval; non-adherent (reference group). 
 
5.4  DISCUSSION 
This is the first study to use a primary healthcare database to assess patterns of 
adherence to GnRH agonists in men with PCa in the UK. Increased adherence was 
observed in men with older age and longer injection intervals for primary GnRH 
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agonists in all analyses. For men on secondary GnRH agonists, increased age was 
the single most contributing factor to increased adherence in all analyses. The 
results of this study support some of the findings observed in for Sweden using the 
PCBaSeTraject database (chapter IV). Adherence in both Sweden and UK was 
influenced by an increased age and a longer injection interval.  
Increased adherence was observed with increased age regardless of whether men 
were on primary or secondary GnRH agonists. The increased adherence observed in 
older men remained significant even with longer follow-up period, reclassification 
and redefinition of outcomes. Previous studies (183, 184) have also shown that 
older individuals have an increased medication adherence, especially in chronic 
illnesses. Moreover, the results from this study support the results from 
PCBaSeTraject (chapter IV), which reinforces that increased age is a contributing 
factor to increased adherence in men with PCa on GnRH agonists.  
Adherence status was also influenced by injection intervals, particularly for men on 
primary GnRH agonists. Longer injection intervals of 90 days and 180 days showed 
an increased adherence as compared to the shorter 28 days’ injection intervals, 
similar to the findings observed in PCBaSeTraject (chapter IV). As discussed in chapter 
IV, this may be explained by the reduced number of visits required by an individual 
on GnRH agonists to be administered the injections. Men on the longer injection 
intervals may simply be more receptive to the less frequent and more convenient 
injection schedules (113).  
A key strength of this study was that it made use of a primary healthcare database 
which covered men attending primary care to be administered GnRH agonists’ 
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injections. However, a high percentage of missing information on socio-
demographic variables and no information being available on stage of PCa in the 
THIN database limited the applicability of the results of this study. 
Further research is required with more data on socio-demographic variables and 
stage of PCa to complement the preliminary findings of this study.  Moreover, it is 
important to understand factors contributing to adherence and non-adherence 
from a patient’s and their clinician’s perspective. Therefore, a qualitative study 
exploring different perspectives will help to better understand overall adherence 
patterns to GnRH agonists in men with PCa in the UK. 
 
5.5  CONCLUSION 
The results of this study confirm findings from chapter IV that increased age and 
longer injection intervals influence adherence patterns to GnRH agonists in men 
with PCa. Further research is required to reinforce the preliminary findings of this 
study. For this thesis, a qualitative approach (chapter VI) was employed to data 
collected from a UK hospital, to better understand the socio-demographic aspects, 
patient and clinician perspectives contributing to adherence patterns to GnRH 
agonists in men with PCa. 
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6. CHAPTER VI – ADHERENCE TO GNRH AGONISTS IN 
PROSTATE CANCER: A QUALITATIVE APPROACH 
In chapters IV and V of this thesis, adherence to GnRH agonists in men with PCa was 
investigated in Sweden and the UK using quantitative methods. The aim of this 
chapter is to better understand factors influencing adherence and non-adherence 
to GnRH agonists in men with PCa using qualitative methods. Most methods of 
measuring adherence only consider quantitative methods. Although this may 
inform patterns of non-adherence, it provides little insight into the reasons 
contributing to non-adherence in patients. The qualitative data in this chapter 
includes measures such as patient and clinician perspectives of factors contributing 
to adherence and non-adherence, which are outside the scope of quantitative 
databases, thus providing an overall representation of the subject being 
investigated.  
 
6.1  BACKGROUND 
A qualitative review by Jin et al. (2008) identified various factors from the literature 
between 1970 to 2005 contributing to therapeutic non-compliance or non-
adherence to medication in general. The review categorised the factors identified 
into patient-centred factors, therapy-related factors, social and economic factors, 
healthcare system factors and disease factors (82). Jin et al.’s (2008) review formed 
the basis for the qualitative research carried out in this project. For the purpose of 
this project, the main factors identified from Jin et al.’s (2008) review were 
combined into patient-related and clinician-related factors (Figures 16 and 17). 
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6.1.1.1 Patient-related factors  
 
Figure 16: Patient-related factors influencing non-adherence highlighted in literature review by Jin et 
al. (2008) (82). 
 
Patient-related factors can include the demographics of a patient such as the age, 
ethnicity, gender, education and marital status. They can also cover factors that 
may arise from the patient himself such as forgetfulness, skipping medications and 
lack of dispensation of a drug. Lack of dispensation of a drug occurs when a patient 
has not collected their prescribed medication from the pharmacy (82).  
Reasons such as ‘drug holidays’ or ‘white-coat compliance’ may also contribute to 
the lack of adherence to medication. Drug holidays occur when a patient takes short 
intervals of time from their medication routine before resuming their medication 
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due to no reason. White-coat compliance is a phenomenon whereby medication 
adherence is positively associated with clinical appointments (196).   
The extent of social support from a spouse or other family members may also 
influence the adherence status of a patient. Having a partner or a family member to 
remind the patient about taking their medication on time and taking care of the 
patient’s health in general may contribute to an increased medication adherence in 
these patients.  
 
6.1.1.2 Clinician-related factors 
 
Figure 17: Clinician-related factors influencing non-adherence highlighted in literature review by Jin et al. (2008) 
(82). 
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Prescribing complex treatment regimens may be one reason how clinicians may 
influence a patient’s adherence to medication. A poor patient-provider relationship 
may also influence medication adherence because it can lead to clinicians not 
having a chance to fully explain the benefits and side-effects of a treatment to a 
patient unwilling to cooperate (197-200).  
The term patient-related care suggests that patients may adhere to their 
medications after making an informed decision in a supportive healthcare 
environment (201). In order to address clinician-related factors contributing to non-
adherence to a medication, it is important to establish a therapeutic alliance 
between a patient and their physician (107, 202). Vlasnik et al. (2005) even 
proposes that a patient having multiple physicians prescribing medication may 
decrease the patient’s confidence in the prescribed treatment. One way to build a 
healthy relationship between a patient and their provider is to actively involve 
patients in their treatment plans right from the beginning (201). Shared decision 
making can help patients to actively engage in their care. Therefore, a positive 
relationship between a patient and their clinician is important to help patients 
understand their disease and the need to adhere to their therapy.  
It is therefore imperative to understand both patient and clinician perspectives 
when it comes to medication adherence. No study has fully investigated adherence 
to GnRH agonists in men with PCa using qualitative methods (such as interviews 
with patients and focus groups with clinicians). Taking into consideration factors 
contributing to medication adherence that are discussed above, this project aimed 
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to understand factors contributing to adherence and non-adherence to GnRH 
agonists in men with PCa.  
 
6.2  METHODS 
The project was divided into three main stages: validation of themes contributing to 
non-adherence by an Oncologist Specialist, interviews with men with PCa on long-
term GnRH agonists and focus groups with healthcare professionals treating men 
with PCa on GnRH agonists. This study was conducted in Guy’s Hospital (Guy’s and 
St Thomas’ Foundation Trust), a large teaching hospital treating around 1,000 men 
with PCa per year. 
6.2.1.1 Stage 1: Validation 
The purpose of validation in qualitative research is to ensure that the research 
question is valid for the desired outcome, that the methodology chosen is 
appropriate for answering the research question and that the study design is 
suitable for the methodology applied (203). This concept was modified for this 
study to validate the methodology and reasons contributing to medication non-
adherence highlighted by Jin et al.’s (2008) review (82). For the validation process, 
an Oncology Specialist with 10 years of experience treating men on GnRH agonists 
at the hospital, went through the study protocol and highlighted any additional 
reasons for non-adherence in relation to the population being studied in this 
project.  
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6.2.1.2 Stage 2: Interviews 
Men with PCa on GnRH agonists were identified by oncology specialists and clinical 
nurse specialists (CNS) from the direct care team. Once identified, eligible men were 
offered the study participant information sheet (section 9.4.2, Appendix) by the 
research team. After an informed consent was obtained, semi-structured interviews 
were held on a one-to-one basis using a topic guide (section 9.4.2, Appendix). The 
interview topic guide included topics discussed in Figures 16 and 17 and any further 
topics highlighted by the validation process in stage 1. Questions were open-ended 
with participants being encouraged to initiate topics that they deemed were 
important. All men were assured that the researchers were interested in 
understanding their views regardless of their adherence status. Each interview 
lasted for a maximum of 45 minutes and were audio recorded, transcribed verbatim 
and anonymised. A total of ten men on GnRH agonists were interviewed where no 
new emerging themes were identified (204).      
6.2.1.3 Stage 3: Focus groups 
Focus groups were conducted for healthcare professionals treating men on GnRH 
agonists. The aim of the focus groups was to identify factors related to adherence 
and non-adherence in the study that were not identified in the literature review 
(82), the validation process (section 9.4.2, Appendix) or the interview stage. 
Moreover, the focus groups also provided a clinical perspective to factors 
contributing to adherence and non-adherence to GnRH agonists in men with PCa. 
The focus groups were held in two separate sessions: one with oncology specialists 
or registrars and one with CNS. The clinicians were invited by their managers to the 
focus groups using the study participant information sheet (section 9.4.2, 
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Appendix). Once informed consent was obtained, the focus groups were run using a 
topic guide (section 9.4.2, Appendix) for a maximum of two hours. The focus groups 
were audio recorded and anonymously transcribed verbatim.  Three clinicians per 
focus group were recruited, as the minimum number of members required for a 
focus group is between 3-5 participants (204). 
6.2.1.4 Ethical approval 
Ethical approval was obtained from the Health Research Authority (HRA) using the 
Integrated Research Application System before the start of the study. The HRA 
approved documents are provided in section 9.4.2 of the Appendix. 
6.2.1.5 Analysis 
All audio recordings were anonymised and given a unique study ID during 
transcription. Interviews (stage 2) and focus groups (stage 3) were analysed using 
thematic analysis as described by Braun and Clarke (2006) (205) which include: 
1. familiarising yourself with your data (includes transcription of audio 
recording) 
2. generating initial codes by identifying repeated patterns in extracts of 
your data 
3. searching for themes by combining the initial codes to form overarching 
themes 
4. reviewing themes to identify coherent themes 
5. defining and naming themes 
6. producing the report which should provide a concise, coherent, logical 
and non-repetitive explanation of the themes. 
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Following familiarisation with the data, initial codes were generated by working 
systematically through the interview and focus group transcripts. Each code was 
determined by the language used by the participant. For example, if the participant 
said, “The fatigue meant that it was very difficult for me to work properly”, the 
sentence was coded under the overarching code, “fatigue”. The initial codes were 
then organised into potential themes (Figure 18) using the software NVIVO (section 
9.2, Appendix). Following discussion of themes with other qualitative researchers in 
the team, the themes were reviewed into coherent themes.  
Men in the interview stage (stage 2) were classified as adherent or non-adherent by 
the clinicians identifying them for the study. All men interviewed were 
recommended to go on the GnRH agonists by their clinician. Men who had never 
missed an injection intentionally were classed as adherent and men who were 
reported to have missed or discontinued their injection without recommendation 
from the clinician were classed as non-adherent. 
 
6.3  RESULTS 
Following validation (stage 1) by an Oncology Specialist of themes highlighted in the 
systematic review by Jin et al. (2008) (82), one-to-one interviews (stage 2) were 
conducted with men with PCa on GnRH agonists. All themes identified until stage 2 
were then discussed with their healthcare professionals in focus groups (stage 3).  
There was a substantial overlap between the themes identified by the interviews 
(stage 2) and focus groups (stage 3). The key themes identified from both the 
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interviews and focus groups were side-effects of treatment, patient belief system, 
benefits outweigh harm, quality of life over quantity of life, social support and 
patient-clinician relationship (Figure 18). 
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Figure 18: Key themes identified from the interviews and focus groups. The number in brackets next to the sub-themes show the number of men in interviews who 
highlighted the issue. Sub-themes without a number was highlighted by focus groups. 
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6.3.1.1 Stage 1: Validation 
The validated protocol is shown in section 9.4.2, Appendix. In addition to the 
patient-centred factors contributing to non-adherence emphasised by Jin et al. 
(2008) (82), the Oncology Specialist highlighted other factors such as: the mixed 
health beliefs of patients on GnRH agonists, the desire to avoid side-effects 
resulting from the hormonal treatment and major life events in the patients’ lives 
that may contribute to non-adherence (for example, a partner being diagnosed with 
cancer or other chronic conditions). 
6.3.1.2 Stage 2: Interviews 
Clinic lists were screened by the direct care team for men with PCa on GnRH 
agonists. Once identified, eligible men were offered the participant information 
sheet by the research team, outlining the purpose of the interviews. Men with PCa 
on GnRH agonists who agreed to take part in the study were interviewed for the 
study. Semi-structured interviews were conducted on a one-to-one basis using a 
topic guide. The interviews lasted on average for 45 minutes. No new emerging 
themes were identified after ten interviews. Table 35 shows the patient 
characteristics for the men interviewed. Seven men were classed as adherent and 
three were classed as non-adherent.  
Table 35: Characteristics of study participants from the interviews. 
Study ID Age Ethnicity Marital Status Adherence Status at 
Recruitment 
ADT-001 63 White-British Married Adherent 
ADT-002 76 White-British Married Adherent 
ADT-003 56 White-British Married Adherent 
ADT-004 66 Black-British Single Adherent 
ADT-005 63 Black-British Single Non-adherent 
ADT-006 53 Black-Other African Single Non-adherent 
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ADT-007 64 Black-British Married Non-adherent 
ADT-008 83 White-British Married Adherent 
ADT-009 53 Black-Caribbean Single Adherent 
ADT-010 63 White-British Married Adherent 
 
Themes identified from the interview stage were: side-effects of treatment, patient 
belief system, benefits outweigh harm, quality of life over quantity of life, social 
support and patient-clinician relationship. 
Side-effects of treatment 
Nine out of ten men interviewed mentioned hot flushes as a side-effect which they 
found quite challenging and embarrassing. Hot flushes at night also led to disrupted 
sleeping patterns.  
“Another side-effect that people think, it’s a bit of a laugh I guess is the hot 
flushes. I myself thought of that but it is, it can be quite debilitating. Um, 
example, every night it wakes me up at least half a dozen times.” 
(ADT-003, 56, adherent) 
One of the most important driving forces for non-adherence in men prescribed 
GnRH agonists were side-effects of the treatment. Six out of ten men interviewed 
agreed that loss of libido was the biggest factor they found difficult to come to 
terms with.  
“If you ask any man, white, black, if once you have.. you don’t have libido. If 
you ask a woman, if you’re a woman and the man is staying with you 
without having the urge, the craving for sex, it’s.. what’s the point.” 
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(ADT-006, 53, non-adherent) 
Loss of libido also affected those who were in a committed relationship. Often men 
felt that they were letting their partners down. 
“Yes I thought uh um I thought I was letting her down and it became very 
difficult to uh explain to anyone what was happening.” 
(ADT-008, 83, adherent) 
Other side-effects that the men interviewed mentioned were weight gain (n = 6), 
mood swings (n = 4), fatigue (n = 4), gynaecomastia (n = 4), impotence (n = 2), loss 
of muscle strength (n = 2), memory loss (n = 1), brittle bones (n = 1) and painful 
injection site (n = 1). 
Patient belief system 
Some men held strong beliefs about their disease that influenced their adherence 
status. Some men believed that GnRH agonists contained “female” hormones that 
they were not willing to be injected with. 
“I don’t believe in this female hormones. There are all these symptoms. The 
ideology you know what it is no? [Interviewer: Yeah] Female hormones in a 
man.” 
(ADT-007, 64, non-adherent) 
Men who held strong religious views believed in a higher deity in keeping them alive 
rather than taking GnRH agonists.  
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“The oestrogen will not stop me from dying tomorrow. So I’m not going to put 
my trust in the oestrogen for my life, I put my trust in God.” 
(ADT-007, 64, non-adherent) 
In addition to believing in God to keep them alive, some men even sought out faith 
healers who they believed could cure their disease. 
“I went to Brazil at one point to see um John of God, this guy who is 
supposed to be able to heal people and stuff..” 
(ADT-009, 53, adherent) 
Aside from religious and cultural views, stigmas against cancer, healthcare services 
and pharmaceutical companies can form barriers against adherence. 
“And I hate to say it but a lot of these things is not materialistic. A lot of 
these things is not for the benefit [laughs] of the person but because of the 
money made from it….. They probably found a cure 15 years ago. And stop 
this and start that. But they’re not gonna produce something that’s going to 
solve the problem if it’s not financially beneficial for them. And I’m aware of 
these things.” 
(ADT-007, 64, non-adherent) 
Some men believed in herbal medications and holistic approaches rather than 
‘Western’ medicine. 
“… growing up in Jamaica, learning about plants, as a youngster growing up, 
about bush, natural herbs, I think that also helps me a lot. Because.. I drink… 
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I’ve been drinking a lot of bush when I first started, when I first found out 
that I had cancer” 
(ADT-005, 63, non-adherent) 
Benefits outweigh harm 
All adherent men recognised having treatment as a necessity to stop their PCa from 
progressing. For them, side-effects were a price to pay for the benefits of having the 
treatment. 
“It seems to be well-established that for most men and for me that it seems 
to be working effectively at containing the identified prostate cancer. Um 
you might say that that’s the price to pay and that would be how I would 
view it.” 
(ADT-001, 63, adherent) 
Quality of life over quantity of life 
Although majority of the men interviewed felt that the necessity of having 
hormonal injections for their cancer outweighed their side-effects, some felt that 
the benefits of having treatments were outweighed by side-effects that they may 
experience or have already experienced.  
“I may live longer but what will be the quality of my life…. I’d rather live long, 
naked, happy and content than go through misery.” 
(ADT-007, 64, non-adherent) 
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Men discontinued treatment due to severe side-effects that they had experienced 
which hindered their quality of life. For example, most men found hot flushes quite 
embarrassing and frustrating. 
“Because I hate going out and I’ve been walking with a towel and I’m 
walking, I’m on the bus and mopping up.. mopping up myself [Interviewer: 
Yeah]. I hate it.” 
(ADT-005, 63, non-adherent) 
Whereas other men were willing to compromise their quantity of life over quality of 
life for their family. 
“I’d much rather have more time with my family even if the quality of that is 
a bit of the best.” 
(ADT-003, 56, adherent) 
Social support 
Having a supportive social unit, whether it is family or friends, was deemed to be an 
important factor influencing adherence by adherent men. 
“An understanding family or close unit connection, I think is really 
important.” 
(ADT-001, 63, adherent) 
One individual discussed about his wife’s role in reminding him about his 
medication. 
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“But yes, certainly my wife particularly is brilliant at helping me remember 
stuff. Um reminding me to, I mean, just taking the medication. It’s a bit of a 
challenge for somebody who has never really taken medication before. So 
she’s very supportive in that.” 
(ADT-003, 56, adherent) 
On the other hand, non-adherent men who were single or not in a committed 
relationship felt that side-effects such as loss of libido worsened if they did not have 
an understanding or stable partner, which in turn, influenced their decision to not 
have the treatment. 
“There’s a lot of difference. And.. if you don’t have… one single partner 
[Interviewer: Mmm], it makes it even worse…… if you’re separated.. you 
haven’t got somebody you trust… it’s killing …… Because you don’t want 
something you do and it will affect your libido, sometimes you want to 
escape it. Maybe a girl is coming to you, you don’t want anything to..” 
(ADT-006, 53, non-adherent) 
Patient-clinician relationship 
Understanding treatment regimens 
Understanding treatment regimens influenced treatment decisions in some men in 
choosing to adhere to GnRH agonists. 
“It wouldn’t get me to the point where I am today if I didn’t understand.” 
(ADT-002, 76, adherent) 
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Misinterpretation of the prescribed treatment in one individual meant that he failed 
to have the injection on time. 
“…. He literally thought that I was still taking the injection… But I said no… 
he’s saying to me that, he thinks that I should be taking the injection as 
well.” 
(ADT-005, 63, non-adherent) 
In addition to the themes identified above, the one-to-one interviews also included 
discussions on change in lifestyle factors such as smoking status, alcohol intake and 
exercise. Men who made changes to their lifestyle made these changes because of 
cancer diagnosis rather than initiating GnRH agonists. No direct link was therefore 
identified for these lifestyle factors contributing to adherence or non-adherence.  
6.3.1.3 Stage 3: Focus groups 
Six clinicians attended two focus groups which lasted for a maximum of one hour. 
Table 36 shows the gender and role of the clinicians.  
Table 36: Characteristics of study participants from the focus groups. 
Study ID Gender Professional Role 
CNS-001 Female Nurse specialist 
CNS-002 Female Nurse specialist 
CNS-003 Female Nurse specialist 
ONC-001 Female Registrar 
ONC -002 Female Consultant 
ONC -003 Male Consultant 
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The themes identified from the focus groups included side-effects of treatment, 
patient belief system, quality of life over quantity of life, social support and patient-
clinician relationship. 
Side-effects of treatment 
Patients’ views on loss of libido were in concordance with assessments made by 
clinicians which were discussed in the focus groups. 
“Yeah and it’s born out of all our holistic needs assessments, if you look at 
the top concern, month in, month out, it’s the sex…… But the problem is that, 
it’s libido, sex drive. And you can’t replace that. So it involves counselling, it 
involves couple therapy, it involves work, it involves adapting to the fact that 
everything’s changed and you’ve got to move forward.” 
(CNS-001, nurse specialist) 
Patient belief system 
Clinicians from the focus groups also agreed that strong beliefs held by men 
prescribed GnRH agonists also influenced their adherence status. 
“I think that cultural thing can be around the cultural view of you as a man. 
In terms of your facility, in terms of your potency, in terms of your body 
shape, all those things. … And you hear people say “I don’t want female 
hormones” and no matter how many times you say it’s not female hormones 
[CNS-002: Mmm], it’s perceived as feminising and demasculating.” 
(CNS-001, nurse specialist) 
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“I’m thinking some… ethnic groups, especially the African people, some 
beliefs that uh.. they can be in control umm of their disease, they can pray a 
lot and that will control the cancer.” 
(ONC-003, consultant oncologist) 
Quality of life over quantity of life 
Clinicians were also aware that some men preferred a better quality of life over a 
quantity of life. 
“And this is a life-limiting condition and for some people, they’d rather have 
very short-term life with quality.” 
(CNS-001, nurse specialist) 
Social support 
Men who were adherent also had an “efficient family” who provided support by 
reminding these men to have their injection on time.  
“Moderator: So there’s no sort of reminders out there, at this point [CNS-002: 
No] to um – 
CNS-002: Other than efficient family.  
CNS-001: Because yeah, I think family.” 
(CNS-001, CNS-002, nurse specialists) 
Patient-clinician relationship 
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Understanding treatment regimens 
From the clinician’s perspective, some men fail to understand the importance of 
their medication. 
“I don’t think they comprehend why they’re on it, you know the importance 
of it and that it matters that if they miss it.” 
(CNS-002, nurse specialist) 
Even after educating men repeatedly, some men simply did not retain the 
information given to them. 
“No I don’t think we can educate them that much more. I think some of it is 
just retention. … they’ll probably attend a seminar … written information. So 
we do give them… all this information..  But some of it, I don’t think, can 
retain it or..” 
(CNS-003, nurse specialist) 
Differences in roles between doctors and nurses 
Role differences between doctors and nurses were highlighted both in the 
interviews and focus groups. Whereas doctors focus on oncological and treatment 
outcomes in their consultations with men on GnRH agonists, nurses address 
functional issues and side-effects in special clinics such as the sexual dysfunction 
clinic and seminars such as the ‘Healthy on Hormones’ seminar run every four 
months at Guy’s hospital.  
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According to the clinicians, men attending these clinics seemed to be aware of what 
issues to discuss with different healthcare professionals even though some men in 
the interviews felt that there was no “continuity” in which doctor they saw in clinic. 
“I think it can be done in a different forum… a seminar setting.. in a offline 
setting. Not in a clinic where they are making treatment decisions and where 
they are hearing about their latest scans and all of that. I think they’d much 
rather discuss what their latest scan shows … first and then talk about 
hormone thing which is kind of an ongoing issue and very rarely is acute 
problem.” 
(ONC-001, registrar) 
Engagement with the health care system 
Clinicians in both focus groups were in concordance about the importance of 
keeping non-adherent men engaged within the health care system.  
“.. for me it’s about leaving the door open, it’s about acknowledging their 
concerns… not trying to change their mind but just very much introducing 
different alternatives … making sure that they’re still engaged. Because some 
people will change their minds.”  
(CNS-001, nurse specialist) 
Keeping non-adherent men engaged from different perspectives and reminding 
them of the consequences of being non-adherent based on evidence may at some 
point convince them to have the treatment. 
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“.. it’s their decision… but we have to make sure that they fully understand 
the, the repercussions.” 
(ONC-002, consultant oncologist) 
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6.4  DISCUSSION 
The results of this qualitative study provide insights into factors contributing to 
adherence and non-adherence to GnRH agonists in men with PCa. Loss of libido was 
the most important factor contributing to non-adherence in some men. Adherent 
men who reported side-effects such as hot flushes, disrupted sleeping patterns and 
weight gain found ways to cope with the side-effects as they saw that benefits of 
the treatment outweighed the harms. However, men who struggled to cope with 
the side-effects wanted a better quality of life than quantity of life and were more 
likely to be non-adherent. Moreover, some men held strong cultural, religious or 
other personal views that contributed to their non-adherence or complete refusal 
of initiating the treatment that they were prescribed. Social support, understanding 
treatment regimens and patient-clinician relationship were other factors that 
influenced adherence to treatment in this study.  
Loss of libido strongly influenced some men’s decision to not adhere to the 
treatment that they were prescribed. One of the interviewees viewed loss of libido 
as the single most important factor for being non-adherent because it was affecting 
his chances of finding a partner.  Loss of libido was also reported as a concern in 58-
91% of men on GnRH agonists in a literature review of studies investigating adverse 
effects of ADT (77). Moreover, 50% of married men on ADT interviewed 
experienced some extent of marital erosion after ADT administration (81). This 
suggests that loss of libido is a cause for concern in both men who are single and in 
a committed relationship.  
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Nurses in the focus group also emphasised that loss of libido was the biggest 
concern that men on GnRH agonists highlighted in their holistic needs assessments 
forms. Sexuality can be influenced by other factors such as body image and self-
perceived masculinity in addition to loss of libido in these men. Based on previous 
evidence, 60% of men receiving hormonal treatment had negative views of their 
body image and felt a loss of their masculinity (206).  
A strong belief system of men in this study also appear to influence adherence to 
treatment. Some men believed that GnRH agonists were “female hormones” which 
they found emasculating to be treated with. In a previous study, 50% men reported 
feeling less masculine after only three months on ADT (207). Psychological factors 
including patients’ beliefs, motivation and a negative attitude towards their 
treatment were found to influence adherence to a treatment in other studies (82). 
Moreover, a negative attitude towards “Western” medication may also be 
heightened by an increased confidence in herbal or natural remedies leading to 
non-adherence to medication in certain cultures, especially in men of Black origin 
(208), which was also reported in the current study. 
The results of this study show that ethnic origin and cultural views of men may 
influence non-adherence to GnRH agonists and this warrants further investigation. 
Out of the sixteen studies identified on ethnicity within Jin et al.’s review (82), 
Caucasians showed an increased adherence to medication compared to other 
ethnicities. This was attributed to the plausible explanation of language barriers and 
lower socio-economic statuses of the minorities included in the study countries. 
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In the current study, all non-adherent men were of Black origin who held strong 
beliefs and stigmas against cancer and ‘Western’ cancer treatments (refer to quotes 
by ADT-005 and ADT-006). Addressing non-adherence to GnRH agonists in this 
ethnic group is particularly important because men of Black origin are diagnosed 
with more aggressive PCa which can affect treatment-outcomes (209). Although 
these belief systems may be challenged it is also important to acknowledge these 
beliefs in order to keep non-adherent men engaged with the healthcare system.  
Men in the interviews who struggled with their side-effects wanted a better quality 
of life than quantity of life. On the other hand, men who were determined to cope 
with their side-effects held a completely opposite viewpoint and believed that the 
benefits of the treatment outweighed the side-effects of the treatment. These two 
groups who belonged to the opposite ends of the spectrum were also observed in 
Moon et al.’s (2017) study on adherence in women with breast cancer (210). 
Adherent men believed that social support in the form of a spouse or other family 
members helped with their adherence in this study. This was also suggested by 
several studies included by Jin et al. (2008) to be the reason why married patients 
were more adherent to medication compared to single patients (82). 
According to clinicians who attended the focus groups in this study, some men 
simply failed to retain information despite being educated. For example, CNS-003 
who is a nurse specialist, thought, “No I don’t think we can educate them that much 
more. I think some of it is just retention”. Although one may expect that a well-
educated patient may be able to better comprehend the therapy they are receiving 
for their disease, Senior et al. (2004) showed that patients without a formal 
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educational qualification had better adherence to cholesterol-lowering medication 
than those with higher educational qualifications (211). Therefore, education level 
and the level of retention in the men interviewed may be explored in future studies 
to determine the role of education in non-adherence to GnRH agonists. 
Having a good patient-clinician relationship contributed to understanding treatment 
regimens and differences in roles of healthcare professionals. Whereas some men 
had a good understanding of their treatment regimens and even tailored their 
discussions corresponding to the roles of their clinicians, understanding treatment 
regimens proved to be too complicated and led to misinterpretations of the 
regimen in other men. Clinicians in this study also felt that it was important to use 
different strategies to keep non-adherent men engaged with the healthcare system.  
As side-effects of GnRH agonists were reported to be one reason for non-adherence 
to GnRH agonists in this study, offering intermittent therapy (a gap between GnRH 
agonists’ injections to minimise the side-effects of GnRH agonists discussed in more 
detail on page 123-124, chapter 4) may lead to the eventual acceptance of 
treatment in these men whilst also acknowledging their reasons for non-adherence. 
 
6.5 CONCLUSION 
In this single-centred study, adherence to GnRH agonists in men with PCa was 
identified to be due to a positive patient-clinician relationship and an understanding 
of treatment regimens among patients. Several multi-factorial reasons such as side-
effects, strong patient belief system and quality over quantity of life were identified 
as contributing to non-adherence in some men. Reasons leading to non-adherence 
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can be multifactorial and unique to each patient. Therefore, supporting non-
adherent men and keeping them engaged with the health care system by employing 
different strategies such as the use of intermittent therapy by clinicians may lead to 
the eventual acceptance of treatment whilst also acknowledging their reasons for 
non-adherence. Further multi-centre studies including larger sample sizes 
representative of care across UK and GP perspectives are required to fully 
understand adherence in men with PCa on GnRH agonists.  
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7. CHAPTER VII – CONCLUSION 
The aim of this thesis was to use real world data to investigate adverse events of 
ADT and to identify patterns and factors influencing adherence to GnRH agonists in 
men with PCa. This chapter provides a summary of the results of the four projects. 
The first project (chapter III) of this thesis was the first study to use real world data 
from six countries to compare the CVD effects of GnRH agonists and GnRH 
antagonists in men with PCa. The results of this study showed that there was an 
increased risk of developing CVD (arrhythmia, HF and stroke) in men with PCa on 
GnRH antagonists who had a HCVDi compared to men on GnRH agonists. This 
finding was contradictory to the pre-clinical studies comparing these GnRH 
analogues and thus requires further investigation. Moreover, this study highlighted 
the challenges of using real world data across the different countries. The results 
emphasised the importance of homogenous definitions for study variables when 
aiming to answer research questions using pooled data from different countries, 
especially in cases where country-specific data is limited. Therefore, the results of 
the first project require further investigation using updated data from countries 
with a larger sample size, including acute CVD events from hospital-based databases 
and information on prescription patterns of GnRH antagonists to address 
channeling bias. Finally, results from the PRONOUCE RCT may also address the 
potential of channeling bias in this observational setting even though the trial only 
covers a one-year follow-up period in which the long-term CVD effects may not be 
addressed. 
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The purpose of the three adherence projects of this thesis was to identify patterns 
of adherence to GnRH agonists in men with PCa in Sweden (chapter IV) and the UK 
(chapter V) and explore reasons for non-adherence from both patient and clinician 
perspectives (chapter VI). The results from PCBaSeTraject Sweden identified increased 
age, advanced cancer stage at diagnosis, longer injection intervals and prior PCa 
treatment as factors contributing to increased adherence. Two of these factors 
were also identified in the analyses based on the UK THIN database: increased age 
and longer injection intervals. This provides evidence for some common factors 
already known from other disease settings that can contribute to adherence in men 
on GnRH agonists.  
Moreover, employing thematic analysis to qualitative data collected from one-to-
one interviews with patients and focus groups with clinicians from a hospital setting 
provided further insight into factors contributing to adherence and non-adherence 
to GnRH agonists in men with PCa. The results of the three projects showed that 
whilst men on long-term GnRH agonists may benefit from longer injection intervals, 
the reasons that lead to non-adherence are multifactorial and unique to each 
patient. Several multi-factorial reasons such as side-effects, strong patient belief 
system and quality over quantity of life were identified as contributing to non-
adherence in some men. Ethnicity also played a major role in non-adherence to 
GnRH agonists, with an increased number of men of Black origin failing to adhere to 
GnRH agonists than men of other origins. Addressing non-adherence in this ethnic 
group is especially important because men of Black origin are diagnosed with more 
aggressive PCa and have worse disease-related and treatment-related outcomes.  
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Although the strong belief systems held by non-adherent men may be challenged, 
acknowledging their role in decision-making concerning their treatments and 
employing strategies such as the use of intermittent treatment regimens to keep 
non-adherent men engaged with the healthcare system may eventually lead to an 
acceptance of treatment. Further multi-centre studies including larger sample sizes 
and GP perspectives are required to fully understand factors contributing to 
adherence and non-adherence in men with PCa on GnRH agonists. 
In conclusion, the findings from six countries highlight the importance of adverse 
effects of ADT in men with PCa on GnRH analogues. For the first time, results have 
shown an increased risk of developing CVD in men with PCa on GnRH antagonists as 
compared to GnRH agonists which requires further clarification from RCTs. If the 
findings are confirmed in further studies and RCTs, it may influence hormonal 
treatment of PCa in men with a prior history of CVD. Moreover, this thesis provides 
insights into methodological issues and challenges of data heterogeneity 
encountered when using real world data. The projects on adherence provide 
evidence for multi-factorial reasons such as side-effects and strong patient belief 
system contributing to non-adherence in men with PCa on GnRH agonists. This 
highlights the importance of using qualitative methods to complement quantitative 
measures in healthcare research. 
  
Page 198 of 281 
 
8. REFERENCES 
1. IARC. CANCER FACT SHEETS: PROSTATE CANCER. 2012. Available at: 
http://gco.iarc.fr/today/data/pdf/fact-sheets/cancers/cancer-fact-sheets-
19.pdf [Accessed: 02/10/2019]. 
2. Kirby R, Patel, MI. Fast Facts: Prostate Cancer. 8 ed. Oxford: Health Press 
Limited. 2012. 
3. Cancer Research UK. Prostate cancer mortality statistics. 2019. [Updated 
16/10/2019]. Available from: https://www.cancerresearchuk.org/health-
professional/cancer-statistics/statistics-by-cancer-type/prostate-
cancer/mortality#ref-. [Accessed: 13/12/2019]. 
4. Muir CS, Nectoux J, Staszewski J. The epidemiology of prostatic cancer. 
Geographical distribution and time-trends. Acta Oncol. 1991;30(2):133-40. 
5. Huggins C, Stevens R, Hodge C. Studies on prostate cancer: II. The effects of 
castration on advanced carcinoma of the prostate gland. Arch Surg. 
1941;43:209-23. 
6. Bourke L, Kirkbride P, Hooper R, et al. Endocrine therapy in prostate cancer: 
time for reappraisal of risks, benefits and cost-effectiveness? Br J Cancer. 
2013;108(1):9-13. 
7. Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence — What is it 
and what can it tell us? N Engl J Med. 2016;375(23):2293-7. 
8. Network for Excellence in Health Innovation. Real world evidence: A new era 
for health care innovation. 2015. Available from: 
https://www.nehi.net/publications/66-real-world-evidence-a-new-era-for-
health-care-innovation/view. [Accessed: 02/10/2019]. 
9. Food and Drug Administration. Use of real-world evidence to support 
regulatory decision-making for medical devices: Draft guidance for industry 
and food and drug administration staff. 2016. Available from: 
https://www.fda.gov/media/99447/download [Accessed: 02/10/2019]. 
10. Zeevi D, Korem T, Zmora N, et al. Personalized nutrition by prediction of 
glycemic responses. Cell. 2015;163(5):1079-94. 
11. GetReal Initiative. IMI GetReal. 2019. Available from: https://www.imi-
getreal.eu/. [Accessed: 02/10/2019]. 
12. Anderson C. Prostate Cancer. 2012. Available from: 
http://keyholeurology.co.uk/prostatecancer.html. [Accessed: 22/09/2019]. 
13. Sooriakumaran P, Srivastava A, Tewari A. Applied Anatomy of the Prostate. In: 
Dasgupta P KR, editor. ABC of Prostate Cancer. ABC Series. West Sussex: 
John Wiley & Sons; 2012. p.1-4. 




BbM%3D. [Accessed: 02/10/2019]. 
15. Kundra  V, Matin SF, Kuban DA. Prostate Cancer. 2015. Available from: 
https://clinicalgate.com/prostate-cancer-4/.[Accessed: 02/10/2019]. 
Page 199 of 281 
 
16. Bonekamp D, Jacobs MA, El-Khouli R, et al. Advancements in MR imaging of 
the prostate: from diagnosis to interventions. Radiographics. 2011;31(3):677-
703. 
17. Drudge-Coates L. GnRH blockers: A changing paradigm in the management of 
prostate cancer. International Journal of Urological Nursing. 2009;3(3):85-92. 
18. Gao W, Bohl CE, Dalton JT. Chemistry and structural biology of androgen 
receptor. Chem Rev. 2005;105(9):3352-70. 
19. Kirby RS, Partin AW, Feneley M, et al. Prostate cancer: Principles and Practice. 
Taylor and Francis, London and New York. 2006. 
20. Chodak GW, Krupski, T. Prostate Cancer eMedicine. 2017. [Updated 
22/07/2017]. Available from: 
http://emedicine.medscape.com/article/1967731-overview.[Accessed: 
22/09/2019]. 
21. Tikkinen KAO, Dahm P, Lytvyn L, et al. Prostate cancer screening with 
prostate-specific antigen (PSA) test: A clinical practice guideline. BMJ. 
2018;362:k3581. 
22. Eastham J. Prostate cancer screening. Investig Clin Urol. 2017;58(4):217-9. 
23. Nair C, Panikkar S, Ray A. How not to miss metastatic spinal cord compression. 
Br J Gen Pract. 2014;64(626):e596-e8. 
24. Thompson JC, Wood J, Feuer D. Prostate cancer: Palliative care and pain relief. 
Br Med Bull. 2007;83(1):341-54. 
25. Epstein JI, Zelefsky MJ, Sjoberg DD, et al. A contemporary prostate cancer 
grading system: A validated alternative to the Gleason ccore. Eur Urol. 
2016;69(3):428-35. 
26. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. 
Part 1: Screening, diagnosis, and local treatment with curative intent-update 
2013. Eur Urol. 2014;65(1):124-37. 
27. Ip S, Dahabreh IJ, Chung M, et al. An evidence review of active surveillance in 
men with localized prostate cancer. Evid Rep Technol Assess. 2011;(204):1-
341. 
28. Shao YH, Demissie K, Shih W, et al. Contemporary risk profile of prostate 
cancer in the United States. J Natl Cancer Inst. 2009;101(18):1280-3. 
29. Klotz L. Active surveillance for prostate cancer: a review. Curr Urol Rep. 
2010;11(3):165-71. 
30. Hamdy FC, Donovan JL, Lane JA, et al. 10-Year Outcomes after Monitoring, 
Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 
2016;375(15):1415-24. 
31. White C, Nimeh T, Gazelle GS, et al. A decision analysis comparing 3 active 
surveillance protocols for the treatment of patients with low-risk prostate 
cancer. Cancer. 2019;125(6):952-62. 
32. van Haute W, van Poppel H. Open Radical Prostatectomy. In: ABC of Prostate 
Cancer. Dasgupta P, Kirby RS. West Sussex: Blackwell Pub Ltd; 2012. p.25-8. 
33. Kumar P, Cahill D. Laparoscopic Radical Prostatectomy. In: ABC of Prostate 
Cancer. Dasgupta P, Kirby RS. West Sussex: Blackwell Pub Ltd; 2012. p.29-32. 
34. Challacombe B, Peabody J. Robotic Radical Prostatectomy. In: ABC of Prostate 
Cancer. Dasgupta P, Kirby RS.West Sussex: Blackwell Pub Ltd; 2012. p.33. 
Page 200 of 281 
 
35. Michaelson MD, Cotter SE, Gargollo PC, et al. Management of complications 
of prostate cancer treatment. CA Cancer J Clin. 2008;58(4):196-213. 
36. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful 
waiting in prostate cancer — 29-Year follow-up. N Engl J Med. 
2018;379(24):2319-29. 
37. Wilt TJ, Jones KM, Barry MJ, et al. Follow-up of prostatectomy versus 
observation for early prostate cancer. N Engl J Med. 2017;377(2):132-42. 
38. American Cancer Society. Prostate Cancer Guide: Radiation therapy for 
prostate cancer. 2015. Available from: 
https://www.cancer.org/cancer/prostate-cancer/treating/radiation-
therapy.html. [Accessed: 02/10/2019]. 
39. Mottet N, van den Bergh RCN, Briers E et al. Prostate Cancer - Treatment. 
2019. Available at: https://uroweb.org/guideline/prostate-cancer/#6 
[Accessed: 03/10/2019]. 
40. Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes after 
monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 
2016;375(15):1425-37. 
41. Reid P, Kantoff P, Oh W. Antiandrogens in prostate cancer. Invest New Drug. 
1999;17(3):271-84. 
42. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral 
androgens in metastatic prostate cancer: A Mechanism for castration-
resistant tumor growth. Cancer Res. 2008;68(11):4447-54. 
43. Anassi E, Ndefo UA. Sipuleucel-T (provenge) injection: The first 
immunotherapy agent (vaccine) for hormone-refractory prostate cancer. P T. 
2011;36(4):197-202. 
44. Beer  TM, Armstrong  AJ, Rathkopf  DE, et al. Enzalutamide in metastatic 
prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424-33. 
45. Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on prostate 
cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant 
prostate cancer. Eur Urol. 2017;71(4):630-42. 
46. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, 
or both to first-line long-term hormone therapy in prostate cancer 
(STAMPEDE): Survival results from an adaptive, multiarm, multistage, 
platform randomised controlled trial. Lancet. 2016;387(10024):1163-77. 
47. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in 
metastatic hormone-sensitive prostate cancer. N Engl J Med. 
2015;373(8):737-46. 
48. Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in metastatic, 
castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352-60. 
49. STAMPEDE. About STAMPEDE [Updated 10/06/2019]. 2019. Available from: 
http://www.stampedetrial.org/participants/about-stampede/. [Accessed: 
29/09/2019]. 
50. Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour 
for newly diagnosed, metastatic prostate cancer (STAMPEDE): A randomised 
controlled phase 3 trial. The Lancet. 2018;392(10162):2353-66. 
Page 201 of 281 
 
51. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and 
mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer. 
2013;49(6):1374-403. 
52. Kockelbergh R, Hounsome L, Mayer E. The epidemiology of urological cancer 
2001–2013. J Clin Urol. 2017;10(1_suppl):3-8. 
53. Franks LM. Latent carcinoma of the prostate. J Pathol Bacteriol. 
1954;68(2):603-16. 




55. Minelli A, Bellezza I, Conte C, et al. Oxidative stress-related aging: A role for 
prostate cancer? Biochim Biophys Acta. 2009;1795(2):83-91. 
56. Olapade-Olaopa EO, Muronda CA, MacKay EH, et al. Androgen receptor 
protein expression in prostatic tissues in Black and Caucasian men. Prostate. 
2004;59(4):460-8. 
57. Ellis L, Nyborg H. Racial or ethnic variations in male testosterone levels: A 
probable contributor to group differences in health. Steroids. 1992;57(2):72-5. 
58. Kantoff P, Carroll PR, D'Amico AV. Prostate cancer: Principles and Practice. 1st 
ed. Philadelphia: Lippincott Williams & Wilkins; 2002; p. 748. 
59. Gann PH. Risk Factors for Prostate Cancer. Rev Urol. 2002;4(Suppl 5):S3-S10. 
60. C Cavanagh H, Rogers KMA. The role of BRCA1 and BRCA2 mutations in 
prostate, pancreatic and stomach cancers. Hered Cancer Clin Pract. 
2015;13(1):16. 
61. Masko EM, Allott EH, Freedland SJ. The relationship between nutrition and 
prostate cancer: is more always better? Eur Urol. 2013;63(5):810-20. 
62. Allen NE, Key TJ, Appleby PN, et al. Animal foods, protein, calcium and 
prostate cancer risk: The European prospective Iinvestigation into cancer and 
nutrition. Br J Cancer. 2008;98(9):1574-81. 
63. Wang Y, Corr JG, Thaler HT, et al. Decreased growth of established human 
prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst. 
1995;87(19):1456-62. 
64. Key TJ, Appleby PN, Allen NE, et al. Plasma carotenoids, retinol, and 
tocopherols and the risk of prostate cancer in the European Prospective 
Investigation into Cancer and Nutrition study. Am J Clin Nutr. 2007;86(3):672-
81. 
65. WCRFI. World Cancer Research Fund International or American Institute for 
Cancer Research Continuous Update Project Report: Diet, nutrition, physical 
activity, and prostate cancer. 2014 [Available from: 
https://www.wcrf.org/sites/default/files/Prostate-Cancer-2014-Report.pdf 
[Accessed: 15/10/2018]. 
66. Brawer MK. Androgen Deprivation Therapy: A Cornerstone in the Treatment 
of Advanced Prostate Cancer. Rev Urol. 2004;6(Suppl 8):S3-S9. 
67. Rick FG, Block NL, Schally AV. An update on the use of degarelix in the 
treatment of advanced hormone-dependent prostate cancer. Onco Targets 
Ther. 2013;6:391-402. 
Page 202 of 281 
 
68. Velcheti V, Karnik S, Bardot SF, et al. Pathogenesis of prostate cancer: Lessons 
from basic research. Ochsner J. 2008;8(4):213-8. 
69. Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of 
advanced prostate cancer. Rev Urol. 2007;9(Suppl 1):S3-S8. 
70. Khan MA, Partin AW. Management of high-risk populations with locally 
advanced prostate cancer. Oncologist. 2003;8(3):259-69. 





72. Broqua P, Riviere PJM, Conn PM, et al. Pharmacological profile of a new, 
potent, and long-acting gonadotropin-releasing hormone antagonist: 
Degarelix. J Pharmacol and Exp Ther. 2002;301(1):95. 
73. Van Poppel H, Tombal B, de la Rosette JJ, et al. Degarelix: A novel 
gonadotropin-releasing hormone (GnRH) receptor blocker— Results from a 1-
yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of 
prostate cancer. Eur Urol. 2008;54(4):805-15. 
74. Gittelman M, Pommerville PJ, Persson B-E, et al. A 1-Year, open Label, 
randomized phase II dose finding study of degarelix for the treatment of 
prostate cancer in North America. J Urol. 2008;180(5):1986-92. 
75. Klotz L, Boccon-Gibod L, Shore ND, A, et al. The efficacy and safety of 
degarelix: a 12-month, comparative, randomized, open-label, parallel-group 
phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-8. 
76. Rhee H, Gunter JH, Heathcote P, et al. Adverse effects of androgen-
deprivation therapy in prostate cancer and their management. BJU Int. 
2015;115 Suppl 5:3-13. 
77. Walker LM, Tran S, Robinson JW. Luteinizing hormone--releasing hormone 
agonists: A quick reference for prevalence rates of potential adverse effects. 
Clin Genitourin Cancer. 2013;11(4):375-84. 
78. Spetz AC, Zetterlund EL, Varenhorst E, et al. Incidence and management of hot 
flashes in prostate cancer. Journal Support Oncol. 2003;1(4):263-6, 9-70, 72-3; 
discussion 7-8, 71-2. 
79. Green HJ, Pakenham KI, Headley BC, et al. Quality of life compared during 
pharmacological treatments and clinical monitoring for non-localized prostate 
cancer: a randomized controlled trial. BJU Int. 2004;93(7):975-9. 
80. Walker LM, Robinson JW. A description of heterosexual couples' sexual 
adjustment to androgen deprivation therapy for prostate cancer. 
Psychooncology. 2011;20(8):880-8. 
81. Navon L, Morag A. Advanced prostate cancer patients' ways of coping with 
the hormonal therapy's effect on body, sexuality, and spousal ties. Qual 
Health Res. 2003;13(10):1378-92. 
82. Jin J, Sklar GE, Min Sen Oh V, et al. Factors affecting therapeutic compliance: A 
review from the patient’s perspective. Ther Clin Risk Manag. 2008;4(1):269-
86. 
Page 203 of 281 
 
83. Kim HS, Freedland SJ. Androgen deprivation therapy in prostate cancer: 
Anticipated side-effects and their management. Current Opin Support Palliat 
Care. 2010;4(3):147-52. 
84. Potosky AL, Knopf K, Clegg LX, et al. Quality-of-life outcomes after primary 
androgen deprivation therapy: Results from the Prostate Cancer Outcomes 
Study. J Clin Oncol. 2001;19(17):3750-7. 
85. Hamilton EJ, Ghasem-Zadeh A, Gianatti E, et al. Structural decay of bone 
microarchitecture in men with prostate cancer treated with androgen 
deprivation therapy. J Clinical Endocrinol Metab. 2010;95(12):E456-63. 
86. Beebe-Dimmer JL, Cetin K, Shahinian V, et al. Timing of androgen deprivation 
therapy use and fracture risk among elderly men with prostate cancer in the 
United States. Pharmacoepidemiol Drug Saf. 2012;21(1):70-8. 
87. Klotz LH, McNeill IY, Kebabdjian M, et al. A phase 3, double-blind, randomised, 
parallel-group, placebo-controlled study of oral weekly alendronate for the 
prevention of androgen deprivation bone loss in nonmetastatic prostate 
cancer: The Cancer and Osteoporosis Research with Alendronate and 
Leuprolide (CORAL) study. Eur Urol. 2013;63(5):927-35. 
88. mith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of 
zoledronic acid to prevent bone loss in men receiving androgen deprivation 
therapy for nonmetastatic prostate cancer. J Urol. 2003;169(6):2008-12. 
89. Hegemann M, Bedke J, Stenzl A, et al. Denosumab treatment in the 
management of patients with advanced prostate cancer: Clinical evidence and 
experience. Ther Adv Urol. 2017;9(3-4):81-8. 
90. Llorente MD, Burke M, Gregory GR, et al. Prostate cancer: A significant risk 
factor for late-life suicide. Am J Geriatr Psychiatry. 2005;13(3):195-201. 
91. Green HJ, Pakenham KI, Headley BC, et al. Altered cognitive function in men 
treated for prostate cancer with luteinizing hormone-releasing hormone 
analogues and cyproterone acetate: a randomized controlled trial. BJU Int. 
2002;90(4):427-32. 
92. Templeton H, Coates V. Evaluation of an evidence-based education package 
for men with prostate cancer on hormonal manipulation therapy. Patient 
Educ Couns. 2004;55(1):55-61. 
93. Jayadevappa R, Chhatre S, Malkowicz SB, et al. Association between androgen 
deprivation therapy use and diagnosis of dementia in men with prostate 
cancer. JAMA Network Open. 2019;2(7):e196562-e. 
94. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease 
during androgen deprivation therapy for prostate cancer. J Clin Oncol. 
2006;24(27):4448-56. 
95. Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases 
cardiovascular morbidity in men with prostate cancer. Cancer. 
2007;110(7):1493-500. 
96. Jones RD, Nettleship JE, Kapoor D, et al. Testosterone and atherosclerosis in 
aging men: Purported association and clinical implications. Am J Cardiovasc 
Drugs. 2005;5(3):141-54. 
97. D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression 
therapy for prostate cancer on the frequency and timing of fatal myocardial 
infarctions. J Clin Oncol. 2007;25(17):2420-5. 
Page 204 of 281 
 
98. Tsai HK, D'Amico AV, Sadetsky N, et al. Androgen deprivation therapy for 
localized prostate cancer and the risk of cardiovascular mortality. J Natl 
Cancer Inst. 2007;99(20):1516-24. 
99. Van Hemelrijck M, Garmo H, Holmberg L, et al. Absolute and relative risk of 
cardiovascular disease in men with prostate cancer: Results from the 
population-based PCBaSe Sweden. J Clin Oncol. 2010;28(1):34778-56. 
100. O'Farrell S, Garmo H, Holmberg L, et al. Risk and timing of cardiovascular 
disease after androgen-deprivation therapy in men with prostate cancer. J Clin 
Oncol. 2015;33(11):1243-51. 
101. Bosco C, Bosnyak Z, Malmberg A, et al. Quantifying observational evidence for 
risk of fatal and nonfatal cardiovascular disease following androgen 
deprivation therapy for prostate cancer: A meta-analysis. Eur Urol. 
2014;68(3):386-96. 
102. Keating NL, O'Malley AJ, Freedland SJ, et al. Does comorbidity influence the 
risk of myocardial infarction or diabetes during androgen-deprivation therapy 
for prostate cancer? Eur Urol. 2013;64(1):159-66. 
103. Jespersen CG, Norgaard M, Borre M. Androgen-deprivation therapy in 
treatment of prostate cancer and risk of myocardial infarction and stroke: A 
nationwide Danish population-based cohort study.Eur Urol.2014;65(4):704-9. 
104. Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy 
with cardiovascular death in patients with prostate cancer: A meta-analysis of 
randomized trials. JAMA. 2011;306(21):2359-66. 
105. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition 
during androgen deprivation therapy for prostate cancer. J Clin Endocrinol 
Metab. 2002;87(2):599-603. 
106. Keating NL, Liu PH, O'Malley AJ, et al. Androgen-deprivation therapy and 
diabetes control among diabetic men with prostate cancer. Eur Urol. 
2014;65(4):816-24. 
107. Aronson JK. Compliance, concordance, adherence. Br J Clin Pharmacol. 
2007;63(4):383-4. 
108. Jimmy B, Jose J. Patient medication adherence: measures in daily practice. 
Oman Med J. 2011;26(3):155-9. 
109. Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication 
adherence. Cochrane Database Syst Rev. 2008(2):CD000011. 
110.  Hopmans SN, Duivenvoorden WC, Werstuck GH, et al. GnRH antagonist 
associates with less adiposity and reduced characteristics of metabolic 
syndrome and atherosclerosis compared with orchiectomy and GnRH agonist 
in a preclinical mouse model. Urol Oncol. 2014;32(8):1126-34. 
111. Lam WY, Fresco P. Medication Adherence Measures: An Overview. BioMed 
Research International. 2015;2015:217047. 
112. Erdkamp F, Boone N, Janknegt R, et al. GnRH agonists and antagonists in 
prostate cancer. GaBI Journal. 2014;3(3):133-42. 
113. Crawford ED, Phillips JM. Six-month gonadotropin releasing hormone (GnRH) 
agonist depots provide efficacy, safety, convenience, and comfort. Cancer 
Manag Res. 2011;3:201-9. 
Page 205 of 281 
 
114. Dhanapal V, Reeves DJ. Bone health management in prostate cancer patients 
receiving androgen deprivation therapy. J Oncol Pharm Pract. 2012;18(1):84-
90. 
115. Chang JI, Bucci J. Unusual side effect from a luteinizing hormone-releasing 
hormone agonist, leuprorelin, in the treatment of prostate cancer: a case 
report. J Med Case Rep. 2016;10(1):323. 
116. Weckermann D, Harzmann R. Hormone therapy in prostate cancer: LHRH 
Antagonists versus LHRH Analogues. Eur Urol. 2004; 46(3):279-84. 
117. Cooper C, Carpenter I, Katona C, et al. The AdHOC Study of older adults' 
adherence to medication in 11 countries. Am J Geriatr Psychiatry. 
2005;13(12):1067-76. 
118. Yavuz A, Tuncer M, Erdoğan O, et al. Is there any effect of compliance on 
clinical parameters of renal transplant recipients? Transpl P. 2004;36(1):120-1. 





120. NICE. Prostate cancer: Diagnosis and management, NG131. 2019. Available 
from: https://www.nice.org.uk/guidance/ng131/resources/prostate-cancer-
diagnosis-and-management-pdf-66141714312133. [Accessed: 03/10/2019]. 
121. NICE. Prostate cancer: Triptorelin (Decapeptyl SR). 2014. Available at: 
https://www.nice.org.uk/advice/esnm30/resources/prostate-cancer-
triptorelin-decapeptyl-sr-pdf-1502680917105349. [Accessed: 03/10/2019]. 
122. George G, Scailteux LM, Garmo H, et al. Real-world insights into risk of 
developing cardiovascular disease following GnRH agonists versus antagonists 
for prostate cancer: A methodological protocol to a study using five European 
databases. Fundam Clin Pharmacol. 2019;33(4):479-99. 
123. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with 
prostate cancer undergoing long-term androgen-deprivation therapy. J Clin 
Oncol. 2006;24(24):3979-83. 
124. Mcleod D, Iversen P, See W, et al. Bicalutamide 150 mg plus standard care vs 
standard care alone for early prostate cancer. BJU international. 
2006;97(2):247-54. 
125.  Petrylak PJ, WM. Androgen Abliation for Prostate Cancer: Mechanisms and 
Modalities. In: Kantoff PC, PR. D'Amico, AV., editor. Prostate Cancer: Principles 
and Practice. Philadelphia: Lippincott Williams & Wilkins; 2002. 
126. Kelly WK, Gomella LG. Androgen deprivation therapy and competing risks. 
JAMA. 2011;306(21):2382-3. 
127. Benson K, Hartz AJ. A comparison of observational studies and randomized, 
controlled trials. N Engl J Med. 2000;342(25):1878-86. 
128. Miettinen OS. The need for randomization in the study of intended effects. 
Stat Med. 1983;2(2):267-71. 
129.  Albertsen PC, Klotz L, Tombal B, et al. Cardiovascular morbidity associated 
with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 
2014;65(3):565-73. 
Page 206 of 281 
 
130. Klotz L, Miller K, Crawford ED, et al. Disease control outcomes from analysis of 
pooled individual patient data from five comparative randomised clinical trials 
of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol. 
2014;66(6):1101-8. 
131. Rosario DJ, Davey P, Green J, et al. The role of gonadotrophin-releasing 
hormone antagonists in the treatment of patients with advanced hormone-
dependent prostate cancer in the UK. World J Urol. 2016;34(12):1601-1609. 
132. Klotz L, Boccon‐Gibod L, Shore ND, et al. The efficacy and safety of degarelix: A 
12‐month, comparative, randomized, open‐label, parallel‐group phase III 
study in patients with prostate cancer. BJU International. 2008;102(11):1531-
8. 
133. Smith MR, Klotz L, van der Meulen E, et al. Gonadotropin-releasing hormone 
blockers and cardiovascular disease risk: Analyses of prospective clinical trials 
of degarelix. J Urol. 2011;186(5):1835-42. 
134. Margel D, Peer A, Ber Y, et al. Cardiovascular morbidity in a randomized trial 
comparing GnRH-agonist and antagonist among patients with advanced 
prostate cancer. J Clin Oncol. 2019;37(15_suppl):5015. 
135.  Buyse M, Molenberghs G, Paoletti X, et al. Statistical evaluation of surrogate 
endpoints with examples from cancer clinical trials. Biom J. 2016;58(1):104-
32. 
136. Scailteux LM, Vincendeau S, Balusson F, et al. Androgen deprivation therapy 
and cardiovascular risk: No meaningful difference between GnRH antagonist 
and agonists - A nationwide population-based cohort study based on 2010-
2013 French Health Insurance data. Eur J Cancer. 2017;77:99-108. 
137. ClinicalTrials.gov. A trial comparing cardiovascular safety of degarelix versus 
leuprolide in patients with advanced prostate cancer and cardiovascular 
disease (PRONOUNCE). [Updated 10/10/2017]. 2017. Available from: 
https://clinicaltrials.gov/ct2/show/study/NCT02663908. [Accessed: 
25/07/2019]. 
138. Kintzel PE, Chase SL, Schultz LM, et al. Increased risk of metabolic syndrome, 
diabetes mellitus, and cardiovascular disease in men receiving androgen 
deprivation therapy for prostate cancer. Pharmacotherapy. 2008;28(12):1511-
22. 
139. Asakawa J, Iguchi T, Tamada S, et al. A change from gonadotropin releasing 
hormone antagonist to gonadotropin releasing hormone agonist therapy does 
not affect the oncological outcomes in hormone sensitive prostate cancer. 
Basic Clin Androl. 2018;28:9. 
140.  Sterne JAC, Hernán MA, Reeves BC, et al. ROBINS-I: A tool for assessing risk 
of bias in non-randomised studies of interventions. BMJ. 2016;355. 
141. Lodwick RK. THIN Database. 2015. Available from: 
https://www.ucl.ac.uk/pcph/research-groups-themes/thin-pub/database. 
[Accessed: 26/01/2018]. 
142.  IMS Health Incorporated. Data Content. 2015. Available from: 
http://csdmruk.cegedim.com/our-data/data-content.shtml.[Accessed: 
26/01/2018]. 
143. Vision Health. 2017. Available from: https://www.visionhealth.co.uk/. 
[Accessed: 26/01/2018]. 
Page 207 of 281 
 
144. Blak BT, Thompson M, Dattani H, et al. Generalisability of The Health 
Improvement Network (THIN) database: Demographics, chronic disease 
prevalence and mortality rates. Inform Prim Care. 2011;19(4):251-5. 
145. Lewis JD, Schinnar R, Bilker WB, et al. Validation studies of the health 
improvement network (THIN) database for pharmacoepidemiology research. 
Pharmacoepidemiol Drug Saf. 2007;16(4):393-401. 
146. Booth N. What are the Read Codes? Health Libr Rev. 1994;11(3):177-82. 
147. ATC/DDD Index 2019 [Updated 13/12/2018]. 2018. Available from: 
https://www.whocc.no/atc_ddd_index/. [Accessed: 03/10/2019]. 
148. Alvarez-Madrazo S, McTaggart S, Nangle C, et al. Data Resource Profile: The 
Scottish National Prescribing Information System (PIS). Int J Epidemiol. 
2016;45(3):714-5f. 
149. Belgian Cancer Registry. 2017. Available from: 
http://www.kankerregister.org/Belgian%20Cancer%20Registry. [Accessed: 
27/01/2018]. 
150. Deliberation No. 16/021 of 15 March 2016 on the communication of coded 
personal health data by the technical unit to the Cancer Registry Foundation 
for the assessment of comorbidity in cancer patients in the context of 
scientific research projects. 
151.  van Herk-Sukel MP, van de Poll-Franse LV, Lemmens VE, et al. New 
opportunities for drug outcomes research in cancer patients: The linkage of 
the Eindhoven Cancer Registry and the PHARMO Record Linkage System. Eur J 
Cancer. 2010;46(2):395-404. 
152. PHARMO. PHARMO Database Network. 2017. Available from: 
http://pharmo.nl/what-we-have/pharmo-database-network/. [Accessed: 
15/09/2018]. 
153. Ameli. SNIIRAM. 2016. Available from: https://www.ameli.fr/l-assurance-
maladie/statistiques-et-publications/sniiram/finalites-du-sniiram.php. 
[Accessed: 15/08/2018]. 
154. Bezin J, Duong M, Lassalle R, et al. The national healthcare system claims 
databases in France, SNIIRAM and EGB: Powerful tools for 
pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26(8):954-962. 
155. Dragomir A, Côté R, White M, et al. Relationship between adherence level to 
statins, clinical issues and health-care costs in real-life clinical setting. Value 
Health. 2010;13(1):87-94. 
156. Mackenbach JP. Health and deprivation. Inequality and the North: by P. 
Townsend P, Phillimore P, Beattie A (eds.) Croom Helm Ltd, London; 1987. p. 
221. 
157. Suissa S. Immeasurable time bias in observational studies of drug effects on 
mortality. Am J Epidemiol. 2008;168(3):329-35. 
158. Said Q. Other Methodological Issues. In: Understanding 
Pharmacoepidemiology.Yang Y, West-Strum, D. USA: McGraw-Hill Com; 2010. 
p.105-20. 
159. Vanderweele TJ, Arah OA. Bias formulas for sensitivity analysis of unmeasured 
confounding for general outcomes, treatments, and confounders. 
Epidemiology. 2011;22(1):42-52. 
Page 208 of 281 
 
160. George G. Scailteux L-M, Garmo H et al. The risk of cardiovascular disease 
following GnRH agonists versus antagonists: Real-world evidence from four 
European countries. Euro Assoc Urol; Copenhagen, Denmark. 2018. 
161. NICE. Degarelix for treating advanced hormone-dependent prostate cancer. 




162. NICE Prostate Cancer: Diagnosis and treatment. 2014. Available from: 
https://www.nice.org.uk/guidance/cg175/evidence/full-guideline-191710765. 
[Accessed: 27/08/2019]. 
163. NICE. Final Appraisal Determination: Degarelix for treating advanced 




164. Haute Autorité de Santé. Firmagon Transparency Committee Opinion. 2012. 
Available from: https://www.has-sante.fr/upload/docs/application/pdf/2013-
01/vantas_ct_11421.pdf. [Accessed: 03/10/2019]. 
165. De Boer J. CFH-rapport 09/19: degarelix (Firmagon®). 2009. Avaialable from: 
https://www.zorginstituutnederland.nl › zinl › 2009/07/27. [Accessed: 
03/10/2019]. 
166. Kolandaivelu K, Leiden BB, O'Gara PT, et al. Non-adherence to cardiovascular 
medications. Eur Heart J. 2014;35(46):3267-76. 
167. Anderson JL, Morrow DA. Acute myocardial infarction. N Engl J Med. 
2017;376(21):2053-64. 
168. Breckenridge AM, Breckenridge RA, Peck CC. Report on the current status of 
the use of real-world data (RWD) and real-world evidence (RWE) in drug 
development and regulation. Br J Clin Pharmacol. 2019;85(9):1874-7. 
169. PIONEER. 2019. Available from: https://prostate-pioneer.eu/. [Accessed: 
28/09/2019]. 
170. IMI. BD4BO. 2019. Available from: https://www.imi.europa.eu/projects-
results/project-factsheets/bd4bo. [Accessed: 25/09/2019]. 
171. Hagel E, Garmo H, Bill-Axelson A, et al. PCBaSe Sweden: A register-based 
resource for prostate cancer research. Scand J Urol Nephrol. 2009;43(5):342-
9. 
172. Kuba S, Ishida M, Nakamura Y, et al. Persistence and discontinuation of 
adjuvant endocrine therapy in women with breast cancer. Breast Cancer. 
2016;23(1):128-33. 
173. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation 
therapy for prostate cancer. J Urol. 2009;181(5):1998-2006; discussion 7-8. 
174. Gomella LG, Singh J, Lallas C, et al. Hormone therapy in the management of 
prostate cancer: Evidence-based approaches. Ther Adv Urol. 2010;2(4):171-
81. 
175. Klotz L, O'Callaghan CJ, Ding K, et al. A phase III randomized trial comparing 
intermittent versus continuous androgen suppression for patients with PSA 
Page 209 of 281 
 
progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK 
Intercontinental Trial CRUKE/01/013. J Clin Oncol. 2011;29(7_suppl):3. 
176. Santoleri F, Sorice P, Lasala R. Leuprorelin and Triptorelin in the treatment of 
Prostate Cancer: Medication adherence, persistence and economic evaluation 
in five years of analysis. Int J Pharm Sci Res. 2014;1(101). 
177. Van Hemelrijck M, Garmo H, Wigertz A, et al. Cohort profile update: The 
National Prostate Cancer Register of Sweden and Prostate Cancer data Base 
— A refined prostate cancer trajectory. Int J Epidemiol. 2016;45(1):73-82. 
178. Sonnebring G. PCBaseSweden - A platform for prostate cancer research 2014 
[Updated 2014]. 2014. Available from: http://ki.se/en/meb/pcbasesweden-a-
platform-for-prostate-cancer-research. [Accessed: 21/09/2019]. 
179. Kozma CM, Dickson M, Phillips AL, et al. Medication possession ratio: 
Implications of using fixed and variable observation periods in assessing 
adherence with disease-modifying drugs in patients with multiple sclerosis. 
Patient Prefer Adherence. 2013;7:509-16. 
180. WHO. Essential medicines and health products. 3. Defined Daily Dose (DDD). 
2019. Available from: https://www.who.int/medicines/regulation/medicines-
safety/toolkit_ddd/en/. [Accessed: 25/09/2019]. 
181. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic 
comorbidity in longitudinal studies: Development and validation. J Chronic 
Dis. 1987;40(5):373-83. 
182. Pettersson B, Varenhorst E, Petas A, et al. Duration of testosterone 
suppression after a 9.45 mg implant of the GnRH-analogue buserelin in 
patients with localised carcinoma of the prostate a 12-month follow-up study. 
Eur Urol. 2006;50(3):483-9. 
183. Dunlay SM, Eveleth JM, Shah ND, et al. Medication adherence among 
community-dwelling patients with heart failure. Mayo Clin Proc. 
2011;86(4):273-81. 
184. Ambardekar AV, Fonarow GC, Hernandez AF, et al. Characteristics and in-
hospital outcomes for nonadherent patients with heart failure: Findings from 
Get With The Guidelines-Heart Failure (GWTG-HF). Am Heart J. 
2009;158(4):644-52. 
185. Chambers SK, Chung E, Wittert G, et al. Erectile dysfunction, masculinity, and 
psychosocial outcomes: A review of the experiences of men after prostate 
cancer treatment. Transl Androl Urol. 2017;6(1):60-8. 
186. Body JJ, von Moos R, Rider A, et al. A real-world study assessing the use of 
bone-targeted agents and their impact on bone metastases in patients with 
prostate cancer treated in clinical practice in Europe. J Bone Oncol. 
2018;14:100212. 
187. Nugin H, Folkvaljon Y, Damber JE, et al. Work-up and treatment of prostate 
cancer before and after publication of the first national guidelines on prostate 
cancer care in Sweden. Scand J Urol. 2018;52(4):277-84. 
188. Sandler HM, Mirhadi AJ. Radical radiotherapy for prostate cancer is the 'only 
way to go'. Cancer Net. 2009;23(10):840-3. 
189. Lycken M, Garmo H, Adolfsson J, et al. Patterns of androgen deprivation 
therapies among men diagnosed with localised prostate cancer: A population-
based study. Eur J Cancer. 2014;50(10):1789-98. 
Page 210 of 281 
 
190. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy 
compared with observation after radical prostatectomy and pelvic 
lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 
1999;341(24):1781-8. 
191. Thompson IM. Flare associated with LHRH-Agonist therapy. Rev Urol. 
2001;3(Suppl 3):S10-S4. 
192. Moretti RM, Montagnani Marelli M, Taylor DM, et al. Gonadotropin-releasing 
hormone agonists sensitize, and resensitize, prostate cancer cells to docetaxel 
in a p53-dependent manner. PLoS One. 2014;9(4):e93713-e. 
193. Kim YS, Sunwoo S, Lee HR, et al. Determinants of non-compliance with lipid-
lowering therapy in hyperlipidemic patients. Pharmacoepidemiol Drug Saf. 
2002;11(7):593-600. 
194. Van Hemelrijck M, Wigertz A, Sandin F, et al. Cohort Profile: The National 
Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 
2.0. Int J Epidemiol. 2013;42(4):956-67. 
195. Coleman T, Lewis S, Hubbard R, et al. Impact of contractual financial 
incentives on the ascertainment and management of smoking in primary care. 
Addiction. 2007;102(5):803-8. 
196. Vermeire E, Hearnshaw H, Van Royen P, et al. Patient adherence to treatment: 
Three decades of research. A comprehensive review. J Clin Pharm Ther.  
2001;26(5):331-42. 
197. Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence 
to combination antiretroviral medication. J Gen Intern Med. 2002;17(10):756-
65. 
198. Elliott WJ, Maddy R, Toto R, et al. Hypertension in patients with diabetes. 
Postgrad Med. 2000;107(3):29-38. 
199. Black HR. Will better-tolerated antihypertensive agents improve blood 
pressure control? JNC VI revisited. Am J Hypertens. 1999;12(S9):225S-30S. 
200. Ickovics JR, Meade CS. Adherence to HAART among patients with HIV: 
Breakthroughs and barriers. AIDS Care. 2002;14(3):309-18. 
201. Vlasnik JJ, Aliotta SL, DeLor B. Medication adherence: Factors influencing 
compliance with prescribed medication plans. Case Manager. 2005;16(2):47-
51. 
202. Bell JS, Airaksinen MS, Lyles A, et al. Concordance is not synonymous with 
compliance or adherence. Br J Clin Pharmacol. 2007;64(5):710-1. 
203. Leung L. Validity, reliability, and generalizability in qualitative research. J 
Family Med Prim Care. 2015;4(3):324-7. 
204. Francis JJ, Johnston M, Robertson C, et al. What is an adequate sample size? 
Operationalising data saturation for theory-based interview studies. Psychol 
Health. 2010;25(10):1229-45. 
205. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res in Psychol. 
2006;3(2):77-101. 
206. Fowler FJ Jr, McNaughton Collins M, Walker Corkery E, et al. The impact of 
androgen deprivation on quality of life after radical prostatectomy for 
prostate carcinoma. Cancer. 2002;95(2):287-95. 
207. Ng E, Woo HH, Turner S, et al. The influence of testosterone suppression and 
recovery on sexual function in men with prostate cancer: Observations from a 
Page 211 of 281 
 
prospective study in men undergoing intermittent androgen suppression. J 
Urol. 2012;187(6):2162-6. 
208. Kumar K, Greenfield S, Raza K, et al. Understanding adherence-related beliefs 
about medicine amongst patients of South Asian origin with diabetes and 
cardiovascular disease patients: A qualitative synthesis. BMC Endocr Disord. 
2016;16(1):24. 
209. Tsodikov A, Gulati R, de Carvalho TM, et al. Is prostate cancer different in 
black men? Answers from 3 natural history models. Cancer. 
2017;123(12):2312-9. 
210. Moon Z, Moss-Morris R, Hunter MS, et al. Understanding tamoxifen 
adherence in women with breast cancer: A qualitative study. Br J Health 
Psychol. 2017;22(4):978-97. 
211. Senior V, Marteau TM, Weinman J. Self-reported adherence to cholesterol-
lowering medication in patients with familial hypercholesterolaemia: The role 








Page 212 of 281 
 
 
9.  APPENDIX 
9.1  TABLES 
Appendix Table 1: Patient characteristics for men with PCa on primary and secondary GnRH agonists 





Primary GnRH agonists Secondary GnRH agonists 
Adherent (%) Non-adherent (%) Adherent (%) Non-adherent (%) 
n 7227 (89.2) 878 (10.8) 4049 (85.5) 689 (14.5) 
     
Age (Years)     
Mean 76.5 75.2 75.9 74.7 
SD 7.8 8.5 7.8 7.8 
     
Age Groups (Years)     
≤ 65 681 (9.4) 121 (13.8) 440 (10.9) 93 (13.5) 
66-74 1936 (26.8) 248 (28.3) 1192 (29.4) 226 (32.8) 
75-84 3546 (49.1) 385 (43.9) 1877 (46.4) 302 (43.8) 
≥ 85 1064 (14.7) 124 (14.1) 540 (13.3) 68 (9.9) 
     
Injection Interval 
(Days) 
    
90 5197 (71.9) 726 (82.7) 2955 (73.0) 568 (82.4) 
180 383 (5.3) 37 (4.2) 215 (5.3) 21 (3.1) 
365 (Implant) 661 (9.2) 53 (6.0) 358 (8.8) 51 (7.4) 
Mixed 986 (13.6) 54 (6.2) 521 (12.9) 33 (4.8) 
Missing 0 8 (0.9) 0 16 (2.3) 
     
Risk Groups at 
Diagnosis 
    
Low Risk 113 (1.6) 50 (5.7) 531 (13.1) 150 (21.8) 
Medium Risk 777 (10.8) 144 (16.4) 1179 (29.1) 228 (33.1) 
High Risk 2594 (35.9) 349 (39.8) 1604 (39.6) 231 (33.5) 
Regional Metastasis 1213 (16.8) 124 (14.1) 488 (12.1) 49 (7.1) 
Distant Metastasis 2490 (34.5) 202 (23.0) 200 (4.9) 20 (2.9) 
Missing 40 (0.6) 9 (1.0) 47 (1.2) 11 (1.6) 
     
Prior PCa Treatment     
Deferred Treatment N/A N/A 1810 (44.7) 340 (49.4) 
Anti-androgens N/A N/A 763 (18.8) 84 (12.2) 
Radical Prostatectomy 
only 
N/A N/A 323 (8.0) 94 (13.6) 
Radiotherapy N/A N/A 875 (21.6) 123 (17.9) 
Radiotherapy after 
Radical Prostatectomy 
    
< 1 year N/A N/A 136 (3.4) 27 (3.9) 
≥ 1 year N/A N/A 142 (3.5) 21 (3.1) 
     
     
Change in CCI* since 
CCI at diagnosis 
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No change 5220 (72.2) 660 (75.2) 2972 (73.4) 527 (76.5) 
Change by 1 1024 (14.2) 119 (13.6) 529 (13.1) 80 (11.6) 
Change by 2 596 (8.3) 69 (7.9) 347 (8.6) 56 (8.1) 
Change by 3 247 (3.4) 15 (1.7) 124 (3.1) 13 (1.9) 
Change by ≥ 4 140 (1.9) 15 (1.7) 77 (1.9) 13 (1.9) 
     
Civil Status     
Single 2710 (37.5) 313 (35.7) 1300 (32.1) 233 (33.8) 
Married 4516 (62.5) 565 (64.4) 2749 (67.9) 456 (66.2) 
Missing 1 (0.01) 0   
     
Year of GnRH 
agonists’ Initiation 
    
2006-2007 2270 (31.4) 314 (35.8) 1019 (25.2) 167 (24.2) 
2008-2009 1998 (27.7) 220 (25.1) 1051 (26.0) 154 (22.4) 
2010-2011 1633 (22.6) 203 (23.1) 1056 (26.1) 166 (24.1) 
2012-2013 1326 (18.4) 141 (16.1) 923 (22.8) 202 (29.3) 
*CCI: Charlson Comorbidity Index.  
 
Appendix Table 2: Patient characteristics for men with PCa on primary and secondary GnRH agonists 





Primary GnRH agonists Secondary GnRH agonists 
Adherent (%) Non-adherent (%) Adherent (%) Non-adherent (%) 
n 7140 (88.1) 965 (11.9) 3959 (83.6) 779 (16.4) 
     
Age (Years)     
Mean 76.5 75.1 75.9 74.7 
SD 7.8 8.5 7.8 7.9 
     
Age Groups (Years)     
≤ 65 675 (9.5) 127 (13.2) 423 (10.7) 110 (14.1) 
66-74 1888 (26.4) 296 (30.7) 1173 (29.6) 245 (31.5) 
75-84 3522 (49.3) 409 (42.4) 1842 (46.5) 337 (43.3) 
≥ 85 1055 (14.8) 133 (13.8) 521 (13.2) 87 (11.2) 
     
Injection Interval 
(Days) 
    
90 5095 (71.4) 828 (85.8) 2871 (72.5) 652 (83.7) 
180 388 (5.4) 32 (3.3) 216 (5.5) 20 (2.6) 
365 (Implant) 681 (9.5) 33 (3.4) 374 (9.5) 35 (4.5) 
Mixed 976 (13.7) 64 (6.6) 498 (12.6) 56 (7.2) 
Missing 0 8 (0.8) 0 16 (2.1) 
     
Risk Groups at 
Diagnosis 
    
Low Risk 110 (1.5) 53 (5.5) 526 (13.3) 155 (19.9) 
Medium Risk 773 (10.8) 148 (15.3) 1173 (29.6) 234 (30.0) 
High Risk 2569 (36.0) 374 (38.8) 1555 (39.3) 280 (35.9) 
Regional Metastasis 1179 (16.5) 158 (16.4) 464 (11.7) 73 (9.4) 
Distant Metastasis 2469 (34.6) 223 (23.1) 195 (4.9) 25 (3.2) 
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Missing 40 (0.6) 9 (0.9) 46 (1.2) 12 (1.5) 
     
Prior PCa Treatment     
Deferred Treatment N/A N/A 1775 (44.8) 375 (48.1) 
Anti-androgens N/A N/A 733 (18.5) 114 (14.6) 
Radical Prostatectomy 
only 
N/A N/A 320 (8.1) 97 (12.5) 
Radiotherapy N/A N/A 869 (22.0) 129 (16.6) 
Radiotherapy after 
Radical Prostatectomy 
    
< 1 year N/A N/A 128 (3.2) 34 (4.5) 
≥ 1 year N/A N/A 134 (3.4) 29 (3.7) 
     
     
Change in CCI* since 
CCI at diagnosis 
    
No change 5151 (72.1) 729 (75.5) 2904 (73.4) 595 (76.4) 
Change by 1 1014 (14.2) 129 (13.4) 517 (13.1) 92 (11.8) 
Change by 2 595 (8.3) 70 (7.3) 341 (8.6) 62 (8.0) 
Change by 3 240 (3.4) 22 (2.3) 121 (3.1) 16 (2.1) 
Change by ≥ 4 140 (2.0) 15 (1.6) 76 (1.9) 14 (1.8) 
     
Civil Status     
Single 2648 (37.1) 375 (38.9) 1259 (31.8) 274 (35.2) 
Married 4491 (62.9) 590 (61.1) 2700 (68.2) 505 (64.8) 
Missing 1 (0.01) 0 0 0 
     
Year of GnRH 
agonists’ Initiation 
    
2006-2007 2235 (31.3) 349 (36.2) 989 (25.0) 197 (25.3) 
2008-2009 1973 (27.6) 245 (25.4) 1027 (25.9) 178 (22.9) 
2010-2011 1629 (22.8) 207 (21.5) 1033 (26.1) 189 (24.3) 
2012-2013 1303 (18.3) 164 (17.0) 910 (23.0) 215 (27.6) 
*CCI: Charlson Comorbidity Index.  
 
Appendix Table 3: Patient characteristics for men with PCa on primary and secondary GnRH agonists 
after 3 years following reclassification of outcomes based on intermittent medication in THIN. 
 
Patient Characteristics 
Primary GnRH Agonists Secondary GnRH Agonists 
Adherent (%) Non-adherent (%) Adherent (%) Non-adherent (%) 
n 3833 (77.9) 1090 (22.1) 303 (71.6) 120 (28.4) 
     
Age (Years)     
Mean  76  74  74  70  
SD 8.0 8.1 8.4 7.8 
     
Age Groups (Years)     
≤ 65 375 (9.8) 140 (12.8) 57 (18.8) 33 (27.5) 
66-74 1003 (27.0) 280 (25.7) 89 (29.4) 56 (46.7) 
75-84 1803 (47.0) 394 (36.2) 126 (41.6) 26 (21.7) 
≥ 85 461 (12.0) 88 (8.1) 31 (10.2) 5 (4.2) 
Missing 161 (4.2) 188 (17.3) 0 0 
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Injection Interval 
(Days) 
    
28 1001 (26.1) 466 (42.8) 66 (21.8) 30 (25.0) 
90 2681 (70.1) 608 (55.8) 228 (75.3) 86 (71.7) 
180 151 (3.9) 16 (1.5) 9 (3.0) 4 (3.3) 
     
Prior PCa Treatment     
Radical prostatectomy N/A N/A 99 (32.7) 49 (40.8) 
Radiotherapy N/A N/A 153 (50.5) 56 (46.7) 
Anti-androgens N/A N/A 51 (16.8) 15 (12.5) 
     
Civil Status     
Single 17 (0.4) 3 (0.3) 4 (1.3) 0 
Married 40 (1.0) 5 (1.5) 6 (2.0) 2 (1.7) 
Missing 1082 (99.3) 1082 (99.3) 293 (96.7) 118 (98.3) 
     
Smoking Status     
Current Smokers 656 (17.1) 186 (17.1) 43 (14.2) 15 (12.5) 
Non-Smokers 24 (0.6) 8 (0.7) 2 (0.7) 3 (2.5) 
Past Smokers 46 (1.2) 9 (0.8) 6 (2.0) 4 (3.3) 
Missing 3107 (81.1) 887 (81.4) 252 (83.2) 98 (81.7) 
     
Ethnicity     
Caucasian 1308 (34.1) 350 (32.1) 106 (35.0) 39 (32.5) 
Black 37 (1.0) 8 (0.7) 1 (0.3) 0 
Asian 7 (0.2) 3 (0.3) 1 (0.3) 0 
Other 8 (0.2) 5 (0.5) 2 (0.7) 0 
Missing 2473 (64.5) 724 (66.4) 193 (63.7) 81 (67.5) 
     
Socio-economic Status     
Lowest or least 
deprived (Townsend 1) 
179 (4.7) 34 (3.1) 16 (5.3) 6 (5.0) 
Low (Townsend 2) 179 (4.7) 39 (3.6) 16 (5.3) 8 (6.7) 
Middle (Townsend 3) 141 (3.7) 24 (2.2) 7 (2.3) 1 (0.8) 
High (Townsend 4) 111 (2.9) 11 (1.0) 7 (2.3) 2 (1.7) 
Highest or most 
deprived (Townsend 5) 
66 (1.7) 15 (1.4) 6 (2.0) 0 
Missing 3157 (82.4) 967 (88.7) 251 (82.8) 103 (85.8) 
     
BMI / obesity     
Normal weight (18.5-
24) 
7 (0.2) 1 (0.1) 1 (0.3) 0 
Underweight (<18.5) 0 0 0 0 
Overweight (25-30) 22 (0.6) 1 (0.1) 2 (0.7) 1 (0.8) 
Obese (>30) 6 (0.2) 1 (0.1) 0 0 
Missing 3798 (99.1) 1087 (99.7) 300 (99.0) 119 (99.2) 
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Appendix Table 4: Patient characteristics for men with PCa on primary and secondary GnRH agonists 
after 3 years following redefinition of outcomes at 50% in THIN. 
 
Patient Characteristics 
Primary GnRH Agonists Secondary GnRH Agonists 
Adherent (%) Non-adherent (%) Adherent (%) Non-adherent (%) 
n 4246 (86.3) 677 (13.8) 352 (83.2) 71 (16.8) 
     
Age (Years)     
Mean  76  74 74  70 
SD 8.0 8.1 8.4 7.6 
     
Age Groups (Years)     
≤ 65 426 (10.0) 89 (13.2) 17 (23.9) 73 (20.7) 
66-74 1141 (26.9) 172 (25.4) 107 (30.4) 38 (53.5) 
75-84 1971 (46.4) 226 (33.4) 138 (39.2) 14 (19.7) 
≥ 85 507 (11.9) 42 (6.2) 34 (9.7) 2 (2.8) 
Missing 201 (4.7) 148 (21.9) 0 0 
     
Injection Interval 
(Days) 
    
28 1119 (26.4) 348 (51.4) 75 (21.3) 21 (29.6) 
90 2969 (70.0) 320 (47.3) 267 (75.9) 47 (66.2) 
180 158 (3.7) 9 (1.3) 10 (2.8) 3 (4.2) 
     
Prior PCa Treatment     
Radical prostatectomy N/A N/A 119 (33.8) 29 (40.9) 
Radiotherapy N/A N/A 175 (50.0) 34 (47.9) 
Anti-androgens N/A N/A 58 (16.5) 8 (11.3) 
     
Civil Status     
Single 19 (0.5) 1 (0.2)  4 (1.1) 0 
Married 42 (1.0) 3 (0.4) 6 (1.7) 2 (2.8) 
Missing 4185 (98.6) 673 (99.4) 342 (97.2) 69 (97.2) 
     
Smoking Status     
Current Smokers 724 (17.1) 118 (17.4) 50 (14.2) 8 (11.3) 
Non-Smokers 26 (0.6) 6 (0.9) 4 (1.1) 1 (1.4) 
Past Smokers 47 (1.1) 8 (1.2) 10 (2.8) 0 
Missing 3449 (81.2) 545 (81.0) 288 (81.8) 62 (87.3) 
     
Ethnicity     
Caucasian 1450 (34.2) 208 (30.7) 121 (34.4) 24 (33.8) 
Black 43 (1.0) 2 (0.3) 1 (0.3) 0 
Asian 9 (0.2) 1 (0.2) 1 (0.3) 0 
Other 20 (0.2) 3 (0.4) 2 (0.6) 0 
Missing 2734 (64.4) 463 (68.4) 227 (64.5) 47 (66.2) 
     
Socio-economic Status     
Lowest or least 
deprived (Townsend 1) 
192 (4.5) 21 (3.1) 19 (5.4) 3 (4.2) 
Low (Townsend 2) 198 (4.7) 20 (3.0) 20 (5.7) 4 (5.6) 
Middle (Townsend 3) 152 (3.6) 13 (1.9) 8 (2.3) 0 
High (Townsend 4) 120 (2.8) 2 (0.3) 7 (2.0) 2 (2.8) 
Highest or most 
deprived (Townsend 5) 
70 (1.7) 11 (1.6) 6 (1.7) 0 
Missing 3514 (82.8) 610 (90.1) 292 (83.0) 62 (87.3) 
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BMI / obesity     
Normal weight (18.5-
24) 
7 (0.2) 1 (0.2) 1 (0.3) 0 
Underweight (<18.5) 0 0 0 0 
Overweight (25-30) 22 (0.5) 1 (0.2) 2 (0.6) 1 (1.4) 
Obese (>30) 7 (0.2) 0 0 0 
Missing 4210 (99.2) 675 (99.7) 349 (99.1) 70 (98.6) 
* BMI: Body Mass Index; N/A: Not available. 
 
9.2 CODES FROM NVIVO 
NVivo version 12 was used to collect codes from stage 2 interviews and stage 3 
focus groups and form themes. The following two sections show figures of the 
codes identified.  
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 Stage 2: Interviews 
 
Page 219 of 281 
 






Page 220 of 281 
 
9.3  PUBLICATIONS 
 Abstracts 
9.3.1.1 Abstract presented as expert-guided poster presentation at the 33rd 
Annual European Association of Urology Congress, 2018, Copenhagen. 
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 Peer-reviewed journal articles 
9.3.2.1 Methodological protocol 
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9.4  HEALTH RESEARCH AUTHORITY APPLICATION AND 
ARRPOVED STUDY DOCUMENTS 
The Health Research Authority (HRA) grants ethical approval for studies conducted 
in England. The HRA approval requires the completion of a research application 
form on the Integrated Research Application System (IRAS) and submission to HRA 
along with the relevant study documents. Once HRA approval, Research and 
Development approval (from the site of study) and Capacity and Capability of 
research team approval (from site of study) is in place, recruitment can begin. The 
following sections include approval letter from the HRA and study documents 
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 Approval letter from the HRA 
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 Study documents 





Gonadotropin-releasing hormone (GnRH) agonists, a form of androgen deprivation 
therapy (ADT), remains the standard treatment for men with advanced prostate 
cancer (PCa). About 50% of all men diagnosed with PCa receive ADT at some stage 
after diagnosis and some may even remain on ADT for the rest of their PCa 
treatment (1, 2). Non-adherence to a treatment regimen may be associated with 
clinical and economic consequences. In men with PCa, non-adherence to GnRH 
agonists may also be associated with worse prognosis (3, 4). 
Non-adherence to GnRH agonists has been a concern early on with patients on 
long-term GnRH agonists. GnRH agonists were first developed as 3-monthly depots, 
however 6-monthly depots were developed soon after in order to increase patient 
compliance and decrease the number of physician visits required for injections (5). 
Unwanted side-effects that are commonly associated with ADT such as, low bone 
density, fatigue and hot flushes, has been suggested to lead to non-adherence to 
treatment regimens (6, 7).  
Patient-related Factors Contributing to Non-adherence  
Previous research has outlined many different factors contributing to non-
adherence to medication. A common reason attributed to medication non-
adherence was lack of dispensation of a drug. This occurs when a patient has not 
collected his/her prescribed medication from the pharmacy. Reasons such as “drug 
holidays” or “white-coat compliance” may also contribute to non-adherence. Drug 
holidays refers to short intervals of time where a patient becomes non-adherent 
before resuming their treatment regimen. White-coat compliance refers to the 
phenomenon whereby patient adherence is positively associated with clinical 
appointments (8). Forgetfulness and skipping medication doses are other patient-
related causes that may contribute to non-adherence (9). 
Adherence Patterns of GnRH Agonists in Prostate Cancer 
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The psychological state of an individual may also be positively associated with 
adherence to a treatment regimen. A patient’s adherence may be improved by the 
extent of social support that he or she may receive, be it from a spouse or other 
family members (10). Moreover, an individual with an excessive drinking or smoking 
history may require a high degree of behavioural change to their current lifestyle in 
order to adhere to a systematic treatment regimen (11).  
Low health literacy and a lack of understanding of the role of treatment regimens 
has been associated with poor adherence to medication in patients (12, 13). For 
instance, PCa men on intermittent GnRH agonists may not be able to fully 
understand the definition of intervals between injections leading to missed doses. 
Therefore, educating patients about their disease, the role of their treatment in 
disease suppression and the treatment regimen increases their active participation 
in treatment (14). 
Clinician-related Factors Contributing to Non-adherence  
Several clinician-related factors may also contribute to non-adherence to 
medication (9). By prescribing complex treatment regimens, physicians may 
contribute to a patient’s adherence. Moreover, failing to fully explain the benefits 
and side-effects of treatments and having a poor patient-provider relationship are 
other factors that may contribute to medication non-adherence (15-18). To address 
clinician-related factors contributing to non-adherence, establishing a therapeutic 
alliance between the physician and patient is important and this is known as 
‘concordance’. According to Bell et al. (2007), concordance is synonymous with 
patient-centred care. And concordance may be one mechanism by which non-
adherence can be better understood (19, 20). 
Quantitative and Qualitative Approaches 
Most traditional methods of measuring adherence only take into account 
quantitative methods that although may inform patterns of adherence, provide 
little insight into the reasons contributing to non-adherence. Whereas a 
quantitative study will investigate the patterns of adherence to GnRH agonists, a 
qualitative study will explore the reasons why men on GnRH agonists may not 
adhere to their treatment regimen. We are currently investigating patterns of 
adherence to GnRH agonists in the UK primary care database, The Health 
Improvement Network and a national Swedish PCa database, PCBaSe. We will now 
use qualitative methods to better understand reasons contributing to non-
adherence to GnRH agonists in men with PCa. We used patient-related and 
clinician-related factors mentioned above as the background for this study. Some 
factors from Jin et al.’s (2008) review are shown in Figure 1 (21).  
Methods 
The factors identified by Jin et al.’s literature review will be validated by an 
experienced specialist oncologist before being used to devise topic guides for 
interviews. The project is divided into two stages: interviews and focus groups 
(Figure 2).  
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Interviews 
Clinic lists will be screened by the direct care team for men with PCa on GnRH 
agonists for a minimum of six months. Once identified, eligible men will be offered 
participant information sheet (PIS) by the research team, outlining the purpose of 
the interviews (Participant Information Sheet (Patient), v.3 dated 03/12/2018). 
Semi-structured interviews will be conducted using a topic guide. The interviews 
will last for approximately 45 minutes and will be audio recorded, anonymised, 
transcribed verbatim and thematically analysed. The interviews will be held in the 
Urology Centre or Cancer Centre at Guy’s Hospital. 
Study participants in this stage are at risk of being distressed when discussing 
sensitive topics during the interview. All participants will be informed by the 
researcher (in the study PIS, consent form and at the beginning of the interview) 
that they may ask the interviewer to stop at any point during the interview. Should 
there still arise a situation where a participant is distressed, the researcher will 
cease the interview immediately and seek the help of the participant’s clinical care 
team to further support the distressed individual. 
Focus Groups 
Focus groups will be conducted for healthcare professionals treating PCa men on 
GnRH agonists in stage one. The focus groups will be held in 2 separate sessions: 
one with oncology specialists and the other with Clinical Nurse Specialists. The aim 
of the focus groups will be to identify any new themes that were not previously 
identified by the literature review [21] and the interviews. The focus groups for staff 
will be held at the Urology Seminar Room at Guy’s Hospital. Staff at and St Thomas’ 
Foundation Trust who have regular contact with PCa men on GnRH agonists will be 
invited to take part. Clinicians will be invited to the focus groups by their managers 
who will first introduce the study and give out the Participant Information Sheet 
(Clinician),v.6 dated 09/01/2019. Clinicians who are interested in taking part will 
then contact the researcher through the contact details given in the PIS. Once 
agreed, the clinicians will sign the Consent Form (Clinician), v.4 dated09/01/2019. 
The focus groups will last between 1-2 hours and will be audio recorded and 
transcribed anonymously.  
Sample Size  
We will aim to interview a minimum of 10 men with PCa on GnRH agonists and keep 
interviewing more men until there are no new emerging themes. This will be the 
point of saturation for our interviews stage. We will aim to recruit at least 3-5 
clinicians per focus group as this seen as the minimum number of members 
required for a focus group [22]. 
Inclusion and Exclusion Criteria 
All men with PCa on GnRH agonists for a minimum of six months will be included in 
the interviews and all clinicians who have direct contact with PCa men on GnRH 
agonists will be invited to take part in the focus groups. No further exclusion criteria 
will be implemented. 
Page 253 of 281 
 
Data Management 
The audio recordings from the interviews and focus groups will be directly saved 
onto a trust computer or laptop and will be destroyed one year following the end of 
study period. Once data is collected from both interviews and focus groups, the 
audio recordings will be transcribed anonymously by the researcher into a 
password-protected excel file on the trust server. The password-protected excel file 
containing the anonymised transcriptions will only be available to the research 
team and will be held on the trust server for five years after the end of study period. 
The end of study period will be 12 months following the recruitment of first 
participant in the interview stage. Both the transcription and analysis process will 
be conducted by the researcher and no external body will be involved in this study. 
Analysis 
Data collected from the semi-structured interviews and focus groups will be 
analysed using thematic analysis. Thematic analysis is a widely used method for 
analysing qualitative data where the analysis aims to identify patterns of meaning 
across a dataset, which can then be used to generate themes. We will identify 
themes in this study through a process of data familiarisation, data coding, theme 
development and revision of themes (following each interview) (23). For this study, 
we will use the six phases of thematic analysis illustrated by Braun and Clarke 
(2006) which include: 
1. familiarising yourself with your data (includes transcription of audio 
recording) 
2. generating initial codes by identifying repeated patterns in extracts of 
your data 
3. searching for themes by combining the initial codes to form overarching 
themes 
4. reviewing themes to identify coherent themes 
5. defining and naming themes 
6. producing the report which should provide a concise, coherent, logical 
and non-repetitive explanation of the themes 
Thematic analysis is the ideal method to evaluate the data collected for this study 
because through thematic analysis of data collected from both the focus groups and 
interviews, we will achieve a coherent interpretation of patterns of non-adherence 
in men with PCa on GnRH agonists.  
Expected Results 
Although reasons contributing to non-adherence to GnRH agonists in men with PCa 
is known among clinicians, this is the first qualitative study to investigate this at a 
large hospital. This study will enable clinicians to understand the barriers and 
challenges to adhering to GnRH agonists so as to better target care pathways to 
improve adherence.  
Dissemination of Results 
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The results of the study will be published in peer-reviewed articles and conferences. 
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___ men on GnRH agonists consented on 
study consent form (v3.0, dated 03/12/2018) 
and interviewed until point of no new 
emerging themes 
Validation by specialist 
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Gonadotropin-releasing hormone (GnRH) agonists, a form of androgen deprivation 
therapy (ADT), remains the standard treatment for men with advanced prostate 
cancer (PCa). About 50% of all men diagnosed with PCa receive ADT at some stage 
after diagnosis and some may even remain on ADT for the rest of their PCa 
treatment (1, 2). Non-adherence to a treatment regimen may be associated with 
clinical and economic consequences. In men with PCa, non-adherence to GnRH 
agonists may also be associated with worse prognosis (3, 4). 
Non-adherence to GnRH agonists has been a concern early on with patients on 
long-term GnRH agonists. GnRH agonists were first developed as 3-monthly depots, 
however 6-monthly depots were developed soon after in order to increase patient 
compliance and decrease the number of physician visits required for injections (5). 
Unwanted side-effects that are commonly associated with ADT such as, low bone 
density, fatigue and hot flushes, has been suggested to lead to non-adherence to 
treatment regimens (6, 7).  
Patient-related Factors Contributing to Non-adherence  
Previous research has outlined many different factors contributing to non-
adherence to medication. A common reason attributed to medication non-
adherence was lack of dispensation of a drug. This occurs when a patient has not 
collected his/her prescribed medication from the pharmacy. Reasons such as “drug 
holidays” or “white-coat compliance” may also contribute to non-adherence. Drug 
holidays refers to short intervals of time where a patient becomes non-adherent 
before resuming their treatment regimen. White-coat compliance refers to the 
phenomenon whereby patient adherence is positively associated with clinical 
appointments (8). Forgetfulness and skipping medication doses are other patient-
related causes that may contribute to non-adherence (9). 
The psychological state of an individual may also be positively associated with 
adherence to a treatment regimen. A patient’s adherence may be improved by the 
extent of social support that he or she may receive, be it from a spouse or other 
family members (10). Moreover, an individual with an excessive drinking or smoking 
Adherence Patterns of GnRH Agonists in Prostate Cancer 
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history may require a high degree of behavioural change to their current lifestyle in 
order to adhere to a systematic treatment regimen (11).  
Low health literacy and a lack of understanding of the role of treatment regimens 
has been associated with poor adherence to medication in patients (12, 13). For 
instance, PCa men on intermittent GnRH agonists may not be able to fully 
understand the definition of intervals between injections leading to missed doses. 
Therefore, educating patients about their disease, the role of their treatment in 
disease suppression and the treatment regimen increases their active participation 
in treatment (14). 
Clinician-related Factors Contributing to Non-adherence  
Several clinician-related factors may also contribute to non-adherence to 
medication (9). By prescribing complex treatment regimens, physicians may 
contribute to a patient’s adherence. Moreover, failing to fully explain the benefits 
and side-effects of treatments and having a poor patient-provider relationship are 
other factors that may contribute to medication non-adherence (15-18). To address 
clinician-related factors contributing to non-adherence, establishing a therapeutic 
alliance between the physician and patient is important and this is known as 
‘concordance’. According to Bell et al. (2007), concordance is synonymous with 
patient-centred care. And concordance may be one mechanism by which non-
adherence can be better understood (19, 20). 
Quantitative and Qualitative Approaches 
Most traditional methods of measuring adherence only take into account 
quantitative methods that although may inform patterns of adherence, provide 
little insight into the reasons contributing to non-adherence. Whereas a 
quantitative study will investigate the patterns of adherence to GnRH agonists, a 
qualitative study will explore the reasons why men on GnRH agonists may not 
adhere to their treatment regimen. We are currently investigating patterns of 
adherence to GnRH agonists in the UK primary care database, The Health 
Improvement Network and a national Swedish PCa database, PCBaSe. We will now 
use qualitative methods to better understand reasons contributing to non-
adherence to GnRH agonists in men with PCa. We used patient-related and 
clinician-related factors mentioned above as the background for this study. Some 
factors from Jin et al.’s (2008) review are shown in Figure 1 (21).  
Methods 
The factors identified by Jin et al.’s literature review will be validated by an 
experienced specialist oncologist before being used to devise topic guides for 
interviews. The project is divided into two stages: interviews and focus groups 
(Figure 2).  
Interviews 
Clinic lists will be screened by the direct care team for men with PCa on GnRH 
agonists for a minimum of six months. Once identified, eligible men will be offered 
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participant information sheet (PIS) by the research team, outlining the purpose of 
the interviews (Participant Information Sheet (Patient), v.3 dated 03/12/2018). 
Semi-structured interviews will be conducted using a topic guide. The interviews 
will last for approximately 45 minutes and will be audio recorded, anonymised, 
transcribed verbatim and thematically analysed. The interviews will be held in the 
Urology Centre or Cancer Centre at Guy’s Hospital. 
Study participants in this stage are at risk of being distressed when discussing 
sensitive topics during the interview. All participants will be informed by the 
researcher (in the study PIS, consent form and at the beginning of the interview) 
that they may ask the interviewer to stop at any point during the interview. Should 
there still arise a situation where a participant is distressed, the researcher will 
cease the interview immediately and seek the help of the participant’s clinical care 
team to further support the distressed individual. 
Focus Groups 
Focus groups will be conducted for healthcare professionals treating PCa men on 
GnRH agonists in stage one. The focus groups will be held in 2 separate sessions: 
one with oncology specialists and the other with Clinical Nurse Specialists. The aim 
of the focus groups will be to identify any new themes that were not previously 
identified by the literature review [21] and the interviews. The focus groups for staff 
will be held at the Urology Seminar Room at Guy’s Hospital. Staff at and St Thomas’ 
Foundation Trust who have regular contact with PCa men on GnRH agonists will be 
invited to take part. Clinicians will be invited to the focus groups by their managers 
who will first introduce the study and give out the Participant Information Sheet 
(Clinician),v.6 dated 09/01/2019. Clinicians who are interested in taking part will 
then contact the researcher through the contact details given in the PIS. Once 
agreed, the clinicians will sign the Consent Form (Clinician), v.4 dated09/01/2019. 
The focus groups will last between 1-2 hours and will be audio recorded and 
transcribed anonymously.  
Sample Size  
We will aim to interview a minimum of 10 men with PCa on GnRH agonists and keep 
interviewing more men until there are no new emerging themes. This will be the 
point of saturation for our interviews stage. We will aim to recruit at least 3-5 
clinicians per focus group as this seen as the minimum number of members 
required for a focus group [22]. 
Inclusion and Exclusion Criteria 
All men with PCa on GnRH agonists for a minimum of six months will be included in 
the interviews and all clinicians who have direct contact with PCa men on GnRH 
agonists will be invited to take part in the focus groups. No further exclusion criteria 
will be implemented. 
Data Management 
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The audio recordings from the interviews and focus groups will be directly saved 
onto a trust computer or laptop and will be destroyed one year following the end of 
study period. Once data is collected from both interviews and focus groups, the 
audio recordings will be transcribed anonymously by the researcher into a 
password-protected excel file on the trust server. The password-protected excel file 
containing the anonymised transcriptions will only be available to the research 
team and will be held on the trust server for five years after the end of study period. 
The end of study period will be 12 months following the recruitment of first 
participant in the interview stage. Both the transcription and analysis process will 
be conducted by the researcher and no external body will be involved in this study. 
Analysis 
Data collected from the semi-structured interviews and focus groups will be 
analysed using thematic analysis. Thematic analysis is a widely used method for 
analysing qualitative data where the analysis aims to identify patterns of meaning 
across a dataset, which can then be used to generate themes. We will identify 
themes in this study through a process of data familiarisation, data coding, theme 
development and revision of themes (following each interview) (23). For this study, 
we will use the six phases of thematic analysis illustrated by Braun and Clarke 
(2006) which include: 
7. familiarising yourself with your data (includes transcription of audio 
recording) 
8. generating initial codes by identifying repeated patterns in extracts of 
your data 
9. searching for themes by combining the initial codes to form overarching 
themes 
10. reviewing themes to identify coherent themes 
11. defining and naming themes 
12. producing the report which should provide a concise, coherent, logical 
and non-repetitive explanation of the themes 
Thematic analysis is the ideal method to evaluate the data collected for this study 
because through thematic analysis of data collected from both the focus groups and 
interviews, we will achieve a coherent interpretation of patterns of non-adherence 
in men with PCa on GnRH agonists.  
Expected Results 
Although reasons contributing to non-adherence to GnRH agonists in men with PCa 
is known among clinicians, this is the first qualitative study to investigate this at a 
large hospital. This study will enable clinicians to understand the barriers and 
challenges to adhering to GnRH agonists so as to better target care pathways to 
improve adherence.  
Dissemination of Results 
The results of the study will be published in peer-reviewed articles and conferences. 
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Patient-centred and clinician-related 
factors influencing non-adherence 
identified from Jin et al. 2008; 
4(1):269-86, Therapeutics and 
Focus group with 
Clinical Nurse 
Specialists 
Focus group with 
oncology 
specialists and 
___ men on GnRH agonists 
approached in clinic with   Participant 
Information Sheet (v3.0, dated 
03/12/2018) for the study and invited 
___ men on GnRH 
agonists declined 
the study 
___ men on GnRH agonists consented 
on study consent form (v3.0, dated 
03/12/2018) and interviewed until 




Comment from oncologist 
Other patient centred factors contributing to non-adherence for patients 
who are on long-term GnRH agonists may include: 
• Mixed health beliefs of patients 
• Desire to avoid side-effects 
• Major life events that a patient may have to go through (for 
example, a partner being diagnosed with cancer or other chronic 
condition) 
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9.4.2.3 Topic guides 
9.4.2.3.1 Stage 2: Interviews 




TOPIC GUIDE FOR SEMI-STRUCTURED INTERVIEWS 
 
Name of Institution: Guy’s and St Thomas’ NHS Trust 
Principle Investigator: Dr Sarah Rudman 
Phone Number and Contact Details: Gincy George  
Clinical Trials Coordinator 
02071887188 | Ext. 57380 
 
The aim of this 1:1 interview is to explore various factors contributing to non-
adherence to the treatment in men with prostate cancer on the GnRH agonists.  
The interview will follow a semi-structured approach with prostate cancer men on 
GnRH agonists for a minimum of six months. The interviewer is not required to 
strictly adhere to the structure below and may ask the following questions in no 
particular order. The interviews will take place in Guy’s Hospital and should last no 
more than a maximum of 45 minutes per study participant.  
 
Some questions to consider during the 1:1 interview: 
The interviewer may ask the following main questions (in no particular order) and if 
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Main Questions Clarifying Questions 
Have you encountered any issues in 






 Would you mind clarifying what 
you meant when you said… 
please? 
 Would you mind expanding a 
little on… please? 
 Would you mind giving an 
example of… please? 
 
Have you made any changes to your 
lifestyle to help you take your 
injections? Can explore lifestyle 
factors such as smoking and alcohol 
intake here. 
What makes it difficult for you to have 
your injection on time? 
What strategies have you used to 
overcome these difficulties? 
What happens when you do 
something ‘out of routine’ e.g. go on 
holiday? 
Do you experience any side-effects 
from your treatment? If so, do you 
think this is contributing to your 
difficulty to having your injection on 
time? 
Does a family member/spouse help 
you remember to take your 
injections? 
Do you think you understand your 
treatment regimen and how the 
injections help treat your prostate 
cancer? May explore clinician-patient 
relationship here if the participant is 
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9.4.2.3.2 Stage 3 Focus groups 
                                                                
 
 
TOPIC GUIDE FOR FOCUS GROUPS 
 
Name of Institution: Guy’s and St Thomas’ NHS Trust 
Principle Investigator: Dr Sarah Rudman 
Phone Number and Contact Details: Gincy George  
Clinical Trials Coordinator 
02071887188 | Ext. 57380 
The aim of these focus groups is to explore various factors contributing to non-
adherence to the treatment in men with prostate cancer on the GnRH agonists. The 
focus groups will be conducted with clinicians from Guy’s and St Thomas’ 
Foundation Trust who treat prostate cancer men on GnRH agonists. The focus 
groups will take place at Guy’s hospital in two 1-2 hours sessions: 
 Session 1: focus group with a minimum of 3 clinical oncologists or registrars 
 Session 2: focus with a minimum of 3 clinical nurse specialists 
The focus groups may follow the structure set below, in no particular order.  
 
Some questions to consider during the focus groups: 
 Do you think there is an issue with non-adherence to GnRH agonists in men 
with prostate cancer in clinic? 
 How does your role help prostate cancer men adhere to their treatment?  
 Do you think men on the treatment fully understand the consequences of 
not taking their injections?  
 How can you as clinicians help with better adherence in to GnRH agonists? 
 From your experience of treating prostate cancer men with GnRH agonists, 
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Discussion of results from 1:1 interviews 
In the last 30-40 minutes of the focus groups, summarise the results from 1:1 
interviews with prostate cancer men on GnRH agonists and discuss the results with 
the clinicians. Conclude with what they as clinicians can do to tackle factors 
highlighted in the interviews to improve adherence to GnRH agonists in men with 
prostate cancer.  
 
9.4.2.4 Participant information sheets 







Participant Information Sheet (Patient) 
 
Name of Institution: Guy’s and St Thomas’ NHS Trust 
Principle Investigator: Dr Sarah Rudman 
Phone Number and Contact Details: Gincy George  
Clinical Trials Coordinator 
02071887188 | Ext. 57380 
You are being invited to take part in an optional research study. Please take the time 
to read the information provided below and ask questions. It is important that you 
understand the risks and benefits of participating in this study so that you can make 
a decision that is right for you. This process is known as Informed Consent.  
You do not have to take part in this study and if you do not take part, it will have no 
effect on your care now or in the future. 
If you do decide to take part, you can change your mind at any time without having 
to give a reason and without any effect on the care you will receive from the medical 
staff. 
Adherence Patterns of GnRH Agonists in Prostate Cancer 
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WHY IS THIS STUDY BEING DONE?  
Men with prostate cancer who have hormonal injections as part of their treatment 
may sometimes not take their injections on time. They may also eventually stop 
taking their injections due to various reasons. We are trying to understand the 
reasons why men may stop taking their injections. This study is being conducted for 
educational purposes as the anonymised results will form part of a PhD project. Gincy 
George (Clinical Trial Coordinator) is a PhD student working as part of the 
Translational Oncology and Urology Research at King’s College London whose PhD 
primarily focuses on men with prostate cancer on long-term hormonal treatment.  
WHO IS ORGANISING AND FUNDING THIS STUDY? 
This study is being conducted by the medical teams in Guy’s and St Thomas’ NHS Trust 
in collaboration with Kings College London (KCL).  
 
HOW WILL IT BE CARRIED OUT? 
This study will take place in Guy’s and St Thomas’ NHS Trust in the United Kingdom. 
Men with prostate cancer who are known to have advanced disease and are on 
hormonal injections will be invited to take part.  
 
WHAT WILL HAPPEN TO ME IF I AGREE TO TAKE PART? 
If you decide to join the study you will be asked to: 
1. Sign the consent form for the study 
2. Spare approximately 45 minutes in a 1:1 interview with the 
researcher who will discuss with you difficulties that you may have 
come across with being on long-term hormonal injections as part of 
your prostate cancer treatment 
 
The interviews will be carried out, audio recorded and transcribed by Gincy George 
(Clinical Trial Coordinator). The interviews will take place in the oncology department 
at Guy’s Hospital, Great Maze Pond, London, SE1 9RT. All transcriptions from the 
interviews will be made anonymous and analysed by Gincy George. 
WHAT ARE THE BENEFITS OF TAKING PART IN THIS STUDY? 
If you take part in the study, you may help the researchers to understand why men 
with prostate cancer find being on long-term hormonal injections so challenging. It is 
important for you to realise that this research study is designed to increase doctors’ 
knowledge of men’s perception of being on hormonal injections and the difficulties 
and challenges they come across which may deter them from discontinuing these 
hormonal injections. 
WHAT ARE THE RISKS OF TAKING PART IN THIS STUDY? 
The study involves spending approximately 45 minutes in a 1:1 interview with the 
researcher asking you questions on what may be sensitive topics.  
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It is important for you to realise that should at any point during the interview you 
may become uncomfortable, you have the right to ask the interviewer to stop the 
interview and seek to destroy the data collected on you so far. 
 
CONFIDENTIALITY ISSUES 
The interviews will be audio recorded. The audio recordings of the study will be 
transcribed anonymously by Gincy George (Clinical Trial Coordinator) and the 
recordings will be destroyed at the end of the study. All data collected from you will 
be given an identification number and will not be labelled with your name or any 
other information that directly identifies you. The connection between the 
identification number and you will only be stored on a password-protected Guy’s and 
St Thomas’ Trust computer as per NHS trust policies.  
 
King’s College London is the sponsor for this study based in London, United 
Kingdom. We will be using information from you and/or your medical records in 
order to undertake this study and will act as the data controller for this study. 
This means that we are responsible for looking after your information and using 
it properly. When all analysis is complete, the audio recordings from the 
interviews will be destroyed by the research team after 1 year following the end 
of study period. The anonymised data (i.e. the transcriptions) from the 
interviews will be archived on the password-protected Guy’s and St Thomas’ 
Foundation Trust server (co-sponsor) for five years following the end of study 
period.  
 
Your rights to access, change or move your information are limited, as we need 
to manage your information in specific ways in order for the research to be 
reliable and accurate. If you withdraw from the study, we will keep the 
information about you that we have already obtained. To safeguard your rights, 
we will use the minimum personally-identifiable information possible. 
 
You can find out more about how we use your information at 
www.kcl.ac.uk/innovation/research/support/ethics/how-does-gdpr-affect-
ethics/king's-college-london-statement-on-use-of-personal-data-in-
research.aspx  (sponsor) and 
https://www.guysandstthomas.nhs.uk/research/patients/about.aspx  (co-
sponsor) and/or by contacting Clinical Trials Coordinator Gincy George on 
gincy.george@gstt.nhs.uk or 0207 188 7188 | Ext 57380. 
 
Guy’s and St Thomas Foundation Trust will use your name and contact details to 
contact you about the research study, and make sure that relevant information 
about the study is recorded for your care, and to oversee the quality of the 
study. Individuals from King’s College London (contracted to Guy’s and St 
Thomas’ Foundation Trust) may look at your medical records to check the 
accuracy of the research study. Guy’s and St Thomas Foundation Trust will pass 
these details to King’s College London along with the  information collected 
from you and/or your medical records. The only people in King’s College London 
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who will have access to information that identifies you will be researchers from 
the research team who need to contact you to invite you to the interview.   
 
WHO HAS REVIEWED THE STUDY? 
The study has been reviewed by the Nottingham 1 Research Ethics Committee. 
WHO DO I CONTACT IF I REQUIRE FURTHER INFORMATION OR HAVE ANY 
CONCERNS? 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions. Please contact: 
Principle Investigator Dr Sarah Rudman, via Clinical Trials Coordinator Gincy George 
on gincy.george@gstt.nhs.uk or 0207 188 7188 | Ext 57380. 
WHAT IF THERE IS A PROBLEM? 
If you have a complaint, you should talk to your research doctor (Dr Sarah Rudman) 
who will do their best to answer your questions. If you remain unhappy, you can make 
a formal complaint through the NHS complaints procedure. Details can be obtained 
through the Guy’s and St Thomas’ Patient Advisory Liaison Service (PALS) on 0207 
1887188, address: PALS, KIC, Ground floor, north wing, St Thomas’ Hospital, 
Westminster Bridge Road, London, SE1 7EH . This study is insured by Guy’s & St 
Thomas’ NHS Foundation Trust under the Clinical Negligence Scheme for trials. 
All professional staff involved in the study hold professional indemnity to work within 
Guy’s and St Thomas’ NHS Trust.  In the event that you are harmed during the 
research and this is due to negligence then you may have grounds for legal action for 
compensation against Guy’s and St Thomas NHS Trust but you may have to pay your 
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Participant Information Sheet (Clinician)  
 
Name of Institution: Guy’s and St Thomas’ NHS Trust 
Principle Investigator: Dr Sarah Rudman 
Phone Number and Contact Details: Gincy George  
Clinical Trials Coordinator 
02071887188 | Ext. 57380 
Aim of the study 
Non-adherence to GnRH agonists has been a concern early on with patients on 
long-term GnRH agonists. Our aim is to determine the factors contributing to non-
adherence to GnRH agonists in men with prostate cancer. This study is being 
conducted for educational purposes as the anonymised results will form part of a 
PhD project. Gincy George (Clinical Trial Coordinator) is a PhD student working as 
part of the Translational Oncology and Urology Research at King’s College London 
whose PhD primarily focuses on men with prostate cancer on long-term hormonal 
treatment. 
Methods  
This study is divided into two stages: interviews and focus groups (Figure 1). 
 
Results from the literature will be firstly validated by an oncologist and will be used 
to devise a topic guide for the interviews. Following the validation process, 1:1 
interviews will be conducted with PCa men on GnRH agonists. Men with PCa on 
GnRH agonists for a minimum of six months will be invited to the interview stage. 
Semi-structured interviews will be conducted using a topic guide that covers all 
themes identified from the previous stages. The interviews will last for 
approximately 45 minutes and will be audio recorded, anonymised, transcribed 
verbatim and thematically analysed. The interviews will be held in the Urology 
Centre or Cancer Centre at Guy’s Hospital. 
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Focus groups will be conducted for healthcare professionals treating PCa men on 
GnRH agonists in stage one. The focus groups will be held in 2 separate sessions: 
one with oncology specialists and the other with Clinical Nurse Specialists. The aim 
of the focus groups will be to identify any new themes that were not previously 
identified by in the literature. The focus groups for staff will be held at the Urology 
Seminar Room at Guy’s Hospital and staff at Guy’s hospital who have regular 
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Patient-centred and clinician-related factors 
influencing non-adherence identified from Jin et 
al. 2008; 4(1):269-86, Therapeutics and Clinical 
Risk Management 
Focus group with Clinical 
Nurse Specialists 
Focus group with 
oncology specialists and 
registrars 
___ men on GnRH agonists approached in clinic 
with   Participant Information Sheet (v 3.0, dated 
03/12/2018) for the study and invited to a 1:1 
interview with researcher 
___ men on GnRH 
agonists declined the 
study 
___ men on GnRH agonists consented on study 
consent form (v4.0, dated 03/12/2018) and 
interviewed until point of no new emerging 
themes 
Validation by specialist 
oncologist  
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Analysis Plan 
Data collected from the semi-structured interviews and focus groups will be 
analysed using thematic analysis. Thematic analysis is a widely used method for 
analysing qualitative data where the analysis aims to identify patterns of meaning 
across a dataset, which can then be used to generate themes. We will identify 
themes in this study through a process of data familiarisation, data coding, theme 
development and revision of themes (following each interview). 
Your involvement 
As health care professionals treating PCa men on GnRH agonists, you are being 
invited to join the focus groups that will be held in two separate sessions: one with 
oncology specialists and the other with Clinical Nurse Specialists. Taking part in this 
study is completely voluntary and you can withdraw from the study at any stage 
during the study, without giving a reason. If you are interested in taking part, please 
contact Gincy George (Clinical Trials Coordinator) via email at 
gincy.george@gstt.nhs.uk or by phone on 02071887188, Ext. 57380. Once you have 
agreed to take part in the study, you will be invited to a focus group that will last 
between 1-2 hours. Before taking part in the focus group, you will be asked to sign 
the study consent form. The focus group will be audio recorded and transcribed 
anonymously.   
Confidentiality issues 
The focus groups will be audio recorded. The audio recordings of the study will be 
transcribed and made anonymous by Gincy George (Clinical Trial Coordinator). 
When all analysis is complete, the audio recordings from the focus groups will be 
destroyed by the research team after 1 year following the end of study period. The 
anonymised data (i.e. the transcriptions) from the focus groups will be archived on 
the password-protected Guy’s and St Thomas’ Foundation Trust server for five years 
following the end of study period. 
King’s College London is the sponsor for this study and Guy’s and St Thomas’ will be 
the co-sponsor for this study who are both based in England, United Kingdom. 
King’s College London will be using information from you in order to undertake this 
study and will act as the data controller for this study. This means that we are 
responsible for looking after your information and using it properly. The co-sponsor, 
Guy’s and St Thomas’ Foundation Trust will keep identifiable information from you 
for five years following the end of study period. Only anonymised information will 
be kept on the King’s College (sponsor) server. Your rights to access, change or 
move your information are limited, as we need to manage your information in 
specific ways in order for the research to be reliable and accurate. If you withdraw 
from the study, we will keep the information about you that we have already 
obtained. To safeguard your rights, we will use the minimum personally-identifiable 
information possible. 
You can find out more about how we use your information at 
www.kcl.ac.uk/innovation/research/support/ethics/how-does-gdpr-affect-
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ethics/king's-college-london-statement-on-use-of-personal-data-in-research.aspx  
(sponsor) and https://www.guysandstthomas.nhs.uk/research/patients/about.aspx 
(co-sponsor) and/or by contacting Clinical Trials Coordinator Gincy George on 
gincy.george@gstt.nhs.uk or 0207 188 7188 | Ext 57380. 
If there is a problem 
If there are any issues or complaint about the conduct of the study, please contact 
the Chief Investigator of the study, Dr Sarah Rudman on gincy.george@gstt.nhs.uk 
who will do their best to resolve any issues. If you remain unhappy, a formal 
complaint can be made through the NHS complaints procedure. Details can be 
obtained through the Guy’s and St Thomas’ Patient Advisory Liaison Service (PALS) 
on 0207 1887188, address: PALS, KIC, Ground floor, north wing, St Thomas’ 
Hospital, Westminster Bridge Road, London, SE1 7EH . This study is insured by Guy’s 
& St Thomas’ NHS Foundation Trust under the Clinical Negligence Scheme for trials. 
All professional staff involved in the study hold professional indemnity to work 
within Guy’s and St Thomas’ NHS Trust.  In the event that you are harmed during 
the research and this is due to negligence then you may have grounds for legal 
action for compensation against Guy’s and St Thomas NHS Trust but you may have 
to pay your legal costs. The normal NHS complaints mechanisms are still available to 
you. 
Study review  
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9.4.2.5 Consent forms 




CONSENT FORM (PATIENT) 
 
Participant Identification Number: _______________________ 
Name of Institution: Guy’s and St Thomas’ NHS Trust 
Principle Investigator: Dr Sarah Rudman 
Phone Number and Contact Details: Gincy George  
Clinical Trials Coordinator 
02071887188 | Ext. 57380 
Please write your initials in each box 
1. I have read the attached Participant Information Sheet (Patient) 
(Version 3.0, dated 03/12/2018) on ‘Adherence Patterns of GnRH 
Agonists in Prostate Cancer‘ and have been given a copy to keep.  
The information has been fully explained to me and I have had an 
opportunity to ask questions about the project and understand why 
the research is being done and any foreseeable risks or 
consequences involved. I also understand that no guarantee can be 
given about the possible results. 
2. I give permission to be contacted regarding participating in an 
interview as part of this study. I understand that my participation is 
voluntary, and any contribution I make within these sessions will be 
anonymised.  
 
3. I give permission for my interview to be audio recorded. All 
information collected will be transcribed, stored and analysed 
anonymously. I understand that the data will be protected by the 
principles of confidentiality and both national and EU data 














Page 279 of 281 
 
4. I give permission for individuals from regulatory authorities or from 
the NHS Trust to look at relevant sections of my medical notes and 
data collected during the study for audits or research monitoring 
purposes. I give permission for these individuals to have access to 
my records for these purposes. 
 
5. I give permission to take part and I understand that my participation 
is voluntary and that I am free to withdraw at any time without 
giving any reason, and without my medical care or legal rights being 
affected. 
 
6. I know how to contact the research team if I need to. 
 




Name of participant (BLOCK CAPITALS) Date  Signature 
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9.4.2.5.2 Stage 3 focus groups: Consent form (clinician) 




CONSENT FORM (CLINICIAN) 
 
Participant Identification Number: _______________________ 
Name of Institution: Guy’s and St Thomas’ NHS Trust 
Principle Investigator: Dr Sarah Rudman 
Phone Number and Contact Details: Gincy George  
Clinical Trials Coordinator 
02071887188 | Ext. 57380 
Please write your initials in each box 
1. I have read the attached Participant Information Sheet (Clinician) 
(Version 6.0, dated 09/01/2019) on ‘Adherence Patterns of GnRH 
Agonists in Prostate Cancer‘ and have been given a copy to keep.  
The information has been fully explained to me and I have had an 
opportunity to ask questions about the project and understand why 
the research is being done and any foreseeable risks or 
consequences involved. I also understand that no guarantee can be 
given about the possible results. 
 
2. I give permission to be contacted regarding the study. I understand 
that my participation is voluntary, and any contribution I make 
within these sessions will be anonymised.  
 
8.  I give permission for the focus groups that I am a part of to be audio 
recorded. All information collected will be transcribed, stored and 
analysed anonymously. I understand that the data will be protected 
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by the principles of confidentiality and both national and EU data 
protection legislation.  
 
9. I give permission to take part and I understand that my participation 
is voluntary and that I am free to withdraw at any time without 
giving any reason, and without my legal rights being affected. 
 
10. I know how to contact the research team if I need to. 
 




Name of participant (BLOCK CAPITALS) Date  Signature 
 
 
Name of researcher    Date  Signature 
 
 
 
 
